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Abstract 
Cellular senescence is a stable cell cycle arrest that normal cells undergo in response 
to a variety of intrinsic and extrinsic stimuli. Being implicated in ageing and age-related 
diseases including cancer it is of great importance to elucidate the signalling pathways 
involved in regulating the senescent state. The p53/p21WAF1 and p16INK4A/pRB tumour 
suppressor pathways have clearly been implicated in senescence, but the critical 
downstream targets of these pathways are unclear. Transcription factors (TFs) regulate 
gene expression at different stages of embryonic development and are key to the 
establishment and maintenance of specific cell fates. My primary goal is to identify TFs 
that act downstream of these pathways. 
To identify the TFs that act downstream of the p53/p21WAF1 and p16INK4A/pRB pathways, 
the previously identified list of differentially expressed transcripts were overlaid with 
known sequence-specific DNA binding factors. The list was then refined by examining 
what happens to their expression, when senescence was bypassed and if the change 
in expression upon senescence is inversely correlated with expression in cancer. 
This identified 10 upregulated and 74 downregulated TFs. Their ability to directly bypass 
senescence was examined in the conditionally immortalized fibroblasts by lentivirus 
mediated RNA silencing or ectopic expression. The MuvB complex (LIN9, LIN37, LIN52, 
LIN54 and RBBP4) associates with the RB-like proteins, DP1 and E2F4 to form a 
repressive complex, DREAM, that induces quiescence. When cells re-enter the cell 
cycle, MuvB dissociates from DREAM and sequentially recruits MYBL2 (B-MYB) and 
FOXM1 to promote cell cycle progression. Reconstitution of B-MYB-MuvB-FOXM1 i.e. 
MMB-FOXM1 complex demonstrated that it can bypass senescence under very 
stringent conditions and that LIN52, FOXM1 and B-MYB were the crucial components. 
Moreover, this required non-phosphorylated LIN52, suggesting a role for 
phosphorylated LIN52 and the DREAM complex in inducing senescence, which is not 
very widely studied. 
Further reconstitution experiments using a cocktail of TFs targeting the up- and down-
regulated factors has revealed the presence of synergy indicating that there are other 
key TFs which remain to be identified. This study has enabled us to identify TFs that 
play a causal role in senescence. This opens the door to identifying their downstream 
targets and lays the foundation for a better understanding of the pathways underlying 
cellular senescence and its therapeutic intervention in cancer and age-related diseases.  
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Impact Statement 
Normal somatic cells divide a fixed number of times before they stop dividing and enter 
a state known as cellular senescence.  Senescent cells are not dead; they are 
metabolically active, remain viable, have a characteristic distinct appearance, but cannot 
divide. Cellular senescence can compromise repair of damaged tissues, wound healing 
and contribute towards ageing, as these processes require cells to divide.  Removal of 
senescent cells can attenuate age-related tissue dysfunction and therefore extend 
healthspan.  Senescence can also act as a potent anti-cancer mechanism, by preventing 
proliferation of potentially cancerous cells. Bypass of cellular senescence which leads 
to a limitless replicative potential, is a key hallmark of cancer cells. 
The mechanisms underlying cellular senescence are not completely understood, such 
as, why cells stop dividing; how do they stop; how do they know when to stop; what the 
critical players are; the pathways involved in making them stop dividing; and how they 
are all integrated.  Transcription factors (TFs) are proteins that can simultaneously 
control the expression of many other proteins and thus play a central role in regulating 
biological processes.  The aim of my thesis was to systematically study transcription 
factors whose expression is altered during senescence to determine if they have a 
causal role in making normal cells stop dividing.  
This thesis presents the identification of 10 TFs which are up-regulated and 74 TFs that 
are down-regulated in senescence. This differential regulation is opposite to that in 
cancer, as cancer is the flip side of senescence.  Some of the identified factors are 
components of a complex called DREAM and its associated components i.e. MMB-
FOXM1 which are formed after disassembly of DREAM complex.  The DREAM complex 
has previously been shown to play a role in regulating quiescence, another form of cell 
cycle arrest which is reversible in contrast to senescence which is essentially 
irreversible. The role of DREAM complex in senescence is not widely studied. Results 
presented within this thesis highlight an important role for DREAM and the associated 
MMB-FOXM1 complex in regulating entry into senescence and how it may be bypassed 
in cancer. Pooling of multiple different TFs has further shown that there may be other 
additional components that remain to be identified and studied further.    
Together this study has contributed in understanding the role of DREAM complex and 
associated components in regulating senescence and has laid the foundation for 
identification of their downstream targets, particularly those targets that may be involved 
in the stability of the senescence as it is a stable growth arrest. Eventually it is hoped 
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that these targets will represent novel, important and direct targets for developing new 
therapies that promote healthier ageing and increase vitality of the older population 
through stimulating regeneration, repair and wound healing, while retaining the tumour 
suppressor properties of senescence, if possible.  These key components also have the 
potential to be new therapeutic cancer targets, for developing small molecule inhibitors 
and activators aimed at inducing senescence in tumours.   
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Chapter 1 Introduction 
An early study published in 1921 by French Nobel laureate, Alexis Carrel claimed 
to have successfully cultured population of cells derived from embryonic chick 
heart tissue in vitro for 34 years (Carrel and Ebeling 1921). This set the prevailing 
belief in the early twentieth century, that all vertebrate cells inherently capable of 
dividing can grow indefinitely when cultured in vitro in the right milieu suggesting 
them to be immortal. This was contradicted in 1961 by the pioneering study 
consisting of a series of experiments conducted by Leonard Hayflick and Paul 
Moorhead. In this study, for the first time they observed that normal diploid 
human cells when cultured in vitro had a limited proliferative potential. After a 
fixed number of divisions, the cells stop dividing which is defined as the ‘Hayflick 
limit' (Hayflick and Moorhead 1961). This stage in which the cells stop dividing is 
now widely known as the biological phenomenon, cellular senescence. 
Hayflick demonstrated that human diploid cell strains stop dividing in vitro after 
a fixed number (40-60) of population doublings. Furthermore, he suggested the 
presence of memory within cultured normal human cells as he observed that 
both human diploid adult and foetal strains which had been cryopreserved, 
remember the population doubling level at which they were frozen and upon 
revival would undergo further population doublings only up to the fixed maximum 
pre-determined population doubling. This led to the conclusion that onset of 
cellular senescence is not related to the absolute calendar time but rather 
depends on the time during which the culture is actively proliferating. Another 
key finding was that the passage potential for adult lung strains was found to be 
significantly lower than the passage potential of foetal lung strains. This for the 
first time suggested the idea of cellular ageing as invitro culture mimics cellular 
ageing (Hayflick 1965).  Since this crucial discovery of cellular senescence in 
1961, apart from notable exceptions of most cell lines and embryonic stem cells, 
senescence has been demonstrated in many different cell types of different 
species including stem cells (Hayflick 1974). 
Senescence can potentially compromise tissue repair and regeneration and 
contribute to tissue and organismal ageing due to the accumulation of senescent 
cells and depletion of stem/progenitor cell compartments and secretion of an 
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array of inflammatory cytokines, chemokines and matrix metalloproteinases 
described as Senescence Associated Secretory Phenotype proteins (SASP) 
(Campisi et al. 2011; Coppé et al. 2010a). Senescence can also lead to the 
removal of defective and potentially cancerous cells from the proliferative pool, 
thereby limiting tumour development and act as a potent tumour suppressor 
mechanism (Campisi 2005). Removal of senescent cells can prevent or delay 
age-related tissue dysfunction and extend healthspan (Baker et al. 2011, 2016). 
Even though the acquisition of limitless replicative potential has been proposed 
to be one of the key events required for malignant transformation, underlying 
signalling pathways and regulating mechanisms controlling senescence are 
poorly understood (Hanahan and Weinberg 2011). A greater understanding of 
the molecular events that lead to cellular senescence is therefore essential if we 
are to prevent tissue dysfunction without increasing the risk of cancer. 
From recent developments in the senescence field, it is now clear that 
senescence entails much more than just growth arrest. Hence, in this chapter, I 
will discuss cellular senescence as a biological phenomenon, its causes, 
characteristic hallmarks and the pathways involved in manifesting cellular 
senescence. Cell cycle and its key regulators will also be discussed. The 
significance of this biological phenomenon in different contexts such as its role 
in vivo, in cancer and ageing will be discussed. Furthermore, this thesis focusses 
on studying the role of the DREAM complex and associated components in 
senescence, the DREAM complex is also discussed. Finally, the model of study 
used in this thesis (CL3EcoR) is explained. 
1.1 Causes of Cellular Senescence 
Since its discovery, several studies have revealed that cellular senescence can 
be caused by a variety of intrinsic and extrinsic stimuli. This led to the 
identification of different types of senescence. Replicative senescence is the 
term coined for the cellular senescence arising due to the limited proliferative 
potential of cells in culture as observed by Hayflick upon serial cultivation 
(Hayflick and Moorhead 1961). However, it is now known that apart from 
replicative senescence, premature senescence can be induced by a variety of 
intrinsic and extrinsic stimuli commonly referred to as Stress-Induced Premature 
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Senescence (SIPS). Morphological and biochemical changes that occur upon 
SIPS is quite similar to replicative senescence. Not much can be said about 
whether all types of senescence induced in vitro in different cell model systems, 
actually occur in vivo within an organism. 
1.1.1 Telomere-dependent Replicative Senescence 
Several studies after Hayflick’s key finding focussed on examining the reason 
behind the finite proliferative potential. One of the well understood intrinsic stimuli 
responsible for this form of growth arrest arising due to proliferative exhaustion 
is shortening of telomeres (Harley et al. 1990; Sedivy and van Deursen 2013). 
Telomeres are the ends of chromosomes which are normally protected by a 
complex of six telomere-specific proteins called the shelterin complex (de Lange, 
2010). Due to the ‘end replication problem’ faced by linear chromosomes, the 
telomeres shorten with each cell division. This arises due to the restricted 5’- to 
3’- unidirectional nature of DNA replication along with the requirement of a primer 
for initiation of DNA synthesis which leads to continuous DNA replication on the 
leading strand as opposed to the discontinuous process on the lagging strand, 
producing short DNA fragments known as Okazaki fragments. These fragments 
are covalently joined by DNA ligase activity later to complete the DNA synthesis 
on the lagging strand. At the 5’- end of the lagging strand, the last primer which 
was added to form the last Okazaki fragment cannot be replaced by DNA, giving 
rise to the end replication problem and hence the loss of 50-200 base pairs of 
telomeric DNA from the end of a chromosome during each S-phase replication  
(Harley et al. 1990; Olovnikov 1973). Hence, continuous cell divisions lead to the 
removal of protective shelterin complex resulting in progressively short and 
dysfunctional telomeres (Martens et al. 2000).  
As telomere shortening induces senescence growth arrest, cancer cells must, 
therefore, overcome this in order to grow indefinitely. This is done by the 
presence of a ribonucleoprotein enzyme called Telomerase which comprises the 
catalytic subunit, telomeric reverse transcriptase (hTERT) and the catalytic RNA 
component (TERC) which acts as a template for hTERT for adding 
hexanucleotide repeats. Telomerase can restore the repetitive telomere DNA de 
novo and prevent telomere shortening (McEachern et al. 2000). In humans, 
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telomerase is found only in a few cells like cancer cells, germ cells and some 
stem cells whereas in mice the number of telomerase expressing cells is greater 
(Campisi 2013). The catalytic RNA is ubiquitous. Human somatic cells lack the 
catalytic subunit of telomerase at a level sufficient to constantly maintain 
telomeres. Therefore, in somatic cells, repeated cell division without telomerase 
leads to critically short and dysfunctional telomeres which elicit a DNA damage 
response (DDR) via the tumour suppressor protein p53. Prolonged DDR 
signalling and p53 activation enforce senescence growth arrest (Fumagalli et al. 
2012). 
1.1.2 Stress-Induced Premature Senescence (SIPS) 
Premature senescence can be induced by other forms of genotoxic stress apart 
from telomere shortening. Genotoxic stress can be caused by endogenous 
factors, for example, progressive telomere shortening due to other factors apart 
from normal cell division like changes in telomeric structure. Exogenous factors 
such as oncogene activation, oxidative stress, DNA damage caused by radiation 
and other small molecules can also lead to genotoxic stress. To combat these 
stresses, premature cellular senescence is induced in cells before achieving the 
maximum fixed doubling potential. Most of the genotoxic stress results in a DDR, 
and growth arrest via activation of p53. Other forms of stress lead to senescence 
via activation of the pRB pathway (Campisi and D’Adda Di Fagagna 2007). A 
recent extensive study conducted by Petrova and colleagues in 2016 analysed 
more than 50 small molecule chemical compounds that can induce premature 
cellular senescence and senescence-like states (Petrova et al. 2016). Their 
study described in detail the basic mechanism of action of different small 
molecule compounds studied, the treatment used, documenting the biological 
senescence markers studied and the signalling pathways involved in manifesting 
senescence (Petrova et al. 2016). It is not very clear whether all these different 
forms of stresses manifest senescence via distinct pathways or a common 
biochemical pathway. 
1.1.2.1 Oncogene-Induced Senescence (OIS) 
OIS was discovered by Serrano and colleagues in 1997 when they demonstrated 
premature permanent senescence growth arrest occurring in G1 phase of the 
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cell cycle due to oncogenic Ras overexpression after a brief period of 
hyperproliferation in the presence of p53 or p16INK4A in vitro (Serrano et al. 1997). 
OIS observed in this study was phenotypically indistinguishable from replicative 
senescence. This study suggested that in addition to replicative senescence 
which occurs due to the cell division counting mechanism, premature 
senescence can occur as a dynamic response to an aggressive mitogenic 
stimulus suggesting a role of OIS as a tumour suppressor mechanism (Serrano 
et al. 1997).  
After this key discovery of OIS, this area was widely researched, which led to the 
identification of several other oncogenes capable of inducing senescence. Not 
only, the expression of an oncogene can lead to OIS but also the loss of tumour 
suppressor is capable of inducing senescence (Gorgoulis and Halazonetis 
2010). Multiple studies after its discovery in vitro, have subsequently shown the 
presence of OIS in vivo as a potent anti-tumour barrier (Chen et al. 2005; 
Sharpless and Sherr 2015). 
Extensive research has shown that OIS can be manifested by different 
overlapping pathways (Gorgoulis and Halazonetis 2010). One of the key 
pathways of OIS manifestation involves DDR arising due to aberrant DNA hyper-
replication (Di Micco et al. 2006), increased levels of reactive oxygen species 
(ROS) (Lee et al. 1999), replication fork reversal (Neelsen et al. 2013) and 
depletion of nucleotide pools (Mannava et al. 2013). Derepression of the 
CDKN2A locus is also a general feature associated with OIS (Kim and Sharpless 
2006; Gil and Peters 2006). The relative importance of one mechanism over the 
other depends on the cell type and varies across species. 
Other strong, persistent or deranged mitogenic signals can also induce cellular 
senescence to suppress tumour formation (Blagosklonny 2003). Cells can 
undergo senescence in response to other forms of proliferative mitogenic signals 
in addition to the aberrant expression of oncogenes; for example, persistent 
stimulation by cytokines like interferon-β triggers senescence mediated by p53 
activation and DDR arising due to the accumulation of ROS (Moiseeva 2006). 
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1.1.2.2 Unresolved DNA Damage Induced Senescence 
Apart from telomere shortening, many cells undergo cellular senescence in 
response to other forms of DNA damage (Nakamura et al. 2008). Directly or 
indirectly generated DNA DSBs (Double-stranded breaks) are potent inducers of 
cellular senescence mostly regulated via the p53-p21WAF1 pathway. DNA DSBs 
can be caused by ionizing radiation, topoisomerase inhibitors, cytotoxic 
chemotherapies and also oxidative stress (Robles and Adami 1998; Chang et al. 
2002; Barascu et al. 2012). It has been observed that a single unresolved DNA 
DSB can induce senescence (Di Leonardo et al. 1994).  
Many anticancer drugs, for example, bleomycin and doxorubicin are capable of 
inducing senescence by causing DNA damage whereas others such as 
palbociclib induce senescence through a different mechanism by inhibiting cyclin 
dependent kinase (CDK) (Petrova et al. 2016).  Additionally, oxidizing agents 
(e.g. H2O2) which lead to the formation of ROS can also cause senescence. ROS 
is also generated by mitochondria via TCA cycle.  The DDR is one of the 
overlapping pathways used by oxidizing agents to manifest senescence 
(Correia‐Melo et al. 2016). ROS are one of the different stimuli commonly used 
to induce premature senescence in in vitro studies. 
1.1.2.3 Epigenetically Induced Senescence 
As mentioned later in the senescence markers section, cellular senescence 
entails changes in chromatin organization which include the formation of 
repressive heterochromatin, known as Senescence-associated heterochromatin 
foci (SAHFs) at many loci which mainly encode pro-proliferative genes (Narita et 
al. 2003). Disruption in the epigenome can also induce cellular senescence. For 
example, histone deacetylase inhibitors (Munro et al. 2004), suboptimal c-Myc 
(Guney et al. 2006) or downregulation of p300 histone acetyltransferase 
(Bandyopadhyay et al. 2002) are considered to act by perturbing chromatin 
organization.  
Epigenetically induced senescence mostly acts by inducing p16INK4A expression 
as opposed to DNA damage-induced senescence which relies mainly on the 
cyclin dependent kinase inhibitor (CDKI), p21WAF1 (Petrova et al. 2016). 
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Therefore, as epigenetic modifiers are capable of maintaining the senescent 
state without inducing any cell stress, epigenetically induced senescence has 
been characterized as ‘causeless’ which makes it similar to the senescence 
observed during developmental stages or during ageing as opposed to DNA 
damage-induced senescence which occurs prematurely due to induction of 
different forms of stress (Petrova et al. 2016). 
1.1.2.4 Mitochondrial Dysfunction Associated Senescence (MiDAS) 
A recent study by Wiley et al., 2016, has set out to show another cause of 
senescence growth arrest, which occurs due to mitochondrial dysfunction and 
which is different from the senescence due to genotoxic stress (Wiley et al. 
2016). Mitochondria normally oxidize NADH to NAD+. Hence, mitochondrial 
dysfunction decreases the NAD+/NADH ratio mostly in the cytosol, leading to 
activation of 5’ adenosine monophosphate activated protein kinase (AMPK), 
followed by subsequent activation of p53 and manifestation of miDAS (Wiley et 
al. 2016).  
The key feature of miDAS is the distinct secretory phenotype which is different 
from SASP caused by genotoxic stress. The SASP caused by miDAS includes 
interleukin (IL)-10, tumour necrosis factor alpha (TNF-α) and chemokine (C-C 
motif) ligand 27 (CCL27) but lacks the normal IL-1 mediated signalling arm. This 
distinct SASP has the potential to alter the differentiation of certain cell types like 
preadipocytes and keratinocytes. Interestingly, miDAS has also been shown to 
occur in vivo in a progeroid mouse which accumulates dysfunctional 
mitochondria suggesting the involvement of dysfunctional mitochondria in driving 
ageing phenotypes (Wiley et al. 2016). 
1.1.2.5 Paracrine Senescence 
It has been recently discovered that senescence can be induced in neighbouring 
healthy,  proliferation competent cells by a primary senescent cell  (Nelson et al. 
2012; Acosta et al. 2013). This type of non-cell autonomous stable growth arrest 
is called paracrine senescence. The manifestation of non-cell autonomous 
senescence occurs mainly because of the SASP produced by a primary 
senescent cell. A study by Acosta et al., 2013, has demonstrated beautifully the 
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non-cell autonomous paracrine transmission of senescence by cells undergoing 
OIS in vivo in both mouse and human models of OIS and also provides insights 
into pathways regulating paracrine senescence (Acosta et al. 2013). Their study 
has identified multiple different SASP components namely, vascular endothelial 
growth factor (VEGF), transforming growth factor (TGF)-family members and the 
chemokines CCL2 and CCL20 mediating paracrine senescence. The TGF 
pathway identified in their study suggests p15INK4B and p21WAF1 involvement 
(Acosta et al. 2013). 
Another study by Nelson et al., 2012, has shown a similar senescence bystander 
effect (Nelson et al. 2012). This study set out to show that senescent cells induce 
a DDR, a characteristic feature of senescence, in neighbouring cells. They found 
that senescence occurs via gap junction-mediated cell to cell contact which leads 
to transfer of ROS, thereby suggesting the involvement of ROS in paracrine 
senescence (Nelson et al. 2012, 2018). 
1.2 The Cell Cycle 
The cell cycle is a sequence of coordinated phases which leads to cell division, 
critical for both development and viability of multicellular organisms. Completion 
of the cell cycle leads to production of two daughter cells upon mitosis. To 
maintain the integrity of the genetic material of the daughter cells, accurate 
replication of DNA must be ensured.  
The cell cycle can be divided into two main phases i.e. Interphase where a cell 
prepares to divide, and the Mitotic phase, where the actual cell division occurs. 
Interphase can be further divided into G1, S and G2 phases (Figure 1.1). Mitosis 
consists of prophase, metaphase, anaphase and telophase (Vermeulen et al. 
2003; Norbury and Nurse 1992).  
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Figure 1.1  Schematic representation of the mammalian cell cycle  
The cell cycle is divided into four phases, G1, S, G2 and M. Different cyclin/CDK complexes that 
are active during specific phase of the cell cycle are indicated. For accurate and efficient 
functioning of the cell cycle, different checkpoints marked in red exist. Cells which are not 
preparing to divide enter the resting G0 phase, such as quiescent cells, senescent cells or 
terminally differentiated cells. 
 
For accurate progression of the cell cycle, it is regulated at various points called 
cell cycle checkpoints. Two-thirds into the G1 phase, there occurs a point called 
the Restriction  point (R point) after which the cell commits to enter into mitosis 
(Pardee 1974). Mitogenic signals like growth factors affect cells in G0 and G1 
phase. Before the restriction point, growth factors allow cells to proceed to G1 
phase from G0 and cells are capable of reverting back to G0 phase upon removal 
of growth factors. In contrast, after the restriction point, cells no longer respond 
to the growth factors/mitogenic signals and can progress to S phase even after 
removal of growth factors. Additionally, other checkpoints exist to ensure correct 
cell cycle at different stages such as, the DNA damage checkpoint and the 
spindle checkpoint (Hartwell and Weinert 1989; Paulavich and Hartwell 1995). 
1.2.1 Cell cycle regulation by cyclins, CDKs and CDK inhibitors 
The tight regulation of the cell cycle is achieved by the action of a group of 
proteins called cyclins and cyclin dependent kinases (CDKs). CDKs are a family 
of heterodimeric serine-threonine protein kinases (Malumbres 2014; Malumbres 
and Barbacid 2005). CDKs were the first regulators of the cell cycle to be 
discovered. The original member now known as CDK1 was first identified in 
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genetic screens as CDC28 (Hartwell et al. 1970) in the budding 
yeast Saccharomyces cerevisiae, and as Cdc2 (Nurse 1975) in the fission 
yeast Schizosaccharomyces pombe, and were demonstrated to be critical for cell 
cycle progression (Russell and Nurse, 1986; Morgan, 1997).  Later, using 
complementation approach, homologues in humans were identified (Draetta et 
al. 1987; Lee and Nurse 1987; Hanks 1987).   
In independent experiments in sea urchin eggs, cyclins were discovered after 
observing that they were degraded periodically at each cell division (Evans et al. 
1983). Since their discovery several different cyclins have been identified that 
associate with specific CDKs during a specific phase of the cell cycle (Pines 
1991). Multiple different CDKs have been identified, which include CDK2, CDK4 
and CDK6 active during G1 phase, CDK2 during S phase and CDK1 during G2 
and M phases (Vermeulen et al. 2003). The levels of CDKs remain relatively 
constant during the cell cycle but their activation at specific stages of the cell 
cycle is achieved by association with cyclins. As is obvious by the name, the 
levels of cyclins oscillate during the cell cycle, which eventually leads to periodic 
activation of CDKs. To control the activity of their target proteins CDKs 
phosphorylate their target proteins during the cell cycle. These proteins work 
together to ensure the co-ordinated and timely regulation of specific transcription 
factors which are required to be active during a particular stage in cell cycle to 
guide cells through cell cycle in orderly fashion (Malumbres 2014).  
In addition to cyclins, the activity of CDKs is also regulated by CDK-Inhibitors 
(CDKI) which act by phosphorylating specific serine, threonine or tyrosine 
residue, in the cyclin-CDK complex. There are two different sub-groups of CDKIs 
which are known as the Cip/Kip family and the INK4A family. The Cip/Kip family 
is made up of three members i.e. CDKN1A (p21WAF1), CDKN1B (p27KIP1) and 
CDKN1C (p57KIP2) and the INK4A family consists of CDKN2A (p16INK4A), 
CDKN2B (p15INK4B), CDKN2C (p18INK4C) and CDKN2D (p19INK4D) (Sherr and 
Roberts 1999). 
1.2.2 The RB family of proteins 
The RB family of pocket proteins is one of the main targets of cyclin-CDK 
complexes and their best-known function is binding to and inactivating E2F 
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leading to repression of transcription of E2F target genes. The three members of 
the pocket protein family are: RB1 (pRB), RBL1 (p107) and RBL2 (p130). These 
proteins share a common bipartite pocket region comprising a LXCXE motif, 
which allows them to interact directly with other proteins (Dyson 1998). 
RB1 (pRB) is the product of retinoblastoma gene RB1 which was initially 
identified as a gene responsible for causing a childhood cancer in the eyes, 
retinoblastoma (Knudson 1971). The wild type RB1 gene is amongst the most 
extensively studied tumour suppressor genes and the product RB1 is known to 
be deregulated or absent in about 90% of cancers (Hanahan and Weinberg 
2011).  
The tumour suppressive action of RB1 can be disrupted by different mechanisms 
such as, dysregulated phosphorylation by cyclinD/CDK4,6 and cyclinE/CDK2 
complexes or mutations in the RB1 gene, most of which occur in the pocket 
domain of RB1 (Huang et al. 1990; Hu et al. 1990). Additionally, viral proteins 
such as SV40LT (Ludlow et al. 1989), HPV Type 16 E7 (Dyson et al. 1989) and 
Adenovirus type 5 E1A (Whyte et al. 1988) act as viral oncoproteins which are 
capable of binding and sequestering RB via the LXCXE motif and thereby 
inhibiting its tumour suppressor activity. It has been demonstrated that distinct 
patterns of phosphorylation of different sub-populations of RB by cyclin 
dependent kinases have the ability to alter the growth controlling functions of RB 
(Mittnacht et al. 1994).  
The RB family of proteins act as ‘gatekeepers’ thereby controlling the cell cycle 
progression from G1 to S phase by interacting with specific TFs and promoter 
regions. pRB is a substrate of CDK which remains bound to the E2F TF thereby 
preventing the activation of the E2F target genes required for S phase entry. pRB 
when dephosphorylated remains bound to E2Fs thereby forming the RB-E2F 
repressive complex. These repressive complexes bind to the promoter regions 
of E2F target genes and inhibit the transcription of genes required for cell cycle 
progression (Fischer and Müller 2017). Additionally, to enhance the transcription 
repression they also recruit factors such as histone deacetylase enzymes 
(HDACs) and the histone methyltransferase SUV39H1. At the G1/S checkpoint 
this inhibition is removed by the phosphorylation of RB by cyclinE-CDK2 which 
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leads to release of E2Fs from RB, thereby promoting the transcription of S phase 
genes and hence the progression of cell cycle  (Zhang et al. 2000). The gene 
expression during late S phase is controlled by association of MuvB (Multi vulva 
class B) with MYBL2 (B-MYB) whereas, during late G2 and M phase the gene 
expression is controlled by binding of MuvB with B-MYB and FOXM1. During G0 
all cell cycle dependent gene expression is repressed by binding of MuvB to 
p130-E2F dimerization partner (DP) forming the repressive DREAM complex. 
This is discussed in detail in section 1.2.4. 
RB plays a key role in skeletal muscle differentiation by associating with myoD, 
a basic helix-loop-helix (bHLH) protein (Magenta et al. 2003; Thorburn et al. 
1993). In addition to the critical functions performed by the RB family of proteins 
in cell cycle regulation, recently a direct functional involvement of the RB family 
of proteins has been reported in DNA repair by non-homologous end-joining 
(Huang et al. 2016; Cook et al. 2015). 
1.2.3 E2Fs 
The E2 factor family (E2F) is a family of TFs which act downstream of the pRB 
family of pocket proteins, therefore play a crucial part in cell cycle regulation. 
E2Fs interact with the members of the pRB family of pocket proteins as well as 
with DP1, DP2 and DP3 as heterodimers (Dyson 1998). RB can interact with 
E2Fs to inhibit their function. The ability of E2Fs to bind to and activate E2 
adenoviral gene promoter led to their discovery (Kovesdi et al. 1986). Eight E2F 
members (E2F1-E2F8) are known in mammals, which play different roles during 
cell cycle regulation by interacting with the target nucleotide sequences present 
in the promoter region of other genes which are essential for transit through the 
cell cycle (Dyson 1998; Helin 1998; Trimarchi and Lees 2002).  
E2Fs perform varied functions and depending on that they can be divided into 
main functional groups: activating (E2F1, 2 and 3) and repressing E2Fs (E2F4 
and E2F5) (Trimarchi and Lees 2002). Activating E2Fs (E2F1-3) are positive 
regulators of transcription which are required for cell cycle progression and 
mainly associate with pRB (Leone et al. 1998, 2000). The importance of 
activating E2Fs is obvious from a study which demonstrated that mutating all 
three activating E2F1-3, leads to complete blocking of proliferation (Wu et al. 
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2001). In contrast, E2F4 and 5 mainly act as negative regulators of the E2F 
regulated promoters and therefore are known to play an important role in cell 
cycle exit and differentiation (Sardet et al. 1995). They are known to interact with 
other members of the RB family. E2F4 can form complexes with all the members 
of family i.e. p130, p107 and RB in some cell types. On the other hand, E2F5 
only forms complexes with p130 (Dyson 1998). It has been shown that in 
response to some cell cycle arrest signals, cells which do not have repressive 
E2Fs are unable to undergo G1 arrest (Gaubatz et al. 2000). E2F7 and 8 act as 
repressive E2Fs. They replace the activating E2F1-3 in late S phase after DNA 
synthesis is completed to reduce the G1/S gene expression in G2/M stage 
(Westendorp et al. 2012; Di Stefano et al. 2003; Christensen et al. 2005). 
1.2.4 The DREAM complex 
Sadasivam and DeCaprio have described the DREAM complex as the master 
coordinator of cell cycle-dependent gene expression (Sadasivam and DeCaprio 
2013). DREAM is a multi-subunit complex formed by the assembly of p130 and 
p107 (RB family of pocket proteins) with Dimerization partner (DP), E2F4-5 and 
a Multivulval class B (MuvB) core complex which represses most if not all gene 
expression in quiescence (Litovchick et al. 2007). The MuvB core complex 
comprises LIN9, LIN37, LIN52, LIN54 and RBBP4 (Sadasivam et al. 2012). 
MuvB complexes, which share an evolutionarily conserved protein core 
(Sadasivam and DeCaprio 2013), were first identified in Caenorhabditis elegans 
where they controlled vulva development (Harrison et al. 2007, 2006; Ferguson 
et al. 1987), Drosophila melanogaster (Lewis et al. 2004), and later in 
mammalian cells (Litovchick et al. 2007; Schmit et al. 2007; Pilkinton et al. 2007) 
and plants (Kobayashi et al. 2015). 
Recent work on studying the DREAM complex in depth has helped to uncover 
and provide a better understanding of the molecular mechanisms controlling the 
precisely timed expression of specific cell cycle-related genes at a specific stage. 
The DREAM complex displays two notable characteristic features. First, the 
DREAM complex can switch functions and exerting opposite effects by 
associating with different components. Second, it consists of different subunits 
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that are capable of binding to distinct promoter DNA elements to regulate gene 
expression. 
1.2.4.1 Co-ordinated Cell cycle gene regulation via DREAM complex and 
associated components 
Discovery of DREAM has offered a more detailed understanding of cell-cycle-
dependent gene regulation by a coordinated and precisely timed expression of 
specific G1/S and G2/M cell cycle genes. The MuvB core complex does not 
change in its composition but it regulates the cell cycle by associating with 
different protein components at different stages during cell cycle progression. 
This allows it to switch its function from a transcription repressor in G0 and G1 
to an activator in S, G2 and M phases of the cell cycle (Sadasivam et al. 2012).  
E2F4,5 and pocket proteins p130/p107 were long known for their role in 
transcriptional repression via E2F sites (Van Den Heuvel and Dyson 2008). 
Therefore, DREAM was initially identified as a complex which binds promoters 
through E2F sites (Litovchick et al. 2007; Schmit et al. 2007; Sadasivam and 
DeCaprio 2013). The mechanistic characteristic of gene regulation by DREAM is 
shared with the RB tumour suppressor which also acts through E2F elements by 
forming similar RB/E2F transcriptional repressor complexes (Fischer and Müller 
2017).  
DeCaprio and colleagues have shown that in mammalian cells, the MuvB core 
complex dissociates from p130 and sequentially recruits B-MYB, during S phase 
to activate late S-phase genes, and FOXM1, in G2 phase, to activate mitotic 
gene expression (Schmit et al. 2007; Sadasivam et al. 2012; Litovchick et al. 
2007). The DREAM complex in addition to the E2F sites is capable of binding to 
DNA with cell cycle genes homology regions (CHRs) like all other MuvB derived 
complexes (Figure 1.2) (Schmit et al. 2009; Müller and Engeland 2010; Müller et 
al. 2012). As the MMB complex does not contain any E2F which would allow its 
binding to the E2F site, therefore, MMB complex exclusively binds to the CHR 
promoter element via the LIN54 component of the MMB complex (Müller et al. 
2012, 2014; Marceau et al. 2016). Interestingly, the CHR promoter element has 
emerged as a key site that plays a central role in cancer signalling pathways 
(Paci et al. 2017). As it is now known that the DREAM complex binds to CHR in 
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addition to E2F, DREAM therefore, has the potential to regulate a larger set of 
genes than RB and perform distinct regulatory functions apart from RB/E2F 
complexes (Müller et al. 2012; Fischer and Müller 2017; Guiley et al. 2015). 
It is still not clear if additional direct binding to DNA occurs via B-MYB and 
FOXM1 when they are present as part of the MMB-FOXM1 complex associated 
with MuvB. The evolutionarily conserved Myb sites for B-MYB binding and 
Forkhead binding motifs for FOXM1 binding are not enriched in the proximity of 
G2/M promoters as opposed to the enriched CHR sites (Müller et al. 2012, 2014). 
This suggests the absence of any sequence-specific binding of B-MYB and 
FOXM1 to G2/M gene promoters and hence their inability in activating the genes 
required for cell cycle progression on their own, without association with MuvB 
complex. However, it has been demonstrated that FOXM1 is also capable of 
binding to non-forkhead binding sites in the genome in addition to binding via 
canonical RYAAAYA forkhead binding motifs (Chen et al. 2013; Sanders et al. 
2015). This atypical and nonspecific binding of FOXM1 might help in enhancing 
the binding of MuvB to the DNA, maybe in a non-canonical way.  
Therefore, the repressive DREAM complex which contains both E2F and MuvB 
can bind to both E2F and CHR elements and repress both G1/S and G2/M genes 
whereas the activator MMB-FOXM1 complex which only has MuvB and lacks 
E2F is capable of only binding to CHR sites and hence is only capable of 
activating G2/M genes. The DREAM complex ensures coordinated and timely 
downregulation of cell cycle genes during cell cycle exit and growth arrest. MuvB 
based complexes can switch by associating with different components which turn 
the MuvB core from a repressor to activator, thereby explaining how MuvB 
binding to the same DNA elements can switch/alter functions from repression to 
activation (Engeland 2017; Fischer and Müller 2017).   
In addition to binding via single E2F or CHR sites, two other DNA elements i.e. 
CDE (cell-cycle dependent element) and CLE (CHR-like element) sites are also 
present to further support the binding of the DREAM complex.  CDE and CLE 
augment the binding of the DREAM complex to DNA. CDE augments the binding 
of DREAM complex to the CHR sites located within promoters. Similarly, CLE 
enhances the binding of the DREAM complex to E2F sites. CDE and CLE are 
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weak binding sites and are not enough for the DREAM complex to bind to these 
sites alone. Hence, they act in tandem with the main binding sites i.e. CHR and 
E2F respectively. Also, a  spacer of four nucleotide bases is required between 
E2F and CLE and between CHR and CDE sites (Müller et al. 2016). Binding of 
DREAM complex to CHR and CLE sites is through LIN54 as LIN54 is the only 
component of the MuvB complex which can interact with DNA in a sequence-
specific manner to regulate G2/M gene expression. Hence, the DREAM complex 
can bind to promoter DNA by four different modes as shown in Figure 1.2 (Müller 
et al. 2016). 
 
Figure 1.2 Different modes of the DREAM complex binding 
The DREAM complex can form two distinct contacts with DNA, namely binding to main elements 
(a) E2F or (b) CHR by E2F4-5 heterodimers and the LIN54 component of MuvB respectively. 
The binding to main promoter elements E2F and CHR can be supported by the (c) CLE and (d) 
CDE sites respectively. CLE and CDE sites are different from E2F and CHR elements and are 
unable to bind to DREAM on their own. As the MuvB complex binds to DNA via the LIN54 
component, therefore, only LIN54 component of MuvB complex is labelled in the diagram. Figure 
from (Engeland 2017). 
 
One-way progression through the cell cycle is ensured by the timely degradation 
of specific proteins via ubiquitin-mediated proteasomal degradation (Teixeira and 
Reed 2013). For example, SCF and APC/CCdh1 have been reported to 
ubiquitinate B-MYB and FOXM1 respectively to cause their ubiquitin-mediated 
proteolysis  (Charrasse et al. 2000; Laoukili et al. 2008). 
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After the completion of the cell cycle, the repressive DREAM complex is reformed 
to promote cell cycle exit or to prevent the entry into the next G1 phase (Figure 
1.3). To reform the DREAM complex after completion of the cell cycle it is 
important to dephosphorylate the pocket proteins phosphorylated by cyclin/CDK 
complexes. Two enzymes which have been implicated in regulating this 
dephosphorylation of pocket proteins are PP1 and PP2A (Kolupaeva and 
Janssens 2013). Interestingly, in a cell, PP1 and PP2A are the most abundant 
family of serine-threonine phosphatases (Virshup and Shenolikar 2009). 
Dephosphorylation of pocket proteins p107 and p130 is conducted by PP2A. On 
the other hand, PP1 is the major phosphatase for dephosphorylating and 
activating RB (Kolupaeva and Janssens 2013; Kurimchak and Grana 2015). This 
dephosphorylation promotes the formation of transcriptionally repressive 
complexes i.e. DREAM and RB-E2F complexes. 
 
Figure 1.3  Role of the DREAM complex in cell cycle regulation. 
Association of MuvB complex (LIN9, LIN37, LIN52, LIN54, and RBBP4) with different factors at 
different phases in cell cycle regulates gene expression during different stages of cell cycle. In 
early phases of cell cycle G0/G1 stage, when cells are arrested, MuvB binds to p130/p107, 
E2F4/DP to form the repressive DREAM complex, which inhibits all cell cycle-dependent gene 
expression and hence arrests cell growth. When cells exit the G0/G1 stage, transcriptional 
repression is released as p130 dissociates from MuvB and E2F allowing activator E2Fs (E2F1-
3) to activate genes required for progression into S phase. MuvB binds to B-MYB in S phase to 
regulate late S phase genes. In G2 phase, MuvB-B-MYB complex recruits FOXM1 followed by 
proteasomal degradation of B-MYB. Active FOXM1 remains bound to MuvB and regulates the 
expression of genes required in the G2-M transition. Figure from (Fischer and Müller 2017). 
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Assembly of the DREAM complex also requires phosphorylation of the LIN52 
component of MuvB core complex at Serine-28. This phosphorylation is achieved 
by DYRK1A kinase, an enzyme identified by Litovchick and colleagues 
(Litovchick et al. 2011). It has been shown by structural analysis that this 
phosphorylation supports the binding of pocket proteins to LIN52 and the MuvB 
core complex (Guiley et al. 2015). The kinase LATS2 is known to phosphorylate 
and activate DYRK1A, eventually leading to gene downregulation and cell cycle 
arrest mediated by the DREAM complex (Tschöp et al. 2011). Active DYRK1 
phosphorylates LIN52-S28 enabling the formation of the DREAM complex and 
thereby shifting the balance from activating MMB-FOXM1 complex to repressive 
DREAM complex. Even though the role of the DREAM complex in cellular 
senescence is not fully understood, Litovchik et al., 2011, have shown that 
disorganization of DREAM complex leads to suppression of Ras-induced 
senescence (Litovchick et al. 2011).  
1.2.4.2 Cell stress and p53 mediated downregulation of cell cycle-related genes 
Initially, the detailed mechanism by which p53 mediates transcriptional 
repression of a plethora of genes was not evident, however this changed after 
the availability of genome-wide ChIP data on binding of p53 and the discovery of 
the mammalian DREAM complex along with its target genes (Litovchick et al. 
2007; Schmit et al. 2007). This led to the observation that p53 induction led to 
the formation of a repressive DREAM complex and therefore the identification of 
the p53-DREAM pathway (Quaas et al. 2012). 
Recently it has been shown that p53 dependent repression is mediated via the 
p53-p21WAF1-DREAM-E2F/CHR pathway (Figure 1.4). Discovery of this pathway 
has also led to the identification of a clearer mechanism explaining how p53 
downregulates a plethora of genes with p21WAF1 being the key mediator. Also, it 
demonstrates the role played by the p53-DREAM pathway in halting cell cycle 
progression in response to a number of stress signals including DNA damage as 
it leads to activation and stabilization of p53 (Horn and Vousden 2007). 
The key step in the p53-DREAM pathway is the upregulation of a CDKI i.e. 
p21WAF1. p21WAF1 was the first identified transcriptional target for p53 (El-Deiry et 
al. 1993). The transcriptional upregulation of p21WAF1 following p53 activation 
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occurs via direct binding of p53 to sites present in the p21WAF1 promoter (Quaas 
et al. 2012). As p21WAF1 is a CDKI it blocks phosphorylation of the pRB related 
pocket proteins, p107 and p130 as well as RB. As described above in the 
unphosphorylated state p107 and p130 proteins bind to the MuvB core complex 
promoting the assembly of repressive DREAM complex. Therefore, activation of 
p53 can shift the equilibrium from the activating MMB-FOXM1 complex to the 
repressive DREAM complex in a p21WAF1 dependent manner (Quaas et al. 2012). 
During this stage, the DREAM complex shows parallel regulation along with pRB 
mediated regulation because lack of phosphorylation of pRB leads to the 
formation of repressive RB/E2F complexes (Dyson 2016).  
 
 
Figure 1.4 Indirect p53-dependent repression via DREAM (p53-DREAM pathway) 
Activation of p53 leads to downregulation of a plethora of genes. This regulation mediated by 
p53 is mostly indirect as p53 does not bind directly to the genes. Instead, p53 directly binds and 
activates CDKI p21WAF1 which leads to hypophosphorylation of p107/p130. Hypophosphorylated 
p107/p130 promote assembly of repressive DREAM complex. DREAM complex then displaces 
the activating MMB-FOXM1 and E2F1-3/DP complex from their target promoters. This switch 
mediated by p53 leads to the indirect downregulation of previously activated genes and hence 
shifts the equilibrium from activating complexes to the repressive complexes. Only LIN54 
component of MuvB is labelled. Figure from (Engeland 2017). 
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Before p53 dependent downregulation, target genes are activated by two 
different mechanisms involving both groups of promoter elements. Activator 
E2F1-3 proteins bind to E2F elements for maximum expression of the genes 
involved in S phase whereas MMB-FOXM1 complex binds to CHR promoter 
elements to upregulate the genes expressed in late G2 and M phase of cell cycle. 
Following activation, E2F or E2F/CLE and CHR or CDE/CHR promoter elements 
bind to DREAM complex to allow downregulation of the upregulated early and 
late cell cycle regulating genes respectively (Müller et al. 2016). 
A recent study by Kurt Engeland using meta-analyses of genome-wide studies 
has identified a catalogue of more than 250 high confidence target genes for the 
p53-DREAM pathway (Engeland 2017). The three pivotal criteria used in the 
identification of these targets were: downregulated mRNA expression of the 
target gene following p53 activation, binding of DREAM component to the target 
gene by ChIP and the presence of E2F or CHR elements in the proximal 
promoter of the target gene (Engeland 2017). 
The data obtained showed that the p53-DREAM pathway regulates a plethora of 
genes grouped into functional groups. These functional groups control different 
cellular functions such as DNA repair, telomere maintenance, cell cycle 
checkpoint control and various other functions. The p53-DREAM pathway 
controls an entire set of genes important for complete cell functions spanning 
from start (G1 phase) to the end of the cell cycle (M phase). This implies that p53 
controls not just partial but entire function of a cell, employing its master 
coordinator functions via DREAM complex mediated mainly by p21WAF1. Hence, 
defects in the p53-pathway contribute to loss of checkpoint control not only at the 
G1/S transition but to all checkpoints up to completion of the cell cycle.  
p53 is known to indirectly downregulate expression of many cell cycle associated 
genes which are required for cell cycle progression. Essentially all the genes are 
downregulated indirectly by p53 as a study has shown that a very small 
percentage of genes about 3%  that are downregulated by p53 are also bound 
by p53 (Fischer et al. 2014) Indirect transcriptional repression by p53 via p21WAF1 
is shown in Figure 1.4. Repression by p53 is largely indirect which involves direct 
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activation of p21WAF1 by p53, followed by formation of different repressive 
complexes such as RB/E2F and DREAM (Fischer et al. 2014).  
Taken together, identification and detailed understanding of the DREAM 
complex has provided the explanation for the precisely timed regulation of the 
G2/M cell cycle genes in addition to the well-established regulation of G1/S cell 
cycle genes by RB mediated repression of E2F TFs. The detailed mechanism of 
regulation of different TFs involved in the cell cycle is presented below in Figure 
1.5. 
 
Figure 1.5 Regulation of different Transcription Factors involved in the cell cycle 
Diagrammatic representation showing the detailed regulatory mechanisms of different TFs which 
regulate gene expression of specific genes required during different stages of cell cycle. Figure 
from (Fischer and Müller 2017). 
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1.3 Hallmarks of cellular senescence  
Mammals contain both mitotic and post-mitotic cells. Only the cells which can 
divide have the potential to initiate cancer and undergo senescence.  Apart from 
growth arrest, a number of characteristics and molecular markers are used to 
identify senescent cells. Till date there is no single characteristic marker which is 
exclusive to senescent cells, nor do all senescent cells display every known 
senescence marker (Campisi 2013).  
1.3.1 Signalling pathways as Hallmarks of senescence 
Cellular senescence growth arrest is largely established and maintained by 
engaging either one or both p53/p21WAF1 and p16INK4A/pRB tumour suppressor 
pathways. Both these pathways are complex as they involve many upstream 
regulators and downstream effectors along with varying side branches (Levine 
and Oren 2009; Chau and Wang 2003). Both pathways are also interlinked and 
crosstalk and regulate each other (Yamakoshi et al. 2009; Zhang et al. 2006; 
Martín-Caballero et al. 2001). These pathways maintain the senescence state 
mainly by inducing widespread changes in gene expression. p53 and pRB are 
the key transcriptional regulators. p21WAF1 acts downstream of p53 and p16INK4A 
acts upstream of pRB. They are crucial components of each pathway as they are 
CDKIs (cyclin-dependent kinase inhibitors) and act as negative regulators of cell 
cycle progression. Hence, prolonged overexpression of any of the above 
mentioned four critical components (p53, pRB, p16INK4A, p21WAF1) is sufficient to 
induce senescence (McConnell et al. 1998). 
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Figure 1.6 Signals and pathways involved in regulating cellular senescence 
The figure depicts various intrinsic and extrinsic stimuli that induce senescence. Major pathways 
involved in manifesting senescence are indicated. It also shows how the two key tumour 
suppressor pathways are interlinked as well. 
 
1.3.1.1 Cell Cycle Arrest and key effector proteins 
Growth arrest which marks the inability of the cell to continue in the cell cycle is 
obviously a key hallmark of a senescent cell. It is different from another form of 
growth arrest known as quiescence, in that senescence occurs in G1 and 
possibly G2 phase of cell cycle (Di Leonardo et al. 1994) as opposed to 
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quiescence which happens in G0 phase. Also, another crucial difference is that 
quiescent cells can resume proliferation in response to appropriate signals 
whereas senescent cells cannot (Campisi and D’Adda Di Fagagna 2007). This 
is beautifully explained by Blagosklonny’s theory of ‘hyperfunction' which states 
that ageing is a quasi-programme, which occurs as a consequence of the 
continuance of the processes occurring during development and growth in early 
life (Blagosklonny 2013). For example, during growth arrest, the nutrient sensing 
pathways like mTOR (mechanistic target of Rapamycin) remains active but now 
as opposed to cell proliferation and growth, it initiates cellular senescence. 
Therefore, the choice between senescence and quiescence is governed by the 
mTOR pathway. Cells with persistent activation of mTOR undergo a stable 
senescent growth arrest, whereas cells in which mTOR is inhibited, undergo a 
reversible quiescence growth arrest (Blagosklonny 2012; Korotchkina et al. 
2010). Apoptosis is defined as a phenomenon of programmed cell death in which 
the remains of a dead apoptotic cell are removed by engulfment by another cell, 
whereas in senescence, the senescent cell is not immediately eliminated and 
remains metabolically active. 
Senescent cells show significant changes in gene expression. These changes in 
gene expression include changes in the expression of genes like cell cycle 
inhibitors (CDKI) (Shelton et al. 1999). CDKs regulate cell cycle progression by 
phosphorylating different proteins. Two key cell cycle inhibitors that are 
expressed by senescent cells are the cyclin-dependent kinase inhibitors p21WAF1 
and p16INK4A. Both of these CDKI are key components of the two major tumour 
suppressor pathways in mammalian cells: which are p53 and pRB pathways 
respectively (Campisi 2001).  
As mentioned before the general block of proliferation is a key feature of a 
senescent cell. Exit from cell cycle can be demonstrated using colony-formation 
assays which gives a direct measure of the proliferation potential of the cells or 
by BrdU/EdU-incorporation assays that measures the DNA synthesis rate. 
Although, this is not very accurate as there could be DNA repair mediated 
synthesis still occurring. Measuring the expression levels of CDKIs p16INK4A and 
p21WAF1 are also key in detecting cell cycle arrest. Despite this, growth-arrest is 
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not a specific unique marker for senescent cells especially because of the 
inability and impracticality to measure it in vivo and in post-mitotic cells. 
Senescent cells in order to maintain their growth arrested state are known to 
repress the expression of genes required for cell cycle progression (Pang and 
Chen 1994). Repression of some of these genes is due to the inactivation of 
transcription factor E2F by pRB by forming the transcriptionally repressive RB-
E2F complex. In some senescent cells, senescence associated heterochromatin 
foci formation by pRB dependent reorganization of chromatin leads to silencing 
of the E2F target genes (Narita et al. 2003). 
 p53 
Nuclear phosphoprotein p53 was identified as a protein that formed an oligomeric 
complex with T antigen of simian virus 40 (SV40) and ironically was initially 
thought to be an oncoprotein (Lane and Crawford 1979; Linzer and Levine 1979).  
p53 is a member of a unique protein family which includes proteins p63 and 
p73.The members of this family are structurally related to each other and they 
can homo-oligomerize and bind to DNA. Although structurally related the 
members of the family perform different functions; p53 acts as a key tumour 
suppressor protein whereas p63 and p73 are mainly involved in organismal 
development (Irwin and Kaelin 2001a, 2001b). p53 is one of the most studied 
proteins. This is not surprising because of the multitude of cellular functions it 
performs such as a key tumour suppressor protein, maintains genome integrity, 
plays role in apoptosis, metabolic regulation, development and DNA repair to 
name a few. Hence, p53 is famously known as a ‘guardian of the genome’ (Lane 
1992; Kastenhuber and Lowe 2017).  
In line with the key role of p53 in tumour suppression as well as in maintaining 
genome integrity, p53 is known to act as a key regulator in cellular senescence, 
via several different mechanisms. Activation of p53 is dependent on various post 
translational modifications such as phosphorylation, methylation, acetylation, 
sumoylation, ubiquitination and neddylation (Kruse and Gu 2009). Interestingly, 
a study by Katherine Webley and colleagues studied different phosphorylated 
states of p53 by using antibodies with phosphorylation sensitive epitopes in 
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senescent fibroblasts (Webley et al. 2000). Distinct post translational 
modifications were demonstrated upon comparing phosphorylation of amino acid 
residues present in both amino and carboxy terminals of p53 during replicative 
senescence and DNA damage induced senescence. Increased Ser-15 
phosphorylation resulting in p53 stabilization was found to be the only common 
change in both types of senescence studied in this study (Webley et al. 2000). 
 p21WAF1 
p21WAF1 is a 21 kDa CDKI protein which is one of the members of the Cip/Kip 
family of CDKI in addition to p27 and p57. It is encoded by the CDKN1A gene.  
p21WAF1 is capable of inactivating all different CDKs, thereby inhibiting cell cycle 
progression. This role was discovered when Harper and colleagues noticed a 
21kDa protein interacting with and inhibiting different cyclin dependent kinase 
proteins in their immunoprecipitation experiments (Wade Harper et al. 1993). 
p21WAF1 inhibits the kinase activity of cyclin-CDK complexes by interacting with 
cyclins through two copies of cyclin binding motifs present in p21 (Cy1 and Cy2). 
This inhibits binding of cyclin/CDK complexes to the RB family of proteins which 
eventually inhibits their phosphorylation and subsequent release of E2Fs and 
hence induces p21WAF1 mediated cell cycle arrest (Chen et al. 1996). As p21WAF1 
is known to interact with and inactivate various cyclin/CDK complexes, it is 
capable of inducing cell cycle arrest at any stage of cell cycle as opposed to 
INK4A family of CDKI which specifically bind and inactivate CDK4 and CDK6, 
hence can induce cell cycle arrest only during G0/G1 phase (Wade Harper et al. 
1993; Pavletich 1999; Sherr 2000). 
p21WAF1 has been shown to be consistently upregulated during senescence 
response induced by different stimuli (Noda et al. 1994; Hernandez-Segura et al. 
2017). During DNA damage p21WAF1 expression is mainly upregulated by direct 
transactivation by p53; additionally, p53 can also activate p21WAF1 in response to 
Ras activation (Macleod et al. 1995). Furthermore, p21WAF1 can be upregulated 
independently of p53 by various other stimulators such as by different nuclear 
receptors including androgen receptors, vitamin D receptors and retinoid 
receptors. Also members of the Krüppel-like factor (KLF) TF family can cause 
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activation of CDKN1A gene by cooperating with p300-CREBBP (Abbas and 
Dutta 2009).  
In addition to the transcriptional control of p21WAF1 by p53 dependent and 
independent mechanisms, p21WAF1 is also controlled at the post translational 
level. As p21WAF1 is an unstable protein, newly synthesized p21WAF1 is stabilized 
by WISp39, a Hsp90 binding tetratricopeptide repeat, which stabilises p21WAF1 
by preventing its proteasomal mediated degradation (Jascur et al. 2005). Also, 
additional post-translational modification such as phosphorylation of p21WAF1 can 
modulate the binding partners of p21WAF1 or change the subcellular location of 
p21WAF1, which ultimately has the potential to alter p21WAF1 function blocking its 
ability to act as a CDKI (Child and Mann 2006). For example, p21WAF1, when 
present inside the nucleus, inhibits cell cycle progression, whereas after 
phosphorylation it gets transported to the cytoplasm where it functions as anti-
apoptotic (Ping et al. 2006). Therefore, p21WAF1 plays multiple different functional 
roles within the cell by regulating different processes (Georgakilas et al. 2017; 
Karimian et al. 2016). 
 p16INK4A 
Replicative senescence is also linked to the derepression of the CDKN2A locus 
which encodes two key tumour suppressor proteins namely p16INK4A and p14ARF. 
p14ARF regulates the stability of p53 by binding and inhibiting MDM2 activity 
which is responsible for proteasomal-mediated degradation of p53 (Kim and 
Sharpless 2006; Gil and Peters 2006). In young tissues, the CDKN2A locus is 
normally expressed at a very low undetectable level whereas it becomes 
derepressed leading to its high-level expression during ageing (Krishnamurthy 
et al. 2004). The molecular mechanisms underlying this derepression are not 
completely understood but to a large extent the derepression has been 
associated with loss of polycomb group of proteins and is independent of p53 
(Jacobs et al. 1999; Bracken et al. 2007). 
p16INK4A is a 16 kDa protein that directly binds to CDK4/6 and blocks the 
formation of cyclinD-CDK4/6 complex, thereby preventing phosphorylation of RB 
and promoting repression of E2F target genes (Serrano et al. 1993). p16INK4A is 
frequently used as a specific and unique marker for senescence as its expression 
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in most normal, untransformed cells and tissues is low or undetectable as 
opposed to accumulated high levels of p16INK4A after senescence induction by 
various stimuli (Hara et al. 1996; Wiley et al. 2017). 
Transcriptional activation of p16INK4A has also been extensively used to report 
senescence in vivo (Demaria et al. 2014; Burd et al. 2013). The expression of 
p16INK4A is also a functional marker of ageing as it has been reported to increase 
in several vertebrate tissues with age (Baker et al. 2016; Waaijer et al. 2012; 
Krishnamurthy et al. 2004; Liu et al. 2009). Loss of the p16INK4A gene or inherited 
mutations in the p16INK4A gene have been related to several cancers particularly 
melanoma (Li et al. 2011a). The inducers of p16INK4A are mostly related to the 
epigenetic changes. 
1.3.1.2 The DNA Damage Response (DDR) 
The DDR is a classical, evolutionarily conserved, robust response that is 
activated in cells with DNA damage such as single-stranded and double-
stranded breaks. Cells are able to deal with DNA damage, but if the damage is 
irreparable, in order to prevent the duplication and passing of damaged DNA to 
the daughter cells, cells must undergo either apoptosis or senescence. Initially, 
it was not clear how a cell decides to choose between apoptosis and senescence 
but now it has been suggested that prominent short-term DNA damage activates 
apoptosis whereas prolonged mild DNA damage induces cellular senescence 
(Petrova et al. 2016). Therefore, it is suggested that persistent DDR signalling 
leads to cellular senescence.  
Classical DDR mainly involves the p53/p21WAF1 tumour suppressor pathway. 
Multiple different DNA damage sensors such as replication protein A (RPA) (Zou 
and Elledge 2003) and the RAD9-RAD1-HUS1 (9-1-1) (Weiss et al. 2002) 
complex detect exposed single-stranded breaks and MRE11-RAD50-NBS1 
(MRN) (Stracker et al. 2004; Moreno-Herrero et al. 2005) complex detect DNA 
double-stranded breaks and recruit the upstream protein kinases ataxia 
telangiectasia mutated (ATM) and ataxia telangiectasia and RAD3-related (ATR) 
to the site of damage (D’Adda Di Fagagna 2008). Although both ATM and ATR 
are activated upon DNA damage, they are known to have distinct DNA 
specificities such as: ATM gets activated predominantly by DSBs whereas ATR 
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in addition to double strand breaks responds to a broad spectrum of DNA 
damage such as genotoxic stress caused by DNA replication stress initiated by 
oncogenes (Maréchal and Zou 2013). Once at the site of damage ATM and ATR 
further phosphorylate and amplify the DDR signal by phosphorylating other DNA 
damage mediator proteins, such as phosphorylation of histone H2AX to form γ-
H2AX which aids in the assembly of other specific DNA repair complexes, 
forming nuclear foci that are stable sites of dynamic accumulation of different 
DDR proteins (Lukas et al. 2003). Dynamic changes in histone modification such 
as histone methylation are also critical for regulating DNA double-strand break 
(DSB) repair by activating ATM kinase (Ayrapetov et al. 2014). This process of 
activation of ATM kinase also contributes to the formation of transient repressive 
chromatin structures which serve to stabilize the damaged chromatin and 
promote assembly of DSB-signalling proteins (Ayrapetov et al. 2014).  
 
Figure 1.7 The DNA Damage Response (DDR) Signalling Pathway 
Diagrammatic representation of the DDR signalling pathway showing the key DNA damage 
sensors, different kinases involved and the effector molecules. Figure from (Sulli et al. 2012). 
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Other downstream diffusible kinases which act far from the site of DNA damage 
such as CHK1 and CHK2 propagate the damage signal by further 
phosphorylating the final effector substrates like p53. Phosphorylation of p53 on 
Serine-20 by CHK2 leads to a reduction in binding affinity of E3 ubiquitin-protein 
ligase MDM2 to p53, leading to an increase in p53 level. p53 is also 
phosphorylated at Serine-15 directly by ATM (Chehab et al. 1999).  CHK1 
negatively regulates CDC25, a dual-specificity protein phosphatase which 
usually promotes G2 to M transition, by phosphorylating Serine-216 leading to 
G2 growth arrest (Peng 1997) Figure 1.7. Eventually, the phosphorylated p53 
activates and upregulates the expression of its transcription target p21WAF1 which 
is a potent universal CDKI and therefore an inhibitor of cell cycle resulting in cell 
cycle arrest (Sulli et al. 2012).  
As most of the senescence-inducing signals eventually impinge on DNA directly 
or indirectly, persistent DDR signalling is a characteristic feature of many 
senescent cells. The DDR signalling pathway has associated features like DNA 
damage foci which can be detected by immunostaining of γ-H2AX; telomere-
dysfunction induced foci (TIF) (Herbig et al. 2006) and DNA segments with 
chromatin alterations reinforcing senescence (DNA-SCARS) (Rodier et al. 
2011). These, or phosphorylated p53, can be used as markers for cellular 
senescence. The challenge relies on the fact that DDR can also be activated by 
other DNA-damaging stimuli which do not lead to the senescent state. 
Furthermore, not all forms of senescence are manifested via DDR (Salama et al. 
2014). 
1.3.1.3 The Senescence-Associated Secretory Phenotype (SASP) 
It has been known for a while that senescent cells affect their microenvironment 
by secreting a number of factors into the vicinity, which affect the behaviour of 
nearby non-senescent cells (Aravinthan 2015). The SASP, therefore, is 
considered as a crucial feature of many senescent cells. It is hypothesized that 
DNA damage is an essential driver of the SASP. The SASP is expressed by cells 
in which senescence was caused by genomic damage or epigenomic 
perturbation leading to prolonged DDR (Campisi 2013). Normal cells in which 
senescence is induced by ectopically expressing p21WAF1 or p16INK4A, do not 
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express SASP despite displaying other characteristic senescence markers 
(Coppé et al. 2011). On the other hand, cells that undergo senescence because 
of DNA damage, dysfunctional telomeres, epigenomic perturbation, mitogenic 
proliferative signals, oxidative stress or other senescence-inducing stimuli are 
known to develop SASP to different extents (Rodier et al. 2009; Pazolli et al. 
2012; Coppé et al. 2010b; Acosta et al. 2008; Kuilman et al. 2008). Similarly, 
induction of senescence by mitochondrial dysfunction presents a distinct 
secretory phenotype (Wiley et al. 2016). 
The main components of SASP include a plethora of soluble signalling factors, 
for example, inflammatory cytokines, chemokines, growth factors and matrix 
metalloproteinases (MMPs) (Coppé et al. 2010a). IL-6 and IL-8 are two main 
SASP components. These factors have been shown to play both positive and 
negative roles in various biological processes such as tissue repair, wound 
healing and tumour progression (Demaria et al. 2014; Coppé et al. 2010a). The 
SASP plays a key role in mediating the pathophysiological activity of senescent 
cells. Hence, SASP factors have been suggested to have deleterious as well as 
beneficial effects (Rodier and Campisi 2011).  
SASP factors control a multitude of functions by playing a role in enhancing 
immune surveillance, tissue repair and remodelling and have also been shown 
to promote reorganization of embryonic structures during developmental stages 
(Demaria et al. 2014; Adams 2009).  On the contrary, chronic presence of some 
of the tissue remodelling and pro-inflammatory SASP factors like interleukins and 
MMPs have been shown to play a role in ageing phenotypes and disease states 
(Coppé et al. 2010a). The beneficial or deleterious effect of the SASP depends 
on the physiological context. 
SASP factors can exert their effects in both autocrine and paracrine fashion. 
Factors like IL-1α and IL-6 act in a cell-autonomous manner to reinforce the 
senescent state whereas many other SASP factors act by exerting non-cell- 
autonomous function, enabling alteration in the behaviour of neighbouring cells 
(Acosta et al. 2008, 2013). SASP members can be secreted into the extracellular 
environment by different methods.  Many members are produced as soluble 
proteins which can be directly secreted, whereas some are initially expressed as 
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transmembrane proteins that require ectodomain shedding for secretion (Stow 
and Murray 2013). Sheddase enzymes like ADAM17 have been reported to be 
upregulated in OIS and cancer and are responsible for regulating the ectodomain 
shedding of many cell membrane-bound SASP factors (Morancho et al. 2015; 
Effenberger et al. 2014). Additionally, to enable more distal functions, such as 
enhancing cancer cell proliferation, some SASP members are secreted in small 
exosome-like extracellular vesicles (Takasugi et al. 2017).  
Triggers activating the SASP are not completely understood but to a large extent 
have been shown to be related to DDR initiated NF-κB activation that mainly 
induces expression of inflammatory cytokines (Ohanna et al. 2011). Studies have 
also demonstrated the involvement of the mTOR pathway in regulating the SASP 
at the post-transcriptional level (Laberge et al. 2015; Herranz et al. 2015; Bent et 
al. 2016). Recent findings have indicated dynamic signalling by NOTCH1, a cell 
surface receptor, as a crucial regulator of SASP composition (Hoare et al. 2016; 
Ito et al. 2017). 
Interestingly last year three different studies collectively implicated the essential 
role of yet another pathway, called cyclic GMP–AMP synthase linked to 
stimulator of interferon genes (cGAS-STING) in mediating SASP and thereby 
regulating cellular senescence (Dou et al. 2017; Yang et al. 2017; Glück et al. 
2017). As described later in section 1.3.2.3, nuclear integrity is compromised 
during senescence due to loss of the nuclear lamina protein, LaminB1, which 
leads to the unusual presence of cytoplasmic chromatin fragments (CCFs) in the 
cytoplasm. The functional relevance of CCFs in the cytoplasm is not clear, but 
the discovery of the cGAS-STING pathway has shown that it promotes SASP in 
primary human cells and in mice and has been shown to play a role in tumour 
suppression due to immune-mediated clearance of premalignant cells (Dou et al. 
2017; Umbreit and Pellman 2017).   
cGAS is a 522 amino acid protein which is a cytosolic DNA sensor that activates 
innate immunity on sensing aberrant double stranded (ds) DNA molecules and 
responds equally to microbial as well as endogenous ligands. After activation by 
binding to CCFs present in cytoplasm, cGAS in the presence of ATP and GTP 
catalyses production of the second messenger molecule 2’3’ cyclic GMP-AMP 
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(cGAMP), which recruits STING thereby activating NF-κB which will lead to 
production of pro-inflammatory molecules (Diner et al. 2013; Ablasser et al. 2013; 
Zhang et al. 2013; Gao et al. 2013; Ablasser and Gulen 2016; Chen et al. 2016). 
Hence, the two key downstream pathways which function after activation of 
cGAS-STING involve activation of interferon and NF-κB  (Barber 2015; Glück et 
al. 2017). 
Results obtained from the study by Yang et al., 2017, have demonstrated that 
cGAS is localised in the cytoplasm of non-proliferating cells whereas it enters the 
nucleus and accumulates on chromatin DNA during mitosis in proliferating cells 
(Yang et al. 2017). This explains the diffuse pattern obtained for cGAS in 
proliferating cells as opposed to the consolidated sharp, bright puncta which 
colocalized with CCFs in senescent cells in the study conducted by Dou and 
colleagues (Dou et al. 2017). Further studies have reported the engagement of 
the cGAS-STING pathway both in vitro and in vivo where cellular senescence 
was induced by different stimuli (Glück et al. 2017; Yang et al. 2017). Loss of 
cGAS compromised senescence in different in vivo models and also accelerated 
the spontaneous immortalisation of mouse embryonic fibroblasts thereby 
highlighting the importance of cGAS in regulating SASP and senescence (Glück 
et al. 2017; Yang et al. 2017). Identification of the cGAS-STING pathway 
provides new insights that nuclear genomic DNA not only acts as a stable nuclear 
entity that encodes genetic information but also serves to act as a ‘danger-signal’ 
to alarm the immune system by inducing the proinflammatory SASP pathway and 
the interferon response. This suggests that this pathway might have evolved for 
fighting infectious DNA in the cytoplasm. Findings till now suggest that the 
function of the SASP might be to help the damaged senescent cell communicate 
with neighbouring cells about their compromised state and initiate tissue repair, 
if feasible, or to stimulate their immune clearance by the immune system 
(Campisi 2013; Iannello et al. 2013).  
The nature of the SASP is nonspecific and immensely heterogeneous which can 
be regulated at multiple different levels. Difficulty in the identification of a general 
regulatory mechanism restricts the use of SASP as an unequivocal marker for 
senescence (Hernandez-Segura et al. 2017; Coppé et al. 2010a). However, the 
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advantage in studying the composition of SASP is that it can be helpful in defining 
different senescence programs and its context (Lecot et al. 2016). For example, 
the presence of growth factors like VEGF and PDGF-A and different MMPs 
indicate the involvement of senescent cells in wound healing and tissue repair 
(Demaria et al. 2014; Jun and Lau 2011) whereas, therapy-induced or age-
related senescent cells are mainly associated with secretion of inflammatory 
factors (Demaria et al. 2017; Baker et al. 2016). 
1.3.1.4 Resistance to Apoptosis 
It is seen that many cells that undergo senescence acquire resistance to 
apoptotic signals (Ryu et al. 2007; Marcotte et al. 2004; Sanders et al. 2013; 
Hampel et al. 2004). Since senescent cells are resistant to apoptosis, it may 
explain why senescent cells keep on accumulating with age. It is still not 
completely clear as to what decides whether a cell will undergo apoptosis or 
senescence. Cell type, nature and intensity of the stress and damage are 
expected to play a role in this decision. Most cells can undergo both senescence 
and apoptosis and both of these pathways communicate with each other and can 
be regulated by p53 (Seluanov et al. 2001). The mechanisms by which 
senescent cells resist apoptosis are not very well understood. For some cells this 
might be due to changes in proteins governing apoptosis (Marcotte et al. 2004; 
Murata et al. 2006) whereas for others, it might be due to preferential activation 
of genes related to senescence growth arrest and by suppression of genes which 
activate apoptosis by p53 (Jackson and Pereira-Smith 2006). 
It has been reported by various studies that senescent cells are resistant to 
apoptosis and anti-apoptotic BCL2 has been shown to play a crucial role in this 
observed resistance to apoptosis. Findings from the study by Ryu et al., 2007, 
confirm that failure to downregulate BCL2 in senescent HDFs is responsible for 
resistance to apoptosis (Ryu et al. 2007). Sanders et al., 2013, explored the 
epigenetic mechanisms involved in conferring resistance to apoptosis in 
senescent HDFs. ChIP experiments demonstrated significant enhancement of 
antiapoptotic BCL2 gene, upon H4K16 acetylation and depletion of H4K20 
methylation. Active transcription of BCL2 in senescent HDFs contribute to 
apoptosis resistance (Sanders et al. 2013).  Antiapoptotic members of the BCL2 
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family such as BCL-XL and BCL-W are upregulated through a combination of 
increased transcription and cap-independent translation in senescent cells, 
allowing them to survive by resisting apoptosis. This study clearly showed 
specific induction of apoptosis in senescent cells after inhibition of BCL-W and 
BCL-XL by siRNA or small molecule inhibitor ABT737 (Yosef et al. 2016).  
The CDKI p21WAF1 maintains the viability of senescent cells under persistent 
DNA damage by protecting them from cell death by restraining caspase and  JNK 
signalling pathways (Yosef et al. 2017). HSP90 aids in the survival of senescent 
cells by stabilization of factors such as Protein Kinase B (AKT) (Fuhrmann-
Stroissnigg et al. 2017). Consistent with established resistance to apoptosis of 
senescent cells, transcript analysis showed increased expression of multiple 
different pro-survival factors in senescent cells making them resistant to 
apoptosis (Zhu et al. 2015; Childs et al. 2014). Hence the resistance to apoptosis 
can be the cause of accumulation of senescent cells and their retention in tissues 
with ageing.  
1.3.1.5 Metabolism 
A number of studies have reported notable changes in cell metabolism in OIS 
which includes changes in glucose, lipid, nucleotide and mitochondrial 
metabolism (Aird and Zhang 2014). As the changes observed in cell metabolism 
during OIS are mostly opposite to the changes observed in tumorigenesis, this 
indicates the involvement of these pathways in the tumour suppressive role of 
OIS (Aird and Zhang 2014). Additionally, to identify novel non-invasive 
biomarkers, a study by James et al., 2015, has analysed the extracellular 
senescence metabolomes generated from fibroblasts rendered senescent by 
proliferative exhaustion and irradiation induced DNA double-strand breaks. 
Interestingly the ECM found in these senescent cells was also found to be 
accumulated in a variety of pathological states such as ageing, inflammation, 
neoplasia and fibrosis (James et al. 2015). Furthermore, a recent study by Wu 
et al., 2017, used a combination of metabolomics and proteomics to show distinct 
metabolic profiles for chemotherapy-induced senescent cells and apoptotic cells 
(Wu et al. 2017).  
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The observed metabolic changes are regulated by p53 and pRB (Wiley et al. 
2016; Takebayashi et al. 2015; Nicolay and Dyson 2013). mTOR activation and 
mitochondrial dysfunction are also capable of inducing metabolic changes 
(Correia‐Melo et al. 2016).  As described previously in 1.1.2.4, mitochondrial 
dysfunction can manifest senescence by activating AMPK which leads to an 
increase in NAD+, therefore contributing to metabolic changes observed in 
senescence (Wiley et al. 2016).  
Even though changes in metabolism have the potential to be exploited as a 
marker for senescence, challenges which exist are first, alterations in metabolism 
can occur as a consequence or cause of other hallmarks of senescence (Wiley 
and Campisi 2016). Secondly, only a few studies have considered the whole 
metabolome of senescent cells, which is very important (Kim et al. 2011b; Wu et 
al. 2017). Furthermore, in depth characterization may help to identify specific 
metabolites as markers for cellular senescence.  
1.3.1.6 Endoplasmic Reticulum (ER) Stress 
ER stress caused by different stimuli such as mutations, oxidative stress, lack of 
chaperones and infections can lead to perturbations in the critical functions of 
ER such as regulating protein synthesis, assembly, folding and transport, leading 
to accumulation of misfolded proteins and proteotoxicity. The unfolded protein 
response (UPR) is a coordinated system of transcriptional and translational 
control that is activated by ER to deal with ER stress. UPR is associated with 
enlargement of ER, reduced protein synthesis and secretion of misfolded 
proteins (Pluquet et al. 2015). 
The UPR involves at least three ER membrane resident proteins, 
namely:  pancreatic ER kinase-like ER kinase (PERK), inositol-requiring enzyme 
1 alpha (IRE1α) and activating transcription factor 6 alpha (ATF6α) (Pluquet et 
al. 2015).  Binding immunoglobulin protein (BiP) is known to bind to PERK, IRE1α 
and ATF6α of UPR and inhibit their function. Upon ER stress, as a consequence 
of UPR, BiP binds to the misfolded and unfolded proteins releasing its binding 
with PERK, IRE1α and ATF6α (Wang and Kaufman 2014). As BiP plays a key 
role in the UPR upon ER stress, this suggests a possible role of BiP in 
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senescence. It was shown by Gulow et al., 2002, that the translational efficiency 
of BiP is markedly increased upon UPR activation (Gülow et al. 2002). 
Data from a study conducted by Druelle et al., 2016, provided the first evidence 
of the involvement of the ATF6α arm of UPR in response to ER stress in the 
induction of senescence in normal human dermal fibroblasts (NHDF) (Druelle et 
al. 2016). By genetically inactivating the three UPR sensors in NHDF, it was 
demonstrated that the ATF6α arm plays a crucial role in regulating the common 
morphological changes related to the senescent phenotype such as cell 
enlargement, cell shape, increase in SA-β gal activity and ER expansion (Druelle 
et al. 2016). Hence, it can be stated that UPR may control the establishment of 
some of the senescence markers. A recent study regarding the ATF6α arm of 
UPR was shown to mediate replicative senescence in normal human dermal 
fibroblasts via upregulation of the COX2/Prostaglandin E2 intracrine pathway 
(Cormenier et al. 2018). ER stress-related senescence has also recently been 
shown to play a role in the pathology of Osteoarthritis chondrocytes (Liu et al. 
2017). 
Expansion of ER during cellular senescence could also be a consequence of the 
increased demand for protein synthesis, maturation and secretion for production 
of SASP. Hence, increased protein secretory activity caused by activation of the 
SASP leads to pressure on the ER-resident protein folding system, resulting in 
increased amounts of unfolded protein species, which as a consequence activate 
the UPR. 
To better characterize the molecular and functional connections between UPR 
and senescence and to identify universal markers, further research is required 
into monitoring ER stress in senescence as it is not a common practice in the 
senescence field. Only a few studies have monitored the role of ER stress in 
senescence, by using RT-qPCR of different downstream genes  (Chen et al. 
2015).  
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1.3.2 Morphological alterations as Hallmarks of senescence 
1.3.2.1 Cell Size and Shape 
One of the most characteristic features of senescent cells in vitro is the enlarged 
and irregular cell shape. Results obtained from a recent study by Bent et al., 
2016, have implicated the activation of PI3K /AKT/mTOR signalling in enlarged 
endothelial senescent cells (Bent et al. 2016). mTORC1 is a key mediator of the 
PI3K /AKT/mTOR, which is known to integrate different stress stimuli and 
modulate cell growth (Lloyd 2013). mTORC1 activation occurs upon senescence 
induction by a variety of stimuli (Blagosklonny 2012).  
One of the contributors to the senescence-associated changes in cell shape is 
the overproduction of vimentin, an intermediate filament protein (Nishio et al. 
2001). Quantitative and structural changes in vimentin are particularly found in 
different types of senescent cells and aged tissues (Hwang et al. 2009). The 
ATF6α arm of UPR described above also controls the changes in cell shape upon 
senescence in addition to enlargement of ER. These changes in cell shape are 
linked to remodelling of the intermediate filament protein vimentin, thereby 
showing that the observed changes related to increased vimentin expression are 
partly under the control of ATF6α arm of UPR (Druelle et al. 2016). 
Even though it is easy to detect a change in cell size and shape by regular bright-
field microscopy, additionally, targeting cytoplasmic proteins such as vimentin or 
actin using immunofluorescence can also be used to assess changes in cell 
shape. The challenge here lies in detection and quantification of change in cell 
size and shape in vivo within an organism. 
1.3.2.2 Increased Lysosomal Content 
Increased lysosomal content and upregulation of many lysosomal proteins is a 
key feature of the senescent state. Enhanced lysosome biogenesis or 
accumulation of old lysosomes could be the reason behind increased lysosomal 
content observed during senescence. The lack of lysosomal removal leading to 
accumulation of lysosomes and hence the enhanced lysosomal content is 
supported by the presence of residual bodies called lipofuscins which consist of 
lipid-containing residues from lysosomal digestion (Georgakopoulou et al. 2013). 
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To detect the enhanced lysosomal content, the most commonly and widely used 
senescent cell marker is measuring the activity of lysosomal enzyme β 
galactosidase at a suboptimal pH of 6.0, designated as senescence-associated 
(SA)-β galactosidase (Kurz et al. 2000; Dimri et al. 1995). Surprisingly, the 
mechanism behind the overexpression of SA-βgal in the senescent state 
remains to be fully explored. Only recently, a study by Hoare et al., 2016 has 
shown that the NOTCH1 pathway negatively regulates GLB1, the gene encoding 
SA-βgalactosidase enzyme at the transcriptional level (Hoare et al. 2016). Even 
though SA-β gal staining is arguably the most common marker used for 
senescence, the challenge relies in its use in live cells and paraffin-embedded 
tissue, limiting its application only to fresh samples. 
Sudan Black B (SBB) can be used as an alternative marker to detect 
accumulation of lysosomes as it selectively binds to lipofuscins. SBB has the 
added advantage that it can be used for paraffin embedded tissue sections unlike 
SA-β gal (Georgakopoulou et al. 2013). Very recently a lipophilic biotin-linked 
SBB-inspired analogue GL13 was designed and synthesized that allowed 
sensitive and specific, antibody enhanced detection of senescent cells 
containing lipofuscin in a wide variety of biological specimens (Evangelou et al. 
2017). 
However, increased lysosomal activity is not a very specific senescence marker; 
the constitutive expression of SA-β gal activity has been observed in non-
senescent cells suggesting that it is not a marker exclusive to the senescent 
state, nonetheless the most commonly used (Kopp et al. 2007). Even more 
importantly it suggested that senescence was not only an artefact of in vitro 
culture but also occurred in the organism. As it also increases with age, so acts 
as an ageing marker. 
1.3.2.3 Nuclear Changes 
Senescent cells, along with morphological changes in cell size and shape, also 
present characteristic changes in their nucleus such as an enlarged nucleus, 
mostly irregular shaped nuclei and chromatin reorganization. Loss of a structural 
protein of the nuclear lamina, LaminB1, is a widespread marker used for 
detection of different types of senescence (Hernandez-Segura et al. 2017; 
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Sadaie et al. 2013). This decline in LaminB1 leads to other nuclear changes such 
as extrusion of fragments of chromatin from the nucleus to cytoplasm called 
CCFs, arising due to the unselective permeability of nuclear envelope (Adams et 
al. 2013). 
The decline in LaminB1 is regulated at the mRNA level due to the reduced 
LaminB1 mRNA stability rather than caspase-mediated degradation observed in 
apoptosis (Freund et al. 2012). Furthermore, a study by Dreesen et al., 2013, 
has reported the involvement of miR-23a, which is upregulated in senescence. 
This targets LaminB1 and reduces its expression (Dreesen et al. 2013). 
Expression of LaminB1 is downregulated by the p53 and pRB pathways and 
does not depend on other senescence associated pathways such as p38 MAPK, 
DDR, ROS and NF-κB (Freund et al. 2012). 
Chromatin reorganization because of senescence induction can also lead to the 
formation of SAHFs, which are heterochromatin domains densely stained by 
DAPI and rich in HP1γ and H3K9me3 of DNA. These appear possibly to silence 
pro-proliferative genes like E2Fs (Narita et al. 2003). However, SAHFs cannot 
be used as a universal marker for senescence as they can be detected only in 
vitro and are mainly observed during OIS. 
1.3.2.4 The composition of the Plasma Membrane 
The plasma membrane of eukaryotic cells allows cells to communicate with the 
extracellular space via regulation of signal transduction pathways and with 
neighbouring cells. A number of studies have reported one consistent change in 
the plasma membrane composition of senescent cells i.e. upregulated 
expression of caveolin-1, an integral structural plasma membrane protein that 
binds tightly to cholesterol (Park et al. 2000; Volonte et al. 2002; Cho et al. 2003, 
2004). Caveolin-1 has been shown to be responsible for altering the morphology 
and adherent properties of senescent cells (Cho et al. 2004; Inomata et al. 2006). 
Direct interaction of caveolin-1 with signalling molecules in the MAPK pathway 
possibly explains the role of caveolin-1 in promoting cellular senescence (Ohno-
Iwashita et al. 2010). Additionally, findings from the study by Volonte et al., 2015, 
indicate that the main mechanism through which overexpression of caveolin-1 
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promotes stress-induced premature senescence is via increased p53 activity 
(Volonte et al. 2015). This increased p53 activity is achieved by downregulating 
silent information regulator 2 homologue 1 (SIRT1), activating ATM and inhibiting 
MDM2 (Volonte et al. 2015). 
Apart from caveolin-1, other plasma membrane proteins have also been reported 
to show altered expression during senescence. Althubiti et al., 2014, identified 
107 plasma membrane-associated proteins by a proteomics screen, that were 
preferentially expressed in senescent cells (Althubiti et al. 2014). The authors 
also developed a simple and specific flow cytometry-based staining protocol for 
two of them, namely density-enhanced phosphatase-1 (DEP-1) and Beta-2 
Microglobulin (B2MG), for rapid detection of senescent cells in culture (Althubiti 
et al. 2014).  
Another very recent study observed the specific expression of an oxidized form 
of vimentin in the plasma membrane of senescent primary human fibroblasts. As 
oxidized vimentin is secreted, it has the potential to be used as a vital and non-
invasive biomarker for studying senescence (Frescas et al. 2017). Remarkably, 
mass spectrometric analysis conducted by Kim et al., 2017, revealed yet another 
cell membrane-associated protein i.e. dipeptidyl peptidase 4 (DPP4) selectively 
expressed on senescent cells and not on proliferative human diploid fibroblasts 
(Kim et al. 2017). Differential expression of DPP4 allows FACS mediated sorting 
of senescent cells using anti-DPP4 antibody. Furthermore, antibody-dependent 
cell-mediated cytotoxicity (ADCC) assays can also be used for therapeutic 
intervention in conditions where it is desirable to eliminate senescent cells, 
making it a promising target (Kim et al. 2017). 
Multiple different studies have indicated the immense potential for development 
of a plasma membrane based novel marker that will allow specific identification 
of senescent cells. Use of this strategy, provides the added advantage of 
allowing the sorting of senescent cells by targeting specific cell membrane-
associated proteins. 
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1.3.2.5 Accumulation of Dysfunctional Mitochondria 
Many studies have shown close links between mitochondrial dysfunction and its 
role in driving and maintaining senescence (Passos et al. 2007; Correia‐Melo et 
al. 2016; Wiley et al. 2016). Senescent cells have an increased mitochondrial 
mass in replicative as well as oncogene-induced senescence and other stress-
induced senescence (Passos et al. 2007; Moiseeva et al. 2009; Passos et al. 
2010; Tai et al. 2017). The membrane potential of these accumulated 
mitochondria is reduced which leads to release of mitochondrial enzymes such 
as endonuclease G, and enhanced ROS production, showing that the 
mitochondria that accumulate during senescence are dysfunctional (Studencka 
and Schaber 2017; Passos et al. 2007). 
Mitophagy is a selective process which predominantly maintains mitochondrial 
turnover by specifically targeting dysfunctional mitochondria to lysosomes for 
hydrolytic degradation by autophagic sequestration (Kim et al. 2007). The 
accumulation of old and dysfunctional mitochondria mainly occurs due to 
reduced mitophagy in senescent cells which is observed both in vitro and in vivo 
(Dalle Pezze et al. 2014; García-Prat et al. 2016). As mitophagy is a selective 
autophagy for mitochondria, the specificity is achieved by dedicated proteins 
such as Parkin and PINK1 which target mitochondria with reduced membrane 
potential for degradation by tagging them with polyubiquitin chains (Deas et al. 
2011). Increased cytoplasmic p53 during cellular senescence has been reported 
to bind to Parkin and inhibit its translocation to dysfunctional mitochondria 
(Hoshino et al. 2013; Ahmad et al. 2015). This provides an explanation for the 
decline in mitophagy and therefore, accumulation of dysfunctional mitochondria 
in senescence.  
Further research by Dalle Pezze et al., 2014, suggested increased mTOR-
dependent mitochondrial biogenesis and decreased mitochondrial fission during 
reduced mitophagy to be the potential driving force behind the accumulation of 
mitochondria during senescence (Dalle Pezze et al. 2014). This study showed 
that mitophagy only affected new mitochondria but not old ones thereby providing 
an explanation for the accumulation of dysfunctional mitochondria possibly due 
 67 
to the impairment in mitochondrial turnover together with increased mitochondrial 
biogenesis (Dalle Pezze et al. 2014).  
 
Figure 1.8 Morphological alterations as Hallmarks of senescence 
This figure depicts the morphological changes that occur during cellular senescence arising as a 
consequence of different molecular pathways involved in senescence. Figure from (Hernandez-
Segura et al. 2018). 
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1.4 Significance of senescence 
Why did senescence originate in the first place?  
Recently it has been shown that senescence can be a normal programmed event 
which occurs during mouse development. Storer et al., 2013, found that 
senescence-associated -galactosidase positive cells were present at two 
signalling centres in embryonic patterning, namely, the apical ectodermal ridge 
and the neural roof plate (Storer et al. 2013). These senescent cells displayed 
features similar to oncogene-induced senescence. Munoz-Espin et al., 2013, 
discovered that senescence occurs at multiple locations including the 
mesonephros and the endolymphatic sac of the inner ear during mammalian 
embryonic development (Muñoz-Espín et al. 2013). It was also shown that 
senescence was strictly dependent only on p21WAF1 and independent of DNA 
damage as cells were found to be negative for the DDR protein γH2AX, p53 or 
other cell cycle inhibitors. Another very recent study by Davaapil et al., 2017, has 
demonstrated cellular senescence to play an intrinsic part in amphibian 
development, uncovering conserved and new roles of senescence in vertebrate 
organogenesis (Davaapil et al. 2017). Overall, these studies suggested that 
senescence is a programmed mechanism during embryonic development and 
might also be the evolutionary origin of damage-induced senescence (Davaapil 
et al. 2017; Storer et al. 2013; Muñoz-Espín et al. 2013).  
It can be hypothesized that senescence was later co-opted during the 
reproductive age as it provides the beneficial effect of tumour suppression. As 
senescence is a form of growth arrest, this inhibition of cellular proliferation can 
then be beneficial as it prevents tumour formation in early life. Cellular 
senescence-related phenotypes can be both beneficial and deleterious, 
depending on the age of the organism (Campisi 2003). Senescence can be 
deleterious in the later part of life as it blocks tissue repair and renewal, promoting 
age-related phenotypes including tumorigenesis (Campisi 2005). This paradox 
of contrasting roles of senescence is a very good example of an important 
evolutionary theory of ageing called ‘Antagonistic Pleiotropy’ which states that 
pleiotropic traits with beneficial early effects would be favoured by natural 
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selection even if these genes had deleterious at later age (Kirkwood and Austad 
2000; Williams 1957). 
1.4.1 Senescence in vivo 
Since Hayflick's discovery about senescence using cultured cells, most of what 
has been known about senescence has largely come from cell culture studies. 
There is now enough evidence to show that senescence is important and occurs 
in vivo (Jeyapalan et al. 2007). With the help of a number of recently discovered 
senescence markers described above, it has been possible to identify senescent 
cells in vivo.  
In addition to the senescent cells detected during development stages, 
senescent cells have also been found in vivo in many renewable tissues like 
epithelia, stroma, haematopoietic system and vasculature of humans, primates 
and rodents (Dimri et al. 1995; Krishnamurthy et al. 2004). Additionally, a study 
by Demaria et al., 2014, has provided another example of the functional 
relevance of senescent cells in vivo (Demaria et al. 2014). This study 
demonstrated the role of senescent endothelial and fibroblast cells in 
accelerating the closure of cutaneous wound by secreting PDGF-AA at the 
wound site, and inducing differentiation of myofibroblasts (Demaria et al. 2014).  
An increase in the frequency of senescent cells is also observed in normal and 
premature ageing skin of primates (Herbig et al. 2006). It has been found that 
cells which express multiple senescence markers accumulate with age (Campisi 
and D’Adda Di Fagagna 2007). Importantly, senescence has now also been 
reported to play a role in regeneration in salamanders (Yun 2015; Yun et al. 
2015). This has provided new insights as it demonstrates that unlike mammals 
where the regenerative capacity deteriorates with age, in species such as 
salamander it remains intact which allows them to undergo multiple rounds of 
regeneration during their lifespan. Surprisingly, during salamander limb 
regeneration, the unexpected presence of a large number of senescent cells is 
observed. Although, by the time the limb had regrown, these senescent cells had 
disappeared by effective and rapid senescent cell clearance which was found to 
be mainly mediated by macrophages. Due to this effective and rapid clearance 
of senescent cells,  the number of senescent cells does not increase upon ageing 
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in salamander as opposed to the observed increase of senescent cells in 
mammals (Yun et al. 2015). This suggests the potential use of effective 
surveillance of senescent cells in boosting the ability to recover from injuries as 
well as in anti-ageing therapies. 
1.4.2 Senescence and Cancer 
The Bright Side: The novel and crucial role of senescence growth arrest which 
has been established until now is that senescence plays a significant role in 
tumour suppression, preventing the organism from developing cancer (Prieur 
and Peeper 2008; Collado and Serrano 2010). There are many examples of 
studies which have demonstrated the role played by senescence in tumour 
suppression in the presence of an oncogene or during the loss of a tumour 
suppressor protein to prevent uncontrolled neoplastic growth (Salama et al. 
2014; Muñoz-Espín and Serrano 2014).  
One such key example is presence of multiple links between genetics of 
melanoma and cellular senescence such as the CDKN2A gene, the commonest 
known high penetrance melanoma susceptibility gene which as described 
previously encodes two key effectors of senescence i.e. p16INK4A and p14ARF. 
The presence of large number of senescent melanocytes that express multiple 
different senescence markers in cutaneous benign nevi also shows the role 
played by senescent cells in tumours. Therefore, evasion of cellular senescence 
is crucial to generation of metastatic cutaneous melanoma (Bennett 2016).  
It is also known that some of the SASP components under certain circumstances 
help in establishing the tumour suppressive growth arrest of senescent cells. For 
example, IL-6, IL-8, IGFBP7 and GROα help establish oncogene-induced 
senescence caused by oncogenes like RAS and BRAF (Kuilman et al. 2008; 
Wajapeyee et al. 2008; Yang et al. 2006; Campisi 2013). If senescence is 
bypassed by disruption of tumour suppressor pathways, cells undergo crisis, 
which occurs when cells continue to divide with short telomeres. During crisis, 
the fusion of chromosomes stimulates mitotic arrest leading to mitotic telomere 
de-protection and cell death which eventually eliminates precancerous cells from 
the population  (Hayashi et al. 2015). Hence, two barriers namely replicative 
senescence and crisis block tumour formation.  
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The Dark Side: There is increasing evidence that senescent cells can drive 
hyperplastic pathology and therefore can stimulate cancer progression. Several 
components of SASP are incriminated in tumour progression, like VEGF, which 
promotes tumour cell driven angiogenesis, and MMP3 which enhances tumour 
cell invasion and metastases by degradation of the extracellular matrix, thereby, 
the basement membrane (Coppé et al. 2006; Liu and Hornsby 2007). 
Furthermore, SASP constituents can also induce the malignant phenotype in cell 
culture studies, the key phenotype being epithelial to mesenchymal transition 
(Laberge et al. 2012). This morphological transition allows transformed epithelial 
cells to intrude and migrate via tissues and promote metastasis by secretion of 
SASP components like IL-6 and IL-8 (Coppé et al. 2008; Parrinello 2005). SASP 
is also capable of causing inflammation by releasing inflammatory cytokines that 
induce infiltration of leucocytes, thereby generating reactive toxic species which 
have the potential to cause DNA damage and hence initiate cancer (Freund et 
al. 2010). 
1.4.3 Senescence and Ageing 
Hayflick for the first time interpreted senescence to be related to ageing at the 
cellular level and possibly at the organismal level in humans, after noticing the 
presence of an inverse correlation between the proliferative potential of isolated 
cells and the age of the donor (Hayflick 1965; Hayflick and Moorhead 1961). It is 
now well established that senescent cells promote organismal ageing. As 
described above, senescent cells are resistant to apoptosis, which leads to 
accumulation of senescent cells with age (Marcotte et al. 2004; Hampel et al. 
2005; Wang et al. 2009a). It is also seen that cells expressing more than one 
senescence markers are comparatively rare in young organisms and their 
number keeps on increasing with age (Campisi and D’Adda Di Fagagna 2007).  
This accumulation of senescent cells can promote age-related pathologies by 
three possible ways. First, senescent growth arrest can attenuate 
stem/progenitor cell reserves which can cause functional decline as a result of 
reduced tissue repair, regeneration and normal replenishment of cells 
(Drummond-Barbosa 2008; Aravinthan 2015). Second, factors secreted by 
senescent cells into their microenvironment affect crucial processes like 
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angiogenesis, differentiation, migration, tissue architecture and cell growth. This 
inappropriate presence can lead to disruption of tissue structure and function 
(Rodier and Campisi 2011). Third, SASP comprises several potent inflammatory 
cytokines (Freund et al. 2010). If not all, most of the age-related pathologies stem 
from low-level, chronic inflammation, a theory described as ‘inflammaging’ 
(Franceschi and Campisi 2014; Franceschi et al. 2007; Chung et al. 2009). The 
inflammatory oxidative damage caused by SASP components creates an 
inflammatory microenvironment which stimulates onset and progression of 
different age-related disorders including cancer (Lecot et al. 2016; Allavena et al. 
2008; Grivennikov et al. 2010).  
Furthermore, different epigenomic changes associated with senescence, such 
as changes in the chromatin state and transcriptional networks, can lead to 
altered gene expression with age and contribute to the age-associated decline 
(Booth and Brunet 2016). The number of studies reporting the involvement of 
senescence in multiple different age-related disorders such as osteoarthritis, 
atherosclerosis, obesity, hair-greying, macular degeneration and sarcopenia is 
constantly increasing  (He and Sharpless 2017; Campisi 2013; De Keizer 2017). 
One of the most fundamental questions about the role of senescence in ageing 
is that of whether the removal of senescent cells has the potential to increase the 
lifespan? This is demonstrated very well by experiments conducted by Baker and 
colleagues (Baker et al. 2011). A transgenic progeroid BUBR1-mouse model was 
used in these experiments in which senescent cells, mainly p16INK4A positive 
cells, could be eliminated by administration of a drug (AP20187). This was based 
on a transgenic strategy wherein a novel transgene INK-ATTAC was designed 
for inducible elimination of p16INK4A positive cells. The removal of p16INK4A 
senescent cells in the premature ageing mouse model protected them from 
several age-related pathologies consisting of cataracts in the eye, sarcopenia in 
skeletal muscle and loss of subcutaneous fat from adipose tissue, thereby 
extending the healthspan (Baker et al. 2011). In a more recent study using the 
same transgene experiments performed in a wild-type non-progeroid mice, 
Baker et al., 2016, demonstrated that naturally occurring p16INK4A cells are also 
involved in the age-related deterioration of multiple organs including eye, kidney, 
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heart and progression of neoplasia (Baker et al. 2016). These experiments 
suggest the possibility of therapeutic removal of senescent cells in preventing or 
delaying dysfunction and extending healthy lifespan.  
As described above in section 1.3.2.3, senescent cells present characteristic 
nuclear changes with compromised nuclear lamina integrity. Recently, a 
premature ageing disease called Hutchinson-Gilford Progeria Syndrome (HGPS) 
has been found to be caused by mutations in the LMNA gene. In HGPS, aberrant 
splicing of the LMNA gene leads to accumulation of a mutant Lamin A protein 
called progerin which interestingly is also produced in senescent cells, 
suggesting the accumulation of progerin to be a factor in physiological ageing 
(Gonzalo et al. 2017).  
1.5 Model of Study 
Cellular senescence is mainly studied by the serial cultivation of primary cells. 
One of the key stumbling blocks in studying senescence in vitro is the 
heterogeneous nature of cells growing in a culture. This heterogeneous 
behaviour occurs because, in a culture, cells tend to senesce asynchronously 
because of the genetic, epigenetic and phenotypic variations between cells. In 
such heterogeneous cultures, there can be senescent cells in early passages 
and proliferating cells towards later passages. Such a state can mask small 
changes in gene expression when comparing actively proliferating cells against 
senescent cells. Study with human cells is further complicated by genetic, 
epigenetic and proliferative variation between different donors as well as 
phenotypic differences between cells within cultures. To simplify this process 
many investigators study stress or irradiation or oncogene-induced senescence 
due to the expression of activated oncogenes such as K-RasV12, Raf or 
BRAFV600E, where it occurs prematurely and can be induced acutely in a 
variety of cell types (Collado et al. 2007). 
To overcome the above-mentioned barriers, a unique conditionally immortalised 
Human Mammary Fibroblasts (HMF) cell model has been used in this study in 
which the cells in a culture can all be made to senesce synchronously. This cell 
line was immortalised by retrovirally introducing hTERT, the catalytic subunit of 
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telomerase (Vaziri and Benchimol 1998; Bodnar et al. 1998) and a temperature 
sensitive (ts) non-DNA binding mutant of SV40 LT antigen (U19tsA58) into early 
passage primary adult interlobular mammary fibroblasts, as either hTERT or 
SV40 LT antigen alone were not sufficient to immortalise these cells (Counter et 
al. 1998; Kiyono et al. 1998). Following this, four different cell lines were created 
(HMF 3A, B, C, D) depending on the discrete order and timing of transduction of 
the two components. It was found that the order and timing of introduction of tsLT 
antigen and hTERT subunit did not affect the generation of immortalised cell line, 
but it affected the genomic stability. Out of the four, HMF3A, was selected, where 
both genes were introduced at early passage with transduction of tsLT antigen 
first followed by hTERT subunit. HMF3A was identified to be the most like 
‘normal' cells in terms of phenotypic stability, temperature sensitivity and showed 
no transformation for more than 300 population doublings post-explantation 
(O’Hare et al. 2001; Hardy et al. 2005).  
The beauty of the model arises from the use of a temperature-sensitive variant 
of the SV40LT antigen. The SV40LT antigen is known to bind and inactivate the 
activity of several proteins including p53 and RB that are known to be important 
in establishing and maintaining the senescent state (Ali and DeCaprio 2001). The 
reason why p53 is activated upon T antigen inactivation in CL3 cells is because 
T antigen is no longer active and thus it is not there to inactivate p53. This 
remarkable conditionally immortalised HMF3A cell line is stringently temperature 
sensitive. They are immortal when grown at a permissive temperature of 33°C - 
34°C, as tsSV40LT antigen is active leading to inactivation of p53 and RB and 
hence senescence cannot occur. On the other hand, when cells are shifted to a 
higher non-permissive temperature of 38°C - 39.5°C, the tsSV40LT thermolabile 
antigen is inactivated, allowing the p53/p21WAF1 and p16INK4A/pRB pathways to 
act and hence stable cellular senescence occurs synchronously within seven 
days (Rovillain et al. 2011). The growth of these cells is entirely dependent on 
the tsLT antigen’s activity to bind and inhibit p53 and pRB activity as telomerase 
remains constitutively active both at the permissive and non-permissive 
temperatures. 
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As these cells are now capable of inducing senescence synchronously in culture, 
making conditionally immortalised HMF3A an appropriate model for dissecting 
the pathways underlying cellular senescence, by investigating the ability of target 
genes to complement the growth of these cells under non-permissive conditions. 
Another reason why this conditionally immortalised HMF3A system represents a 
potential system for addressing the aims of this thesis, is due to the fact that the 
transcriptional changes that occur upon the conditional HMF3A growth arrest 
directly correlate with the transcriptional changes that occurred upon replicative 
senescence in normal human mammary fibroblasts (Hardy et al. 2005).   
This HMF3A model was further refined by Drs Louise Mansfield and Emily 
Rovillain by engineering the HMF3A cells to express a full length murine 
ecotropic retroviral receptor to facilitate efficient retroviral infection. Introduction 
of the murine ecotropic receptor provided the advantage of increased 
transduction efficiency along with increased safety as ecotropic viruses unlike 
amphotropic viruses are incapable of infecting human cells. After the introduction 
of the murine ecotropic receptor, 24 single cell clones were selected to create a 
refined clonal model to produce a consistent and homogeneous population as 
opposed to studying senescence bypass in the mixed population of HMF3AEcoR 
cells. After growing the 24 clones, 6 fast growing clones were selected for further 
analysis and compared to the mixed cell population of parental HMF3AEcoR in 
terms of growth rates, irreversibility, infectibility with retroviruses and temperature 
dependent growth. Even though all 6 clones exhibited temperature-dependent 
growth, Clone 3 (CL3EcoR) cells most closely mirrored the parental cells in their 
temperature dependent growth characteristics. They undergo stable growth 
arrest within seven days at the high non-permissive temperature of 38°C which 
is essentially irreversible, express SA-β- galactosidase, the most common and 
widely used marker for senescence and exhibit the same changes in morphology 
as mixed population of parental cell line HMF3AEcoR (Rovillain et al. 2011). 
Hence, CL3EcoR cells were validated to be a representative of the mixed 
population of parental HMF3AEcoR cells. 
Furthermore, CL3EcoR cells demonstrated similar results like HMF3AEcoR wherein 
the growth arrest was predominantly dependent upon p53/p21WAF1 pathway 
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since it is most efficiently abrogated when it is inactivated. While inactivation of 
the p16INK4A/pRB pathway also prevented growth arrest, it was much less 
efficient and occur in a much smaller number of cells compared to when p53-
p21WAF1 was inactivated. This support the possibility of both pathways acting in 
parallel and pRB does not necessarily always act downstream of p53 to induce 
senescence. Microarray expression profiling studies were conducted on these 
CL3EcoR cells (Rovillain et al. 2011).  
 
Figure 1.9 Generation of the CL3EcoR cells. 
This figure describes the stepwise engineering of the conditionally immortalised human 
mammary fibroblasts CL3EcoR cells used in this thesis, from the human breast primary fibroblasts. 
The clonal selection was conducted to produce a homogeneous cell population. 
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1.6 Project aims 
The aim of this project was to prioritize and identify TFs from the previously 
identified differentially expressed genes when CL3EcoR cells undergo senescence 
and investigate their functional role in cellular senescence of CL3EcoR cells. It is 
known that mechanisms underlying senescence growth arrest primarily involve 
p53/p21WAF1 and p16INK4A/pRB tumour suppressor pathways (Adams 2009), but 
it is not known what makes the growth arrest stable; what the critical targets are; 
and what downstream transcription factors are involved, as they are likely to be 
the key for the establishment and maintenance of the senescent state. Hence, 
the main aim of this thesis was to identify transcription factors that act 
downstream of the p53/p21WAF1 and p16INK4A/pRB pathways to regulate 
senescence growth arrest. To achieve this goal, I will: 
 Prioritize and shortlist the differential TFs from the previous microarray 
study conducted in the lab in CL3EcoR cells. 
 Prepare expression constructs for the prioritized TFs. 
 Determine if silencing the expression of up-regulated TFs individually 
bypasses senescence. 
 Determine if ectopic expression of down-regulated TFs individually 
bypasses senescence. 
 Determine if reconstituting the active DREAM associated complex i.e. 
(MMB-FOXM1) bypasses senescence. 
 Identify the critical components of the MMB-FOXM1 complex that play a 
crucial role in bypassing cellular senescence. 
 Identify if there is a cocktail of TFs that when used in conjunction will 
synergize to bypass senescence efficiently.  
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Chapter 2 Materials and Methods 
2.1 Mammalian cell culture 
All the cell culture experiments were performed in a designated Class II biosafety 
cabinet within a containment level II laboratory following aseptic techniques to 
ensure sterility. 
Cell lines used for the study:  
- HMF3ACL3EcoR (CL3EcoR) cells were used to study bypass of senescence. 
- HEK 293T cells were used to prepare lentiviruses for transducing CL3EcoR 
cells. 
Culture medium used: High glucose, pyruvate Dulbecco’s Modified Eagle 
Medium from Life Technologies, Gibco® supplemented with 10% volume per 
volume (v/v) heat-inactivated Foetal Calf Serum (FCS), 100 units/ml Penicillin, 
100 µg/ml Streptomycin and 2 millimolar L-Glutamine. 
2.2 Maintaining the Cell Lines 
CL3EcoR: Cells were passaged at a stage when they were close to confluency, 
using 1 ml 1X Trypsin-EDTA solution (0.05%) per flask to detach adherent cells. 
Medium was removed, and the cells were washed with sterile phosphate 
buffered saline (PBS) without calcium and magnesium. This was done to remove 
traces of culture medium as it contains FCS which is known to inhibit trypsin 
activity. Trypsin was left on cells for one minute at 33°C, following which the cells 
were tapped to detach them from the flask. The flasks were then checked for 
complete detachment of cells under a microscope. The cells were resuspended 
in complete DMEM and centrifuged at 1000 rpm for three minutes. The cell pellet 
was then re-suspended in fresh medium. 
If a specific number of cells were to be seeded, 13 µl sample of the suspension 
was added on to C-chip disposable haemocytometer from NanoEntek for 
counting. The appropriate volume of cell suspension (according to split ratio or 
cell number) was transferred to the required number of flasks and culture 
medium was added to make up the volume to 15 ml for T-75 and 7 ml for T-25.  
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CL3EcoR cells were maintained in T-75 flasks at 33°C at 5% CO2, with 1:5 
passaging twice a week (normally Monday and Thursday).  
HEK293T: HEK293T cells were obtained from ATCC and grown in 10 cm culture 
dishes at 37°C at 5% CO2. They were passaged at 1:5 on Mondays and 
Wednesday and at 1:6 on Fridays after checking for confluency. When re-
suspending HEK293T, cells had to be vigorously pipetted to break up cell clumps 
to ensure that cells grew as a monolayer. 
The experiments were all done at almost the same passage level, by repeatedly 
going back to frozen stocks. 
2.3 Freezing cells 
To keep stocks of the cell lines to be used for experiments, they were stored in 
liquid nitrogen. Cells when close to confluence were trypsinized, resuspended in 
medium and centrifuged at 1000 rpm for three minutes to remove trypsin. The 
cell pellet was then resuspended in Freezing Medium which comprised FCS 
supplemented culture medium with 10% DMSO (dimethyl sulfoxide). 1 ml 
aliquots of cells in freezing medium were then transferred to labelled cryovials. 
Cryovials were stored overnight at -80°C in several layers of tissue or in a 
freezing container to gradually decrease the temperature and prevent cells from 
the sudden shock of a very low temperature. Cryovials were then transferred to 
liquid nitrogen the next day.  
2.4 Reviving cells from Liquid Nitrogen 
Cells were thawed rapidly at 37°C in a water bath and added to 9 ml of complete 
medium and centrifuged at 1000 rpm for three minutes. The medium was 
aspirated quickly to remove DMSO which is toxic to cells at warm temperatures. 
The cell pellet was then gently resuspended in a required volume of fresh 
medium and plated in T25 flasks/10 cm dishes and incubated at the appropriate 
temperature and 5% CO2. When the cells reached sub-confluence, they were 
then passaged as described above.   
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2.5 Packaging of Lentiviral Constructs 
Lentiviruses were used to stably transduce CL3EcoR cells. The ORF’s (Open 
Reading Frame) for each gene of interest was inserted into either pLX301 or 
pLEX-MCS lentiviral vectors by recombinational cloning or by DNA manipulation. 
shRNAmiRs for upregulated TFs were inserted into the pGIPZ lentiviral vector 
Figure 2.1. Lentiviral stocks were prepared in HEK293T cells using the following 
protocol: 
Day 1: HEK293T cells were seeded by splitting a nearly confluent plate at a ratio 
of 1:5 and incubating the cells in complete DMEM overnight at 37C. 
Day 2: Transfection was carried out by preparing a mix consisting of 1.5 µg of 
lentiviral vector DNA, 1 µg of lentiviral Gag/Pol expression vector and 1 µg of 
VSV-G viral envelope expression vector pMDG.2 (UCL RNAi silencing 
consortium) in a total volume of 15 µl (made up with Tris: EDTA buffer, TE at pH 
8.0). In a separate microcentrifuge tube, 200 µl of reduced serum Opti-MEM (Life 
Technologies, Gibco®) medium was added. To this tube 10 µl of FuGENE 6-
Transfection Reagent (Promega) was added to the centre of the tube and mixed 
by flicking. 15 µl of prepared transfection mix was added to the Opti-
MEM/FuGENE mix. This final mix was flicked to mix all the contents and allowed 
to stand for 15 minutes at room temperature. Meanwhile, the medium on the 
HEK293T cells was replenished with fresh medium very gently along the sides 
of the dish to prevent detachment as HEK293T cells detach rapidly. After 15 
minutes the Opti-MEM/DNA/FuGENE mix was added dropwise to HEK293T 
cells and swirled gently and incubated overnight at 37°C and 5% CO2 / 20% O2. 
Day 3: The medium was changed to high serum medium i.e. DMEM containing 
15% FCS in the morning. 
Day 4: To harvest Round 1 lentivirus, the supernatant was collected in a 10 ml 
syringe and filtered through a 0.45-micron filter into a fresh tube and frozen 
immediately at -80C, if the infections were not done with the fresh lentivirus the 
same day. 10 ml high serum medium was again added gently to the cells and 
incubated at 37C overnight. 
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Day 5: Round 2 viruses were collected the same way as described above and 
aliquots stored immediately at -80C until required. 
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C. 
 
 
 
 
Figure 2.1 Maps of lentiviral vectors used. 
A. pLX301 B. pLEX-MCS and C. pGIPZ 
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2.6 Lentiviral Infection 
Lentiviral infections were carried out as follows: 
Day 1: CL3EcoR cells were counted using a C-chip haemocytometer and seeded 
at a density of 100,000 cells per T-25 flask. 
Day 2: Appropriate lentiviruses produced by above-described protocol were 
thawed, if the freshly harvested virus was not used. A 5 ml (for down-regulated 
TFs) or 2 ml (for up-regulated TFs) aliquot of lentivirus was added to each flask 
of CL3EcoR cells. To increase the efficiency of transduction, double infections 
were conducted where lentivirus was added twice within a span of 10 to 12 hours 
approximately. To facilitate infection Polybrene (hexadimethrine bromide, 
Millipore) was added at a working concentration of 8 µg/ml from the stock of 10 
mg/ml. The volume of medium in the flask was made up to 7 ml by adding 
complete DMEM.  
Day 3 and 4: Fresh medium was added, and flasks were incubated at 33C for 
two days. 
Day 5: To select for successfully and stably transduced cells, the medium was 
changed to selection medium which contained puromycin (2 µg/ml or 6 µg/ml) as 
puromycin is the mammalian selection marker for the lentiviral vectors used i.e. 
pLX301, pLEX-MCS and pGIPZ.  
Day 6 and 7: Flasks containing the selection medium were incubated at 33C for 
at least two days. 
Day 8: Flasks were examined under a phase contrast tissue culture microscope 
to see if there were enough numbers of survivors to reseed 35,000 or 50,000 
cells in triplicate. If yes, then cells were trypsinized and reseeded at the 
appropriate number in triplicate in T-75 flasks and incubated overnight at 33C 
to adhere and stabilize. If not, the survivors were allowed to grow at 33C until 
enough cells were present with a medium change. A control flask was always 
plated along with the experiment, in which non-infected CL3EcoR cells were 
maintained simultaneously. After adding selection medium by Day 8 normally 
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90% of the cells are dead in the control flask. This is done to confirm that 
selection had worked successfully, also confirmed successful transfection. 
Day 9: The following day the cells were shifted to the non-permissive 
temperature: 37.8C-38.9C. Cells were then maintained at the non-permissive 
temperature for three weeks with weekly medium change with 15 ml of complete 
DMEM.  
To determine the extent of senescence bypass, flasks were stained after three 
weeks with 2% Methylene blue stain in 50% ethanol and 50% distilled water. 
After removing the medium from the flasks, the stain was added and incubated 
for at least 30 minutes and then washed under running tap water. After air drying, 
the flasks were photographed, and the number of densely growing colonies 
visible as blue foci were quantified.  
A combination of qualitative and quantitative approaches was used to determine 
the extent of senescence bypass. For quantitative analysis, two different 
approaches were taken. First, the growing dense blue colonies were 
independently counted twice manually on a lightbox, using a non-biased 
approach by randomly selecting the flask to be counted. The second approach 
used the Definiens Developer XD software wherein, an algorithm was developed 
by Dr Matthew Ellis (Image analyst, Division of Neuropathology, UCL) to 
calculate the area of the flask stained blue. This enabled determination of the 
extent of senescence bypass, as the higher the area covered in blue, the 
stronger is the bypass potential. To see if both the methods used generated 
similar results, the data for every experiment was plotted as ‘Number of growing 
colonies' when counted manually as well as ‘Percentage area stained' when 
calculated by the software. 
2.7 Mycoplasma Testing 
To maintain clean contamination free cell lines LookOut® Mycoplasma PCR 
detection kit (Sigma-Aldrich) was used. It is a highly sensitive method to detect 
Mycoplasma and Acholeplasma contamination in cell cultures. The whole 
procedure was done in four steps which are as follows: 
 84 
Preparation of Sample: Samples to check for Mycoplasma were derived from the 
medium supernatant of cultures of cell lines i.e. CL3EcoR and HEK293T after they 
had reached 90-100% confluence. DNA was extracted using GenEluteTM Blood 
genomic DNA Kit from Sigma Aldrich after boiling 500 µl of the supernatant 
collected at 95°C for five minutes.  
PCR Set up: The DNA isolated after the extraction procedure was used to set up 
the PCR reaction as follows. The total volume for each PCR reaction was 25 µl. 
Table 2.1 Constituents of PCR reaction for mycoplasma test 
 
 Sample Positive 
Control 
Negative 
Control 
DNA 
Polymerase/Rehydration 
Buffer 
23 µl 25 µl 23 µl 
Sample Volume 2 µl - - 
DNA free water - - 2 µl 
 
DNA Polymerase/Rehydration Buffer Preparation: The required volume of the 
Rehydration Buffer was pipetted into a clean amplification tube and the required 
volume of DNA polymerase was added. For JumpStart Taq Polymerase with 2.5 
units/µl, a volume of 0.5 µl is required per reaction. The DNA 
Polymerase/Rehydration Buffer was carefully mixed by flicking the tube. 
Tube preparation: Appropriate number of tubes for the negative control and 
samples were removed from the bag. Protective films from the tubes were peeled 
off and 23 µl of the prepared DNA polymerase/Rehydration Buffer was added to 
each reaction tube. 2 µl of DNA free water was added to the negative control and 
2 µl of the sample was added to each sample reaction tube. The appropriate 
number of positive control reaction tubes were removed from the bag and 
labelled. 25 µl of the prepared DNA polymerase/Rehydration Buffer was added 
to each tube. 
 85 
Incubation: The contents of each tube were mixed thoroughly by flicking the 
tubes. The liquid in the tube was collected at the bottom of the PCR tube and 
incubated at room temperature for five minutes, followed by thermal cycling. 
Thermal Cycler Program: The following thermal cycler program was used for the 
PCR reaction on a MJ Research PTC-200 Thermal cycler: 
40 cycles         94°C for 30 seconds 
                         55°C for 30 seconds 
                         72°C for 40 seconds 
Cool down to 4-8°C. 
Agarose Gel and Evaluation: 1.2% standard agarose gel was used with a 5 mm 
comb. 8 µl of each PCR reaction was directly loaded. The loading buffer was pre-
included in the PCR mixture. Electrophoresis was stopped after the dye had 
migrated approximately 2.5 cm. 
 
 
 
 
 
 
 
Figure 2.2 Relevant amplicon bands for Mycoplasma testing. 
The negative control samples show a distinct 481 bp band. Internal controls appear in every lane 
indicating a successful PCR. The positive control shows a band at 259 bp along with the internal 
control 481 bp band. Mycoplasma positive samples, if any should show bands in the range of 
260±8 bp. The intensity and thickness of the band (260±8 bp) is an indication of the extent of 
mycoplasma contamination. 
 
 86 
2.8 Bacterial Manipulations 
2.8.1 Bacterial strains 
For most of the transformations, plasmid manipulation and preparations 
conducted in this study, competent cells made from the JS4 Escherichia coli 
strain, which is a recA derivative of MC1061 (a kind gift from J. Sedivy, Brown 
University) were used (Sedivy et al. 1987). DH5-α super-competent cells from 
ThermoScientific were also used. One Shot™ ccdB Survival™ 2 T1R Competent 
Cells (ThermoScientific) were used for propagation of plasmids containing the 
ccdB gene. In this thesis, they were used for propagating the Gateway 
destination entry vector pLX301. 
2.8.2 Medium and Bacterial growth 
E. coli were grown in Luria Base (LB) Broth (25 g/l Luria Broth Base; Invitrogen) 
or Super broth [(10 g MOPS (4- Morpholinepropanesulphonic acid) sodium salt 
(Sigma), 20 g yeast extract (Oxoid), and 32 g tryptone (Oxoid) per litre].  15 g/l 
of agar (Oxoid) was added when LB agar was prepared.  To make up the 
medium, all the components were dissolved in distilled water and autoclaved for 
20 minutes at 121°C under high pressure.  Desired antibiotics were added as 
appropriate: kanamycin (Sigma) was added at a final concentration of 50 µg/ml, 
ampicillin (Sigma), spectinomycin (Sigma) and carbenicillin (Sigma) was added 
at a final concentration of 100 µg/ml, and chloramphenicol was added to a final 
concentration of 30 µg/ml. 
2.8.3 Bacterial Transformation 
For bacterial transformations, competent JS4 cells were used. Each 50 µl aliquot 
of JS4 competent cells was thawed on ice. The JS4 strain can be made up to a 
maximum volume of 1 ml using cold sterile 0.1 M CaCl2. The required number of 
sterile Eppendorf tubes were pre-chilled on ice. 100 µl of the JS4 cells were 
aliquoted into each pre-chilled tube. DNA was added to the bacteria and the 
reactions swirled gently and incubated on ice for 30 minutes. After 30 minutes, 
JS4 cells were given a heat shock for 90 seconds at 42C. After the heat shock, 
tubes were incubated on ice for 2 minutes. 500 µl of LB broth was added to each 
tube and incubated at 37°C without shaking for an hour. After one-hour cells 
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were spun on a desktop centrifuge at 13000 rpm for one minute to pellet the 
bacteria. The pellet was re-suspended in a small volume and plated on a LB agar 
plate containing the appropriate antibiotic. Plates were then incubated at 37°C 
for >16hours. 
For DH5-α super-competent cells and One Shot™ ccdB Survival™ 2 
T1R Competent Cells the same transformation protocol described above was 
used with heat shock given for only 30 seconds and 250 µl of the S.O.C. medium 
provided with the kit was used. 
2.9 DNA Manipulations 
2.9.1 Genomic DNA isolation  
From cell culture supernatant:  
To extract DNA from the supernatant of cell cultures to check for Mycoplasma, 
GenEluteTM Blood genomic DNA Kit Protocol from Sigma Aldrich was used.  
To 200 µl of the supernatant boiled at 95°C for 5 minutes, 20 µl of Proteinase K 
solution was added in a 1.5 ml microcentrifuge tube and vortexed. 200 µl of Lysis 
Solution was added to the sample and vortexed thoroughly for 15 seconds as a 
homogeneous mixture is essential for efficient lysis. The tube was then incubated 
at 55°C for 10 minutes. 500 µl of the Column Preparation Solution was added to 
each pre-assembled GenElute Miniprep Binding Column and centrifuged at 
12,000xg for one minute. Flow through liquid was discarded. This step 
maximises binding of DNA to the membrane resulting in more consistent yields. 
200 µl of absolute ethanol (95-100%) was added to the lysate and mixed 
thoroughly by vortexing for 5 to 10 seconds to produce a homogenous solution. 
The entire contents of the tube were transferred to the treated column and 
centrifuged at ≥ 6500xg for 1 minute. The collection tube containing the flow 
through liquid was discarded and a new 2 ml collection tube was placed on to 
the column. 500 µl of Wash Solution diluted with ethanol was added to the 
column and centrifuged for 3 minutes at maximum speed. The collection tube 
containing the flow through liquid was discarded and a new 2 ml collection tube 
was placed on to the column. The column must be free of ethanol before eluting 
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the DNA. The column was centrifuged for an additional one minute at maximum 
speed to get rid of any residual ethanol. The collection tube containing the flow 
through was discarded and a new 2 ml collection tube was placed on to the 
column. To elute the DNA, 200 µl of the Elution Solution was directly pipetted 
into the centre of the column and incubated for five minutes at room temperature 
to increase the elution efficiency. After five minutes the tube was centrifuged at 
≥6500g for one minute to elute the DNA.  
From growing cells:  
To extract genomic DNA from cells that were stably transduced with the mixture 
of 73 TFs (Pool 73) and had bypassed senescence at the non-permissive 
temperature, Illustra Nucleon Genomic DNA Extraction Kit from GE healthcare 
was used. The Illustra Nucleon blood and cell culture 1 (BACC1) protocol was 
used as it was designed for genomic DNA isolation from 1 to 3 x 106 cultured 
cells. 
Cell Preparation: Stably transduced CL3EcoR cells growing at 38.9C for three 
weeks were trypsinized and collected by centrifugation at 600xg for 5 minutes at 
4C. The supernatant was discarded very gently without disturbing the pellet. 
Cell Lysis: The cell pellet was resuspended in 1.0 ml Reagent A provided in the 
kit and left on ice for 5 minutes. After five minutes, tube was centrifuged at 
1300xg for 5 minutes and the supernatant was discarded. To the pellet, 350 µl 
of Reagent B was added. The tube was vortexed briefly to resuspend the pellet. 
The suspension was transferred to 1.5 ml microcentrifuge tube. 
Deproteinization: 100 µl of sodium perchlorate solution was added. The tubes 
were mixed by hand, by inverting the capped tube at least 7 times. 
DNA Extraction: 600 µl of chloroform was added and mixed by hand, by inverting 
the capped tube at least 7 times.150 µl of Nucleon resin was added without 
remixing the phases. The tube was then centrifuged at 350xg for 1 minute.  
DNA precipitation: Without disturbing the Nucleon resin layer which is brown in 
colour, the upper phase (approximately 450 µl) was transferred to another clean 
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1.5 ml microcentrifuge tube. To precipitate the DNA, 2 volumes, i.e. 900 µl, of 
cold absolute ethanol was added. The preparation was then mixed by inversion 
until the precipitate appeared. 
DNA Washing: To pellet the DNA the microcentrifuge tube was centrifuged at top 
speed for five minutes. The supernatant was discarded. The same step was 
repeated after addition of 1 ml of cold 70% (v/v) ethanol and mixing several times. 
The pellet was left for airdrying for at least 20 minutes to ensure that all the 
ethanol had evaporated. The DNA was then dissolved in an appropriate volume 
of TE buffer. 
2.9.2 Small scale plasmid preparation 
QIAprep Spin Miniprep Kit from Qiagen was used.15 ml of bacterial culture grown 
overnight from a single colony or glycerol stock was pelleted by centrifugation at 
4000 rpm for 10 minutes at room temperature. The pelleted bacterial cells were 
resuspended in 250 µl of buffer P1 and the contents transferred to a 
microcentrifuge tube. 350 µl of buffer P2 was added and mixed thoroughly by 
inverting the tubes 4 to 6 times until the solution becomes clear. 490 µl of buffer 
N3 was added and mixed immediately and thoroughly by inverting the tube 4 to 
6 times. The tubes were then centrifuged at 13,000 rpm in a bench top micro-
centrifuge for 10 minutes. Supernatant from the tube was carefully pipetted on to 
a QIA prep spin column and centrifuged for one minute at 13,000 rpm. Flow 
through was discarded. The QIA prep spin column was washed by adding 500 
µl buffer PB, centrifuged for a minute at 13,000 rpm and the flow through was 
discarded. QIA prep spin column was washed again by adding 750 µl of buffer 
PE, centrifugation for one minute at 13000 rpm and discarding the flow through. 
To remove any residual wash buffer, the column was centrifuged again for one 
min at 13,000 rpm. QIA prep column was placed in a clean 1.5 ml microcentrifuge 
tube. To elute DNA, 50 µl buffer EB (10 mM Tris.Cl, pH 8.5) was added to the 
centre of the QIA prep spin column and allowed to stand for three minutes. After 
the incubation, the tube was centrifuged at 13,000 rpm for two minutes to elute 
the DNA. The microcentrifuge tube was labelled and stored at -20°C. 
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2.9.3 Large scale plasmid preparation 
Large-scale plasmid preparation was done for pMDG.2 and p8.91 plasmids used 
for lentivirus production by QIA filter plasmid Maxi Kit from Qiagen. 1 µl of each 
of these plasmids were transformed into JS4 cells when the quantity of DNA was 
running low. A single colony was picked and used to inoculate 10 ml of LB super 
broth with antibiotic overnight at 37°C with shaking at 220 rpm. Next day this 
culture was used to inoculate 250 ml of super broth plus antibiotic in a sterile 
conical flask. Cultures were grown at 37°C shaker incubator at 220 rpm for 48 
hours. After 48 hours the bacterial culture was harvested by centrifugation at 
8000 rpm for 15 minutes at 4°C. The pellet obtained was completely 
resuspended in 10 ml of buffer P1 by vigorous vortexing. 10 ml of buffer P2 was 
added and mixed by inverting the sealed tube 4 to 6 times. The tube was then 
incubated at room temperature for 5 minutes. During this incubation, the cap was 
screwed on to the outlet nozzle of the QIA filter Cartridge and placed in a QIA 
rack. After five minutes, 10 ml pre-chilled buffer P3 was added to the lysate and 
mixed immediately and thoroughly by inverting the tube 4 to 6 times. The lysate 
was then poured into the barrel of the QIA filer Cartridge and incubated at room 
temperature for ten minutes. Meanwhile, the QIAGEN-tip was equilibrated by 
applying 10 ml buffer QBT and allowing the column to empty by gravity flow. After 
ten minutes the cap from the QIA filter cartridge was removed from the outlet 
nozzle. The Plunger was gently inserted into the QIA filter Cartridge and the cell 
lysate was filtered into the equilibrated QIAGEN-tip. The lysate was allowed to 
enter the resin under gravity. The QIAGEN-tip was washed with 2 x 30 ml Buffer 
QC. The DNA was eluted into a clean 50 ml tube, with 15 ml of Buffer QF. The 
DNA was precipitated by adding 10.5 ml isopropanol, mixed and allowed to stand 
for five minutes.  The tube was centrifuged at 8000 rpm for 15 minutes at 4°C. 
The supernatant was carefully decanted, and the transparent pellet washed with 
1 ml 70% ethanol at room temperature and transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 13000 rpm for ten minutes in a benchtop 
microcentrifuge. After carefully removing the supernatant the pellet was air-dried 
and the DNA dissolved in a suitable volume of TE buffer, pH 8.0 and stored at -
20°C. 
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2.9.4 Gel extraction 
Gel extraction was done for cloning desired fragments, using QIAquick® Gel 
extraction kit from Qiagen. All the centrifugation steps were done at maximum 
speed i.e. 13000 rpm on a tabletop microcentrifuge. DNA restriction fragments 
separated on an agarose gel were viewed with a long wavelength UV emission 
transilluminator. The desired band was excised using a clean sharp scalpel and 
transferred to a 1.5 ml microfuge tube. The gel slice was weighed in a colourless 
microcentrifuge tube. 3 volumes of buffer QG was added to 1 volume gel (100 
mg~100 µl). To dissolve the gel slice, the tube was incubated at 50ºC on a heat 
block for about 10 minutes with intermittent vortexing. 1 gel volume of 
isopropanol was added to the sample and mixed. QIAquick spin column was 
placed on a 2 ml collection tube provided in the kit. For DNA to bind, the sample 
was applied to the QIAquick column and centrifuged for one minute. Flow 
through was discarded and the QIAquick column was placed back onto the same 
tube. 750 µl of wash buffer PE was added to the QIAquick column and 
centrifuged for one min. Flow through was discarded and the column was again 
placed back. To remove the residual buffer the QIAquick column was centrifuged 
again, any flow through was discarded and the column was placed on a clean 
1.5 ml microcentrifuge tube. Finally, to elute the DNA 50 µl buffer EB (10 mM 
Tris.HCl, pH 8.5) was added to the centre of QIAquick membrane. To increase 
the efficiency, after adding the buffer EB, the tube was allowed to stand for three 
minutes and then centrifuged for two minutes to elute the DNA. 
2.9.5 DNA Quantification 
DNA concentration was determined by measuring the optical density of the 
solution at 260 nm (OD260) using a Nanodrop 1000 (Thermo Scientific). The 
following equation was used to calculate the DNA concentration: 1 OD unit at 
260 nm= 50 µg/ml of DNA 
2.9.6 DNA Sequencing 
DNA sequencing was undertaken to verify the various constructs at different 
stages in this study. Sequencing reactions were carried out in THERMO- FAST® 
non-skirted 96-well plates from Thermo Scientific. BigDye® Terminator v1.1 
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Cycle Sequencing Kit from Applied Biosystems was used. 1 µl plasmid DNA at 
a concentration of about 150 ng/µl was added. 
Table 2.2 Sequencing reaction constituents 
 
Reagents 1x sequencing reaction 
Big Dye Mix 1 µl 
Better Buffer (Microzone) 5 µl 
Primer (5 µM) 0.75 µl 
Betaine (Sigma Aldrich) 3 µl 
ddH2O 4.25 µl 
Total volume 15 µl 
 
Reactions were set up in accordance with the above protocol. The plate was 
covered and given a pulse spin. PCR reactions were run on a Biorad DNA engine 
Tetrad® 2 Thermal Cycler machine. Details of the PCR cycle are: Initial 
denaturation at 96ºC for 1 min; 25 cycles of Denaturation at 96ºC for 30 seconds, 
Annealing at 50ºC for 15 seconds, Extension at 60ºC for 4 minutes. After a final 
extension for 5 minutes, the reaction was put on hold at 4ºC for an indefinite time. 
To purify extension products, the following protocol was used:  
To each sequencing reaction, 3.75 µl of 0.125 M EDTA was added ensuring the 
solution was pipetted into the bottom of the well. 45 µl of 100% absolute ethanol 
was added to each reaction and mixed. After 15 minutes at room temperature, 
the plate was centrifuged at 3000xg for 30 minutes at 4°C. The plate was inverted 
on to a paper towel and spun at 185xg for one minute. After that 60 µl of 70% 
ethanol was added and the plate was centrifuged at 1650xg for 15 minutes at 
4°C. The plate was again inverted on to a paper towel and spun at 185xg for one 
minute. To remove final traces of ethanol the plate was left uncovered at room 
temperature for 15 minutes. The plate was stored at -20°C and the sequencing 
reaction was run by the Human Genetics group at MRC Prion Unit on a 3730xI 
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DNA Analyzer (Applied Biosystems). To analyse the sequences, Applied 
Biosystems Sequence Scanner software v1.0 was used. 
Later for sequencing, samples were outsourced to SourceBioScience 
(https://www.sourcebioscience.com/). 
2.9.7 Gateway Recombinational Cloning 
Some constructs used in this study were prepared by Prof. Parmjit Jat and to 
complete the list the remaining were ordered from DNASU plasmid repository as 
Gateway adapted Entry clones and prepared using the following protocol: 
LR Clonase™ II enzyme mix from ThermoFisher Scientific was used for Gateway 
Recombinational Cloning of ORFs of genes into the pLX301 destination vector. 
The components mentioned in the table below (Table 2.3) were added to a 1.5 
ml microcentrifuge tube at room temperature and mixed.  
Table 2.3 Gateway Recombination Cloning constituents 
 
Entry clone from DNASU (50-150 ng) 1-7 µl 
Destination Vector pLX301 (150 ng/µl) 1 µl 
TE buffer, pH 8.0 To 8 µl 
 
The LR Clonase™ II enzyme mix was thawed on ice for about two minutes and 
vortexed briefly twice for about two seconds each. 2 µl of LR Clonase™ II 
enzyme mix was added to each reaction and mixed well again by vortexing 
briefly. LR Clonase™ II enzyme mix was returned to -20°C immediately after use. 
The reactions were incubated at 25°C overnight. 1 µl of the Proteinase K solution 
(2 µg/µl) was added to each sample to terminate the reaction and vortexed 
briefly. The samples were then incubated at 37°C for ten minutes. 
1 µl of each LR reaction was used to transform 100 µl of JS4 competent cells 
according to the protocol described in section 2.8.3 and selected for resistance 
to Ampicillin.  
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2.9.8 Multicistronic PCR cloning 
To construct the multicistronic vectors, multiple sequential PCR reactions were 
performed. The conditions and various different parameters for each of the 
primary, secondary and tertiary PCR reactions are indicated in detail in Table 
2.4.   
 
 
 
 
 
For setting up 50 µl PCR reactions, template DNA was used at 10ng per reaction. 
Template DNA along with the forward and reverse primers (at a final 
concentration of 0.5 µM) were added to the master mix. The master mix was 
composed of 10 mM dNTPs (at a final concentration of 200 µM), 1.5 µl DMSO, 
5X Phusion HF Buffer (at a final concentration of 1X) and 0.5 µl of Phusion High-
Table 2.4 PCR cycling parameters and conditions to construct multi-cistronic constructs. 
The table describes the different parameters and cycling conditions used for recombinant PCR. 
Each PCR reaction correlates to either the primary (P), secondary(S) and tertiary(T) reaction 
based on the construction of single, double and triple constructs respectively. PCR reactions are 
grouped together, and colour coded for a clear explanation of the set of reactions conducted to 
create each multi-cistronic construct. Additional notes present the optimisation of the different 
Mg++ concentrations used to amplify different constructs.  
* PCR cycle used at the start of every amplification reaction. 
** PCR cycle used at the end to terminate every amplification reaction 
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fidelity DNA polymerase from Thermofisher Scientific. The final reaction volume 
was made up to 50 µl with RNase/DNase free water. 
2.10  Protein Analysis 
2.10.1  Preparation of total protein extracts 
Fresh medium was added to the cell cultures the day prior to making lysates. For 
some of the constructs, there were only a few CL3EcoR cells growing at the non-
permissive temperature which had bypassed senescence, therefore, cells from 
two flasks were trypsinized, pooled and replated on a 10 cm dish. Cell cultures 
were harvested at about 80% confluency on the day of lysis. For lysis, cells were 
washed twice with cold PBS. One ml of RIPA lysis buffer (50 mM Tris-HCl, pH 
8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate; Sigma Aldrich) supplemented 
with 2 µl of Protease Inhibitor Cocktail (2 mM 4-[2-aminoethyl] benzenesulphonyl 
fluoride [AEBSF], 1 mM EDTA, 130 µM Bestatin, 14 µM E-64, 1 µM Leupeptin 
and 0.3 µM Aprotinin; Sigma Aldrich) was added, making sure that the whole 
surface was covered. Cells were incubated for thirty minutes on ice. Meanwhile 
1.5 ml microcentrifuge tubes were labelled and pre-chilled on ice. After thirty 
minutes cells were scraped off and transferred to pre-chilled microcentrifuge 
tubes. To shear the DNA, lysates were passed three times through a 21-gauge 
needle and centrifuged at 10,000 rpm at 4°C for thirty minutes. The supernatant 
was collected and transferred to a fresh pre-chilled microcentrifuge tube and 
stored at -20°C. 
2.10.2  Determination of Protein concentration 
Protein concentrations were determined using the Bradford assay. To determine 
the concentration lysates were thawed on ice and diluted fivefold in PBS. To 
make a standard curve, BSA standards prepared in PBS were used (0 µg/ml, 
125 µg/ml, 250 µg/ml, 500 µg/ml, 750 µg/ml, 1000 µg/ml, 1500 µg/ml, 2000 
µg/ml). 5 µl of each of the BSA standard was pipetted in triplicate into a 96 well 
clear plate making sure there were no bubbles in the wells. 5 µl of the samples 
to be analysed were pipetted in triplicate into the rest of the plate again avoiding 
bubbles. The Bradford reagent was mixed by inverting the bottle and 250 µl of 
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the reagent was added to each well using a multichannel pipette. The plate was 
sealed with a plate cover evenly across and incubated at room temperature for 
ten minutes. The absorbance was measured at 595 nm on a Tecan plate reader 
and the absorbance plotted against the protein concentration of BSA standards. 
The regression coefficient was calculated, and the unknown sample 
concentrations determined. 
2.10.3  Sodium-Dodecyl-Sulphate-Polyacrylamide-Gel-Electrophoresis 
20 µg of each cell lysate was heated at 90°C for five minutes with 4X Sample 
buffer (50% glycerol, 5% lithium dodecyl sulphate, 5% Tris (hydroxymethyl) 
amino methane and 1% HCl; Bio-Rad Laboratories Ltd.) and fractionated by 
SDS-PAGE (7% for FOXM1 and B-MYB and 12% for LIN52 SDS-PAGE gels 
were used). Electrophoresis was done at a constant voltage of 100V in running 
buffer (25 mM Tris, 190 mM Glycine, 0.1% [w/v] SDS). Protein samples were 
fractionated alongside a Novex™ Sharp Pre-stained protein standard marker 
from ThermoFisher Scientific.  
2.10.4  Western blotting of SDS-PAGE 
After the samples were separated by SDS-PAGE, the proteins were transferred 
on to a nitrocellulose membrane by electrophoretic transfer in a wet tank blotting 
system in transfer buffer (25 mM Tris, 190 mM glycine and 20% [v/v] methanol). 
The transfer was done at 90V for ninety minutes. After transfer, the nitrocellulose 
membrane was blocked in 5% skimmed milk powder or BSA in PBS for at least 
one hour at room temperature. After five quick washes with 0.05% (v/v) PBST, 
the membrane was incubated with primary antibody diluted at 1:1000 dilution in 
5% BSA overnight at 4°C. Next day the membrane was washed with 0.05% (v/v) 
PBST (ten minutes each at room temperature) for at least one hour. The blot was 
then incubated with HRP (Horseradish Peroxidase) conjugated secondary 
antibody at 1:2000 dilution in PBST for one hour at room temperature. The blot 
was washed again for one hour with 0.05% (v/v) PBST (ten minutes each at room 
temperature).  For developing, Western Lightning Plus-ECL from PerkinElmer 
was used. Chemiluminescence Reagent was prepared by mixing equal volumes 
of Enhanced Luminol Reagent and the Oxidizing Reagent. The membrane was 
incubated in Chemiluminescence Reagent for one minute with gentle agitation. 
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Excess chemiluminescence reagent was removed. The membrane was then 
placed in a cassette and exposed to an auto-radiographic film for different times 
varying from 30 seconds to 20 minutes. Films were then developed in the dark.  
2.10.5  Antibodies used 
To test ectopic expression in this study the following primary antibodies were 
used (Table 2.5). HRP conjugated polyclonal goat Anti-rabbit (P044801-2) and 
Anti-mouse (P044701-2) secondary antibodies were used at 1:2000 dilution from 
Agilent Dako. 
Table 2.5 Antibodies used  
 
Target Host Clonality Supplier Dilution Cat 
number 
LIN52 Rabbit Polyclonal LifeSpan 
BioSciences 
1:1000 LS-
C165783 
B-MYB Mouse Monoclonal MerckMillipore 1:1000 MABE886 
FOXM1 Rabbit Polyclonal Santa Cruz 
Biotechnology 
1:1000 sc-502 
β-tubulin Rabbit Polyclonal Santa Cruz 
Biotechnology 
1:1000 sc-9104 
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Chapter 3  Identification of upregulated and 
downregulated TFs, preparation of expression 
constructs and assessment of their functional role in 
senescence 
3.1 Identification of up-regulated and downregulated TFs 
3.1.1 Objectives 
Transcription factors (TFs) are the family of distal effector proteins that regulate 
gene expression at different stages of embryonic development and are key to 
the establishment and maintenance of specific cell fate by ensuring the correct 
expression of specific genes at an appropriate time and place (Levine and Tijan 
2003; Bustamante et al. 2005; Vaquerizas et al. 2009). They also play a central 
role in regulating biological processes by controlling cell function and how cells 
respond to various stimuli. Defining the key TFs and dissecting the underlying 
transcriptional networks is therefore important for defining the phenotype of a 
particular cell or disease state.  
Even though acquisition of a limitless replicative potential has been proposed to 
be one of the key events required for malignant transformation, we still do not 
fully know the transcriptional networks that underlie entry into senescence, the 
signal transduction pathways and how the diverse signals that result in 
senescence are all integrated. Several studies have reported the involvement of 
two key tumour suppressor pathways namely, p53/p21WAF1 and p16INK4A/pRB, in 
achieving and maintaining senescence growth arrest. However, the critical 
downstream TFs involved in these pathways are not known.  
Hence, the objective of this section of this chapter is to identify and refine the list 
of upregulated and downregulated TFs that might play a key role in manifesting 
cellular senescence.  
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3.1.2 Identification of differential transcription factors that underlie 
cellular senescence 
The present work is an extension of the previous work undertaken in my lab 
where microarray expression profiling studies were conducted to identify 
changes in gene expression upon senescence (Rovillain et al. 2011). If changes 
in gene expression that were identified are specific to senescence growth arrest, 
the changes should be reversed upon its abrogation. Genome wide expression 
profiling coupled with inactivation of the p53-p21WAF1 and/or p16INK4A-pRB 
pathways, in the CL3EcoR cells, using SV40 LT (wt_LT) antigen, HPV16/18 E7, 
Adenovirus E1A, GSEp53 (dominant negative p53), E2F-DB (dominant negative 
E2F), p53shRNA (pRS_p53) and p21WAF1 shRNA (pRS_p21WAF1) yielded a 
comprehensive catalogue of genes whose levels are altered upon senescence 
comprising 3059 up-regulated and 5005 down-regulated transcripts (Rovillain et 
al. 2011). It was also observed that expression of these differentially expressed 
transcripts was reversed when senescence was bypassed.  
MicroRNAs(miRNA) are key regulator molecules which aid in post-transcriptional 
gene expression by RNA silencing. They play a crucial role in maintaining many 
cellular processes, for example, metastasis, cell proliferation, differentiation, cell 
cycle, apoptosis etc. Interestingly previous expression profiling studies 
conducted in the lab also investigated the involvement of microRNAs in 
senescence to identify senescence specific microRNA expression in CL3EcoR 
cells. Functional validation of the top 15 downregulated miRNAs by ectopic 
expression and senescence bypass assay in CL3EcoR cells revealed six miRNAs 
namely, miR186, miR195, miR218, miR25, miR372 and miR423, which 
bypassed growth arrest (Rovillain 2011). 
Luscombe and colleagues have presented a high quality and comprehensive 
census of TFs in the human genome. Their study lists 1391 manually curated 
sequence specific DNA binding factors and also proposed their function, 
evolutionary conservation and genomic organization (Vaquerizas et al. 2009). 
Therefore, the starting key step in this project was to overlay the previously 
identified 3059 up-regulated and 5005 down-regulated transcripts with the 1391 
manually curated sequence-specific DNA binding transcription factors identified 
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by Luscombe and colleagues (Vaquerizas et al. 2009). The purpose of this 
overlay was to identify DNA binding transcription factors from the list of 
previously identified differential genes as in this thesis we are interested in 
studying the functional role of transcription factors. 
The results of this overlay identified a total of 462 differentially expressed 
candidate DNA binding transcription factors of which 124 were up-regulated and 
338 were down-regulated. The top 23 up- (positive numbers for log2 fold change 
indicated as GA) and down-regulated (negative numbers for log2 fold change 
indicated as GA) TFs are shown below in Figure 3.1. The overlays showed that 
differential expression of the TFs was reversed when senescence was bypassed; 
however, the reversal is clearer for the down-regulated TFs than it is for the up-
regulated TFs as depicted in Figure 3.1. 
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A. GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21 mir186 mir195 mir218 mir25 mir372 mir423
BMP2 2.45 -5.05 -3.39 -4.46 -3.48 -3.08 -1.46 -1.85 -0.14 0.25 0.67 -1.20 -1.73 0.78
ARID5B 1.78 0.22 -0.27 -0.97 -0.27 -0.74 -0.77 -1.39 -2.33 -2.52 -2.39 -1.88 0.25 -2.40
GPR155 1.68 -1.27 -1.03 -0.65 -1.07 -1.30 -1.29 -1.11 -1.64 -1.66 -1.69 -1.74 -1.16 -1.81
ZMAT3 1.66 -1.60 -1.14 -0.07 -0.70 -0.24 -1.83 0.16 -2.03 -1.54 -1.46 -2.03 -0.91 -1.38
CD36 1.61 -1.08 -0.61 -1.15 -0.88 -0.90 -0.75 -1.10 -1.76 -1.59 -1.72 -2.07 -1.53 -1.96
NR3C2 1.58 -2.63 -1.84 -1.40 -0.94 0.09 -0.85 -1.04 -0.79 -0.99 -0.66 -0.45 -0.36 0.28
ZBTB1 1.52 -0.94 0.15 -2.57 -1.58 -1.73 -0.83 -1.01 -1.00 -0.69 -0.82 -0.59 -0.63 -0.48
RORA 1.31 -1.62 -0.76 -0.77 -1.09 -1.62 -0.62 -0.67 -0.58 -1.02 -1.61 -1.33 0.11 -2.26
ZNF432 1.23 -0.96 -0.85 -0.72 -0.97 -0.86 -0.61 -0.36 -2.17 -2.18 -2.92 -1.97 -1.27 -2.48
STAT1 1.23 -1.16 -1.60 -1.53 -1.14 -1.82 -0.78 -1.12 0.48 -0.57 -0.59 -0.60 -1.00 -1.63
FBN1 1.23 0.16 0.97 -1.14 -0.19 -0.88 0.06 0.03 -1.19 -1.80 -2.19 -0.97 0.09 -2.33
RUNX1 1.12 -0.84 -1.03 -1.15 -0.63 -0.71 -0.63 -0.65 -2.25 -1.98 -1.58 -1.88 -1.02 -1.51
OSR1 1.10 -0.80 -0.46 -3.54 -1.36 -2.29 -0.94 -0.75 -1.78 -2.91 -2.93 -2.92 -0.58 -4.07
AFF1 1.10 -1.03 -0.74 -1.25 -0.52 -0.30 -0.84 -0.87 -0.68 -0.67 -0.50 -0.57 -0.39 -0.22
FAM44A 1.09 -0.73 -0.56 -0.88 -0.68 -0.76 -0.85 -0.81 -0.54 -0.89 -0.43 -0.79 -0.56 -0.78
RGS7 1.08 -0.36 -0.45 -0.16 -0.08 0.12 -0.16 -0.47 -1.16 -1.67 -1.25 -1.57 0.25 -1.60
DEPDC6 1.07 0.26 1.10 -0.26 0.13 -0.41 0.53 0.26 -1.77 -2.14 -1.47 -1.89 -1.77 -2.16
CREB3 1.05 -0.84 -0.67 -0.85 -0.51 -0.47 -0.55 -0.62 -0.65 -0.68 -0.58 -0.78 -0.34 -0.79
SP110 1.04 -0.85 -1.24 -1.19 -0.67 -1.06 -0.48 -0.86 0.66 -0.42 -0.25 -0.67 -0.63 -1.19
STAT2 0.97 -0.25 -0.55 -0.89 -0.31 -0.72 -0.18 -0.21 0.41 -0.30 -0.48 -0.48 -0.34 -0.70
FAM171B 0.95 -0.61 -0.39 -0.03 -0.26 -0.36 -0.86 -0.26 -0.69 -0.90 -0.84 -0.80 -0.69 -0.66
LGR4 0.93 -0.49 0.41 -0.47 -0.59 -1.04 0.47 0.19 -1.07 -1.00 -1.00 -0.81 -0.14 -0.80
EPAS1 0.93 -1.44 -0.78 -3.25 -1.00 -0.94 -0.85 -0.52 -0.78 -0.72 -0.59 -0.79 -0.45 -0.35
B. GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21 mir186 mir195 mir218 mir25 mir372 mir423
DEPDC1 -3.27 3.69 3.46 3.62 3.14 3.47 3.16 2.80 2.66 2.86 2.49 2.92 1.73 3.06
DEPDC1B -3.05 3.26 2.48 4.14 2.62 3.03 2.34 2.29 2.79 2.30 2.70 2.93 1.89 2.64
E2F8 -2.85 3.07 2.70 3.63 2.24 1.52 1.76 1.14 1.66 2.06 1.31 1.86 1.55 0.90
HMGB2 -2.84 2.89 2.45 3.28 2.46 2.46 2.25 1.66 2.37 2.65 2.42 2.59 1.48 2.40
FOXM1 -2.66 2.57 2.19 2.56 2.07 2.31 2.08 1.89 2.53 2.29 2.41 2.26 1.28 2.42
EZH2 -1.88 1.73 1.38 1.51 1.36 1.15 0.97 0.92 1.65 1.68 1.43 1.66 1.06 1.47
B-MYB -1.85 1.70 1.15 3.15 1.00 1.09 0.98 0.80 1.56 1.60 1.50 1.60 1.85 0.88
HOXA3 -1.73 0.60 1.12 1.38 0.16 0.07 0.34 0.57 0.47 0.80 1.19 0.72 -0.56 0.80
SSRP1 -1.70 1.26 1.15 1.24 1.05 0.83 0.82 0.84 1.38 1.12 1.38 1.28 0.64 1.49
ID1 -1.64 1.51 1.54 0.03 0.85 0.20 0.70 0.76 0.29 0.05 0.08 0.71 0.82 -0.66
H1FX -1.64 1.65 0.74 2.28 0.86 0.68 0.79 1.05 1.57 1.55 1.50 1.23 0.76 1.11
TOX -1.56 0.96 0.74 -0.12 0.51 0.91 1.55 0.49 1.30 -0.54 0.40 0.46 0.44 -0.39
BNC1 -1.56 0.81 0.33 0.85 1.58 2.05 0.86 0.68 2.32 2.99 3.22 2.59 -0.34 3.72
HMGB1 -1.54 1.10 1.15 1.17 0.64 0.95 0.90 0.72 0.59 0.81 0.60 0.97 0.64 0.75
WHSC1 -1.52 1.60 1.41 1.10 1.13 1.03 1.03 0.84 1.78 1.40 1.47 1.69 0.98 1.57
PRMT3 -1.51 0.53 0.63 1.15 0.89 1.23 0.72 0.59 0.73 1.25 1.15 0.84 0.03 1.40
H1F0 -1.50 1.16 0.73 1.66 0.34 0.01 0.65 0.34 1.28 1.17 1.03 0.92 0.45 0.27
DLX2 -1.42 -0.56 -0.77 0.44 -0.40 -0.96 -0.55 0.00 -0.15 -0.27 0.11 0.48 0.68 -0.10
YEATS4 -1.39 1.09 1.26 1.31 0.70 0.81 0.44 0.51 0.84 1.07 1.01 1.01 0.58 1.06
C14orf106 -1.38 2.27 1.79 2.32 1.28 1.29 1.45 1.01 0.68 1.06 0.25 1.38 0.87 1.24
ZNF639 -1.34 0.88 1.05 0.27 0.53 0.28 0.53 0.25 0.68 1.01 0.46 0.92 0.49 0.79
ZNF22 -1.34 0.59 0.49 1.03 -0.29 0.24 0.22 0.18 0.97 0.88 0.51 1.22 0.90 0.10
RNF138 -1.30 0.88 0.49 0.99 0.94 0.99 0.62 0.59 0.68 1.01 0.58 0.91 0.72 0.73
Figure 3.1 TFs differentially expressed upon senescence growth arrest (GA).  
GA represents the log2 fold change between CL3EcoR cells at 38°C relative to CL3EcoR cells at 
34°C. A. The top 23 up-regulated TFs (positive numbers for log2 fold change indicated as GA 
shaded in red). B. The top 23 down-regulated (negative numbers for log2 fold change indicated 
as GA shaded in green) TFs are presented. Also shown is the effect on expression when 
senescence was bypassed using SV40 LT (wt_LT) antigen, HPV16/18 E7, Adenovirus E1A, 
GSEp53 (dominant negative p53), E2F-DB (dominant negative E2F), p53shRNA (pRS_p53), 
p21WAF1shRNA (pRS_p21WAF1), miR186, miR195, miR218, miR25, miR372 and miR423. Hence, 
the log2 fold change from column 2 onwards indicates expression in various additionally 
engineered cells where senescence has been bypassed relative to CL3EcoR cells at 34°C. The 
changes in expression was reversed upon senescence bypass as depicted by the reversal of 
colour. Log2 fold change of less than 0.50 and -0.50 is indicated by light red and light green 
shades respectively. Data source: (Rovillain 2011). 
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The list of candidate TFs was further refined by performing another overlay. The 
aim of this second overlay study was to refine the list of identified 462 differential 
DNA binding factors from the first overlay, to identify TFs for which expression is 
not only differential when the cells undergo senescence arrest but is also 
reversed completely when senescence was bypassed upon inactivation of the 
p16INK4A/pRB and/or p53/p21WAF1 pathways, or by ectopic expression of miRs 
that can bypass senescence in CL3EcoR cells (Rovillain 2011).  
This reduced the list of candidate TFs to 39 up- and 128 down-regulated which 
exhibited complete reversal after abrogation of senescence shown in Table 3.1 
and Table 3.2 respectively. The overlays were done with the help of Dr. Holger 
Hummerich, a bioinformatician at MRC Prion Unit who routinely handles large 
amounts of microarray data and undertakes such analyses for members of the 
MRC prion unit. 
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Table 3.1 List of 39 shortlisted differential up-regulated TFs which showed complete reversal 
after senescence bypass. 
 
 
  
GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21 mir186 mir195 mir218 mir25 mir372 mir423
GPR155 1.68 -1.27 -1.03 -0.65 -1.07 -1.30 -1.29 -1.11 -1.64 -1.66 -1.69 -1.74 -1.16 -1.81
CD36 1.61 -1.08 -0.61 -1.15 -0.88 -0.90 -0.75 -1.10 -1.76 -1.59 -1.72 -2.07 -1.53 -1.96
ZNF432 1.23 -0.96 -0.85 -0.72 -0.97 -0.86 -0.61 -0.36 -2.17 -2.18 -2.92 -1.97 -1.27 -2.48
RUNX1 1.12 -0.84 -1.03 -1.15 -0.63 -0.71 -0.63 -0.65 -2.25 -1.98 -1.58 -1.88 -1.02 -1.51
AFF1 1.10 -1.03 -0.74 -1.25 -0.52 -0.30 -0.84 -0.87 -0.68 -0.67 -0.50 -0.57 -0.39 -0.22
OSR1 1.10 -0.80 -0.46 -3.54 -1.36 -2.29 -0.94 -0.75 -1.78 -2.91 -2.93 -2.92 -0.58 -4.07
FAM44A 1.09 -0.73 -0.56 -0.88 -0.68 -0.76 -0.85 -0.81 -0.54 -0.89 -0.43 -0.79 -0.56 -0.78
CREB3 1.05 -0.84 -0.67 -0.85 -0.51 -0.47 -0.55 -0.62 -0.65 -0.68 -0.58 -0.78 -0.34 -0.79
FAM171B 0.95 -0.61 -0.39 -0.03 -0.26 -0.36 -0.86 -0.26 -0.69 -0.90 -0.84 -0.80 -0.69 -0.66
EPAS1 0.93 -1.44 -0.78 -3.25 -1.00 -0.94 -0.85 -0.52 -0.78 -0.72 -0.59 -0.79 -0.45 -0.35
ZNF846 0.88 -0.88 -0.87 -0.91 -0.59 -0.78 -0.44 -0.26 -1.00 -0.99 -0.91 -1.22 -1.25 -0.95
LARP6 0.87 -1.37 -0.69 -1.77 -0.97 -1.02 -0.52 -0.80 -0.83 -0.98 -0.66 -0.99 -0.49 -0.84
PLXNA3 0.86 -0.61 -0.62 -0.45 -0.61 -0.62 -0.47 -0.56 -1.14 -1.53 -1.40 -1.07 -0.37 -1.38
ETV7 0.83 -1.64 -1.77 -0.63 -0.92 -1.44 -1.69 -1.85 -0.96 -1.54 -1.22 -1.82 -0.71 -1.95
SLC22A4 0.82 -2.28 -1.49 -3.80 -2.01 -1.32 -1.02 -1.13 -0.62 -0.44 -1.01 -0.56 -0.04 -0.41
ZBTB47 0.79 -0.86 -0.18 -1.12 -0.95 -0.96 -0.49 -0.63 -1.13 -0.93 -1.24 -1.14 -0.94 -1.29
ZNF226 0.72 -0.63 -0.52 -0.19 -0.76 -0.47 -0.50 -0.48 -0.91 -0.61 -0.78 -0.62 -0.84 -1.16
NR1H4 0.69 -1.05 -0.83 -1.08 -0.87 -1.05 -0.99 -1.08 -0.73 -0.95 -1.00 -1.18 -0.91 -1.10
PPARA 0.69 -1.01 -0.33 -1.18 -0.83 -0.89 -0.65 -0.64 -0.22 -0.55 -0.56 -0.61 -0.51 -0.50
C5orf41 0.68 -1.15 -0.57 -0.85 -0.96 -1.00 -0.70 -0.72 -1.05 -1.05 -1.08 -1.00 -1.19 -0.62
CUL4B 0.68 -0.87 -0.62 -1.18 -0.55 -0.66 -0.24 -0.65 -0.53 -0.69 -0.92 -0.43 -0.53 -0.49
RARB 0.67 -0.70 -0.99 -0.64 -0.27 -0.56 -0.34 -0.42 -0.04 -1.16 -0.90 -0.80 -0.93 -1.12
KIAA0415 0.65 -0.84 -0.40 -0.78 -0.56 -0.74 -0.90 -0.93 -0.58 -0.53 -0.33 -0.68 -0.67 -0.34
ZNF561 0.60 -0.52 -0.18 -0.64 -0.42 -0.61 -0.60 -0.15 -0.91 -1.28 -1.04 -1.07 -0.62 -1.24
C20orf194 0.58 -0.56 -0.31 -0.73 -0.62 -0.64 -0.43 -0.58 -1.23 -1.23 -1.48 -1.08 -0.22 -1.39
PLXNB3 0.58 -0.42 -0.82 -0.57 -0.27 -0.31 -0.44 -0.16 -1.07 -1.25 -1.00 -1.16 -0.46 -1.25
ZNF691 0.58 -0.43 -0.15 -0.05 -0.27 -0.39 -0.10 -0.05 -0.25 -0.20 -0.13 -0.20 -0.29 -0.41
ZNF557 0.56 -1.14 -0.81 -0.87 -0.65 -0.68 -0.46 -0.34 -0.94 -0.52 -0.60 -0.65 -0.30 -0.70
BCL6 0.53 -0.24 -0.31 -0.84 -0.50 -0.69 -0.33 -0.37 -0.79 -0.74 -1.01 -0.73 -0.27 -0.89
TFEC 0.53 -0.43 -0.37 -0.65 -0.20 -0.20 -0.14 -0.12 -0.56 -0.55 -0.26 -0.78 -0.69 -0.66
ZNF565 0.52 -0.25 -0.24 -0.37 -0.68 -0.88 -0.47 -0.55 -0.88 -0.92 -1.45 -0.67 -0.36 -1.46
NFAT5 0.49 -0.21 -0.12 -0.27 -0.29 -0.28 -0.45 -0.35 -0.86 -0.84 -1.01 -0.57 -0.53 -0.66
CHD6 0.45 -0.47 -0.23 -0.33 -0.48 -0.52 -0.20 -0.18 -0.50 -0.36 -0.87 -0.51 -0.14 -1.00
ZNF419 0.45 -0.62 -0.41 -0.23 -0.48 -0.52 -0.24 -0.25 -0.85 -1.09 -1.01 -0.83 -0.46 -1.41
ZNF319 0.39 -0.63 -0.31 -0.63 -0.45 -0.49 -0.65 -0.62 -0.35 -0.31 -0.17 -0.28 -0.18 -0.30
ZNF277 0.36 -0.62 -0.16 -0.11 -0.35 -0.10 -0.08 -0.44 -0.38 -0.35 -0.39 -0.39 -0.53 -0.11
ZNF627 0.36 -0.40 -0.04 -0.49 -0.40 -0.67 -0.22 -0.21 -0.35 -0.40 -0.31 -0.33 -0.18 -0.64
ZNF771 0.31 -0.33 -0.49 -0.14 -0.25 -0.26 -0.21 -0.13 -0.09 -0.03 -0.11 -0.14 -0.16 -0.15
NFE2L1 0.30 -0.48 -0.32 -0.46 -0.41 -0.37 -0.45 -0.59 -0.57 -0.63 -0.51 -0.68 -0.55 -0.58
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Table 3.2 List of 128 shortlisted differential down-regulated TFs which showed complete reversal 
after senescence bypass. 
 
 
…. 
GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21 mir186 mir195 mir218 mir25 mir372 mir423
DEPDC1 -3.27 3.69 3.46 3.62 3.14 3.47 3.16 2.80 2.66 2.86 2.49 2.92 1.73 3.06
DEPDC1B -3.05 3.26 2.48 4.14 2.62 3.03 2.34 2.29 2.79 2.30 2.70 2.93 1.89 2.64
E2F8 -2.85 3.07 2.70 3.63 2.24 1.52 1.76 1.14 1.66 2.06 1.31 1.86 1.55 0.90
HMGB2 -2.84 2.89 2.45 3.28 2.46 2.46 2.25 1.66 2.37 2.65 2.42 2.59 1.48 2.40
FOXM1 -2.66 2.57 2.19 2.56 2.07 2.31 2.08 1.89 2.53 2.29 2.41 2.26 1.28 2.42
EZH2 -1.88 1.73 1.38 1.51 1.36 1.15 0.97 0.92 1.65 1.68 1.43 1.66 1.06 1.47
B-MYB -1.85 1.70 1.15 3.15 1.00 1.09 0.98 0.80 1.56 1.60 1.50 1.60 1.85 0.88
SSRP1 -1.70 1.26 1.15 1.24 1.05 0.83 0.82 0.84 1.38 1.12 1.38 1.28 0.64 1.49
H1FX -1.64 1.65 0.74 2.28 0.86 0.68 0.79 1.05 1.57 1.55 1.50 1.23 0.76 1.11
HMGB1 -1.54 1.10 1.15 1.17 0.64 0.95 0.90 0.72 0.59 0.81 0.60 0.97 0.64 0.75
WHSC1 -1.52 1.60 1.41 1.10 1.13 1.03 1.03 0.84 1.78 1.40 1.47 1.69 0.98 1.57
PRMT3 -1.51 0.53 0.63 1.15 0.89 1.23 0.72 0.59 0.73 1.25 1.15 0.84 0.03 1.40
H1F0 -1.50 1.16 0.73 1.66 0.34 0.01 0.65 0.34 1.28 1.17 1.03 0.92 0.45 0.27
YEATS4 -1.39 1.09 1.26 1.31 0.70 0.81 0.44 0.51 0.84 1.07 1.01 1.01 0.58 1.06
C14orf106 -1.38 2.27 1.79 2.32 1.28 1.29 1.45 1.01 0.68 1.06 0.25 1.38 0.87 1.24
ZNF639 -1.34 0.88 1.05 0.27 0.53 0.28 0.53 0.25 0.68 1.01 0.46 0.92 0.49 0.79
RNF138 -1.30 0.88 0.49 0.99 0.94 0.99 0.62 0.59 0.68 1.01 0.58 0.91 0.72 0.73
KNTC1 -1.19 1.44 1.31 1.05 1.00 0.70 0.81 0.63 0.94 1.22 0.66 1.15 0.55 1.15
DUSP12 -1.16 0.27 0.49 0.34 0.11 0.23 0.28 0.19 0.56 0.48 0.47 0.53 0.41 0.39
TFAM -1.06 0.70 0.54 0.97 0.78 0.90 0.43 0.47 0.81 0.91 0.92 1.07 0.50 1.20
TEAD4 -1.06 0.93 0.51 1.08 0.71 0.78 0.45 0.36 1.00 1.07 1.24 0.97 0.99 1.08
TCF19 -1.04 1.49 1.27 1.21 1.22 0.89 0.75 0.83 1.37 1.04 1.04 1.11 1.29 0.69
TWIST1 -1.03 1.51 1.45 0.48 0.65 0.41 0.80 0.46 1.26 0.81 0.66 0.82 0.82 0.49
HMGB3 -1.01 1.42 1.48 1.28 1.23 1.36 1.20 1.12 1.69 2.03 1.60 1.80 0.70 1.64
UNK -1.00 0.43 0.57 0.61 0.24 0.23 0.17 0.28 0.27 0.48 0.40 0.37 0.09 0.23
PCGF6 -1.00 0.50 0.42 0.87 0.65 0.65 0.50 0.46 0.78 1.00 1.10 0.98 0.67 1.25
HMG2L1 -1.00 0.79 0.68 0.73 0.38 0.24 0.23 0.23 0.47 0.55 0.36 0.48 0.13 0.52
CTCF -1.00 0.83 0.75 0.84 0.47 0.34 0.20 0.22 0.63 0.73 0.50 0.77 0.52 0.52
ZNF496 -0.99 0.39 0.25 0.68 0.18 0.23 0.27 0.15 0.82 0.74 0.45 0.62 0.51 0.46
NUFIP1 -0.98 0.27 0.32 0.01 0.07 0.44 0.28 0.20 0.22 0.48 0.43 0.40 0.30 0.54
HOXA9 -0.94 0.75 1.33 1.82 0.14 0.11 0.48 0.73 0.71 0.32 0.42 0.46 0.49 0.16
DEK -0.94 1.09 1.08 1.07 0.96 0.86 0.92 0.82 0.69 0.94 0.63 0.96 0.33 1.00
HOXA7 -0.93 0.73 0.99 1.06 0.02 0.13 0.31 0.42 0.64 0.35 0.22 0.41 0.61 0.08
EWSR1 -0.93 0.44 0.54 0.59 0.30 0.24 0.42 0.40 0.56 0.52 0.41 0.66 0.40 0.48
ATF1 -0.93 0.83 1.06 0.36 0.46 0.42 0.56 0.06 0.57 0.65 0.55 0.62 0.06 0.55
ZNF511 -0.92 0.60 0.76 0.60 0.47 0.45 0.24 0.34 1.15 1.29 1.50 1.13 0.59 1.37
PSMD11 -0.91 0.57 0.37 0.65 0.61 0.49 0.22 0.29 0.90 0.90 0.93 0.72 0.25 0.86
ELK4 -0.89 0.25 0.10 0.63 0.34 0.48 0.40 0.39 0.90 1.04 0.89 1.02 0.59 1.14
TTF1 -0.86 0.60 0.59 0.83 0.56 0.73 0.45 0.33 0.64 0.82 0.66 0.78 0.28 1.08
PDS5B -0.86 0.89 0.81 1.17 0.52 0.87 0.69 0.74 0.30 0.72 0.23 0.94 0.77 0.66
TSHZ1 -0.85 0.87 1.29 0.47 0.10 0.45 0.81 0.80 0.52 0.36 0.14 0.29 0.13 0.24
SF3A3 -0.85 0.55 0.44 0.30 0.47 0.29 0.11 0.22 0.77 0.65 0.68 0.54 0.07 0.61
U2AF1 -0.84 0.74 0.66 0.50 0.60 0.53 0.53 0.49 0.87 0.91 0.79 0.80 0.43 0.84
POGK -0.84 0.41 0.19 1.10 0.20 0.30 0.12 0.23 0.52 0.44 0.45 0.41 0.39 0.48
HOXA2 -0.83 0.52 0.47 1.06 0.25 0.24 0.26 0.37 0.53 0.28 0.74 0.44 0.04 0.50
CIZ1 -0.83 0.61 0.53 0.44 0.33 0.51 0.33 0.35 0.49 0.43 0.55 0.39 0.06 0.68
ADNP2 -0.83 0.43 0.40 0.58 0.25 0.19 0.23 0.09 0.59 0.72 0.53 0.45 0.22 0.54
RAD51 -0.82 0.87 0.73 1.29 0.67 0.69 0.74 0.44 0.85 0.66 0.79 0.64 0.63 0.57
CBFB -0.82 0.60 0.24 0.74 0.62 0.67 0.21 0.31 0.53 0.44 0.59 0.76 0.50 0.82
SP3 -0.81 0.43 0.51 0.59 0.34 0.29 0.30 0.22 0.04 0.15 0.07 0.38 0.04 0.19
DUS3L -0.81 0.47 0.14 0.30 0.28 0.53 0.25 0.25 1.21 1.29 1.31 0.98 0.72 1.27
NRF1 -0.80 0.62 0.48 0.63 0.31 0.36 0.41 0.24 0.69 0.56 0.54 0.61 0.28 0.45
UBE2K -0.78 0.36 0.54 0.14 0.20 0.12 0.17 0.10 0.27 0.09 0.07 0.44 0.27 0.26
SP1 -0.77 0.93 0.73 0.92 0.44 0.41 0.31 0.32 0.85 0.63 0.65 0.72 0.25 0.74
PHB2 -0.77 0.49 0.52 0.76 0.40 0.49 0.36 0.34 0.63 0.65 0.79 0.62 0.38 0.66
DMAP1 -0.77 0.48 0.54 0.84 0.34 0.33 0.35 0.29 0.64 0.52 0.56 0.43 0.39 0.30
FOXK2 -0.76 0.27 0.26 0.36 0.28 0.32 0.27 0.05 0.77 0.65 0.75 0.43 0.23 0.52
ZNF326 -0.75 0.36 0.80 0.19 0.20 0.33 0.35 0.24 0.45 0.73 0.59 0.66 0.28 0.93
TFDP1 -0.75 1.09 0.71 0.98 0.80 0.74 0.41 0.53 0.93 0.96 0.97 0.84 0.49 0.95
MTA1 -0.73 0.92 0.86 1.31 0.32 0.38 0.26 0.19 0.32 0.62 0.63 0.37 0.17 0.51
GTF2F1 -0.73 0.31 0.25 0.14 0.20 0.20 0.14 0.06 0.52 0.48 0.56 0.39 0.09 0.44
POLE3 -0.71 0.77 0.85 0.70 0.81 0.85 0.59 0.45 0.82 0.84 1.14 0.86 0.29 1.17
NOC4L -0.71 0.26 0.12 0.08 0.19 0.49 0.33 0.20 0.73 0.93 0.68 0.62 0.28 0.69
GLI3 -0.71 0.59 0.29 0.29 0.21 0.13 0.22 0.12 0.88 0.91 0.60 0.69 0.45 0.66
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…. 
  
GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21 mir186 mir195 mir218 mir25 mir372 mir423
SLC30A9 -0.70 0.54 0.66 0.55 0.49 0.56 0.19 0.04 0.43 0.22 0.27 0.63 0.28 0.50
PPP2R3B -0.70 0.28 0.29 0.59 0.30 0.33 0.34 0.16 1.02 1.07 1.05 0.79 0.62 1.10
PSMD12 -0.69 0.20 0.32 0.38 0.41 0.52 0.20 0.23 0.63 0.57 0.56 0.75 0.40 0.82
MRPL28 -0.69 0.36 0.47 1.00 0.41 0.45 0.24 0.34 0.58 0.53 0.78 0.60 0.28 0.57
THAP11 -0.68 0.49 0.59 0.75 0.27 0.19 0.15 0.31 0.81 0.86 0.75 0.79 0.57 0.56
RBM27 -0.68 0.50 0.60 0.59 0.30 0.35 0.26 0.15 0.08 0.23 0.10 0.46 0.06 0.51
E2F1 -0.68 0.58 0.34 0.47 0.50 0.42 0.39 0.48 0.51 0.52 0.53 0.49 0.41 0.40
SMARCE1 -0.67 0.49 0.56 0.66 0.44 0.54 0.46 0.45 0.60 0.71 0.56 0.61 0.41 0.54
IKZF4 -0.67 0.28 0.25 0.40 0.10 0.04 0.08 0.14 0.38 0.25 0.31 0.22 0.18 0.29
AHCTF1 -0.67 0.53 0.48 0.56 0.39 0.58 0.54 0.48 0.30 0.45 0.03 0.71 0.27 0.93
LARP5 -0.66 0.38 0.30 0.33 0.39 0.35 0.14 0.07 0.22 0.42 0.39 0.50 0.45 0.63
CUL1 -0.66 0.33 0.23 0.27 0.21 0.18 0.28 0.09 0.47 0.55 0.53 0.47 0.30 0.72
ZNF664 -0.65 0.44 0.44 0.94 0.35 0.35 0.11 0.18 0.02 0.27 0.34 0.27 0.13 0.44
COPS3 -0.65 0.63 0.58 0.62 0.74 0.76 0.42 0.45 0.53 0.59 0.71 0.47 0.27 0.59
ZNF530 -0.64 0.28 0.19 0.50 0.17 0.27 0.23 0.26 0.68 0.45 0.42 0.83 0.55 0.38
TCF3 -0.64 0.65 0.59 0.29 0.35 0.33 0.22 0.03 0.65 0.62 0.64 0.55 0.36 0.49
SUZ12 -0.64 0.80 0.58 0.97 0.67 0.87 0.38 0.32 0.42 0.80 0.37 0.63 0.16 0.75
SP4 -0.64 1.06 0.70 1.78 0.70 0.84 0.72 0.69 0.44 0.56 0.30 0.58 0.25 0.62
TCF7L2 -0.63 0.59 0.79 0.79 0.27 0.17 0.24 0.04 0.25 0.44 0.57 0.54 0.20 0.75
RBAK -0.63 0.27 0.09 0.48 0.11 0.27 0.07 0.09 0.43 0.57 0.64 0.26 0.25 0.55
PRR3 -0.63 0.47 0.19 0.41 0.57 0.33 0.41 0.47 0.75 0.59 0.86 0.63 0.22 0.52
GABPB1 -0.63 0.38 0.15 0.37 0.26 0.25 0.17 0.18 0.62 0.54 0.57 0.64 0.35 0.66
E2F2 -0.63 0.44 0.25 1.01 0.36 0.30 0.26 0.07 0.84 0.83 0.74 0.74 0.27 0.35
CDC5L -0.63 0.56 0.44 0.54 0.32 0.17 0.32 0.32 0.47 0.54 0.36 0.67 0.35 0.54
ARID2 -0.63 0.60 0.66 1.08 0.32 0.56 0.16 0.24 0.30 0.65 0.35 0.43 0.30 0.64
ZBED3 -0.62 0.70 0.26 1.78 0.54 0.36 0.30 0.08 0.14 0.49 0.50 0.22 0.23 0.01
ZNF207 -0.61 0.31 0.36 0.35 0.29 0.32 0.29 0.24 0.44 0.48 0.42 0.60 0.41 0.43
MATR3 -0.60 0.60 0.63 0.62 0.47 0.40 0.38 0.33 0.21 0.28 0.20 0.56 0.25 0.52
GTF2H2 -0.60 0.27 0.46 0.46 0.31 0.32 0.23 0.09 0.26 0.36 0.30 0.54 0.29 0.43
ZNF828 -0.58 0.61 0.28 0.66 0.25 0.18 0.06 0.05 0.05 0.28 0.04 0.09 0.29 0.13
USP39 -0.58 0.30 0.36 0.47 0.38 0.16 0.24 0.19 0.65 0.54 0.72 0.43 0.23 0.52
HP1BP3 -0.57 0.91 0.81 0.73 0.49 0.33 0.51 0.37 0.46 0.26 0.05 0.49 0.22 0.30
THAP7 -0.56 0.43 0.20 0.37 0.26 0.11 0.26 0.42 0.67 0.67 0.76 0.55 0.55 0.59
NR2C2 -0.56 0.48 0.25 0.32 0.18 0.15 0.09 0.07 0.60 0.67 0.49 0.50 0.15 0.60
NFX1 -0.56 0.38 0.53 0.59 0.41 0.28 0.17 0.35 0.28 0.14 0.16 0.43 0.32 0.39
DOT1L -0.56 0.57 0.18 0.46 0.18 0.14 0.23 0.19 0.74 0.69 0.41 0.64 0.42 0.25
DPF1 -0.55 0.45 0.32 0.11 0.28 0.31 0.05 0.14 0.13 0.17 0.03 0.31 0.06 0.02
UBTF -0.54 0.70 0.61 0.69 0.39 0.33 0.35 0.18 0.32 0.17 0.19 0.38 0.17 0.18
DVL2 -0.54 0.44 0.20 0.62 0.34 0.30 0.29 0.32 0.51 0.63 0.51 0.45 0.38 0.46
CHD2 -0.54 0.53 0.78 0.08 0.31 0.21 0.35 0.09 0.21 0.12 0.47 0.13 0.04 0.18
NFYC -0.52 0.34 0.26 0.10 0.29 0.10 0.24 0.19 0.66 0.39 0.66 0.16 0.16 0.39
MBD3 -0.52 0.43 0.32 0.54 0.31 0.20 0.22 0.21 0.59 0.51 0.50 0.51 0.30 0.47
MYST2 -0.51 0.40 0.44 0.53 0.36 0.45 0.25 0.17 0.46 0.65 0.73 0.46 0.22 0.49
FARSA -0.51 0.08 0.20 0.12 0.12 0.13 0.29 0.28 0.36 0.28 0.44 0.29 0.12 0.38
EP400 -0.51 0.42 0.43 0.29 0.35 0.45 0.22 0.17 0.57 0.48 0.34 0.42 0.27 0.50
ZFP161 -0.50 0.41 0.35 0.28 0.30 0.32 0.23 0.31 0.57 0.55 0.51 0.43 0.40 0.53
SMAD4 -0.50 0.59 0.73 0.83 0.30 0.28 0.22 0.20 0.27 0.57 0.28 0.27 0.14 0.33
TOE1 -0.49 0.39 0.09 0.23 0.36 0.11 0.34 0.28 0.77 0.72 0.79 0.51 0.25 0.65
ZNF586 -0.48 0.63 0.13 0.84 0.33 0.35 0.34 0.27 0.92 0.53 0.34 0.71 0.68 0.11
TADA2L -0.48 0.53 0.36 0.68 0.46 0.35 0.31 0.34 0.68 0.70 0.75 0.49 0.45 0.62
MYNN -0.48 0.68 0.68 0.43 0.48 0.23 0.45 0.31 0.23 0.51 0.12 0.60 0.28 0.49
RBM6 -0.47 0.52 0.37 0.49 0.20 0.44 0.36 0.28 0.17 0.21 0.04 0.22 0.11 0.17
RBM10 -0.47 0.55 0.55 0.61 0.24 0.25 0.21 0.27 0.69 0.67 0.63 0.54 0.38 0.47
FOXJ2 -0.47 0.27 0.49 0.02 0.20 0.14 0.09 0.04 0.31 0.29 0.36 0.26 0.26 0.20
FGD1 -0.47 0.54 0.27 0.18 0.35 0.35 0.22 0.31 0.56 0.64 0.64 0.54 0.41 0.65
ZNF830 -0.46 0.20 0.38 0.49 0.15 0.27 0.12 0.09 0.49 0.59 0.45 0.43 0.21 0.32
ZNF318 -0.46 0.55 0.15 0.55 0.11 0.09 0.19 0.25 0.40 0.29 0.29 0.36 0.39 0.33
ZNF124 -0.44 0.20 0.05 0.80 0.14 0.47 0.47 0.46 0.38 0.43 0.20 0.42 0.21 0.67
STAT3 -0.44 0.79 0.39 0.39 0.41 0.40 0.20 0.17 0.33 0.23 0.56 0.29 0.04 0.63
ZBTB26 -0.37 0.26 0.04 0.40 0.12 0.22 0.34 0.29 0.53 0.72 0.70 0.73 0.24 0.82
FARSB -0.37 0.24 0.59 0.18 0.41 0.32 0.32 0.28 0.49 0.39 0.36 0.44 0.24 0.38
MLLT1 -0.30 0.57 0.52 0.38 0.29 0.16 0.23 0.16 0.26 0.17 0.10 0.08 0.03 0.12
ZNF839 -0.29 0.28 0.48 0.23 0.03 0.20 0.04 0.08 0.02 0.27 0.38 0.14 0.01 0.40
YBX1 -0.25 0.43 0.30 0.32 0.42 0.46 0.26 0.26 0.32 0.26 0.39 0.29 0.12 0.37
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DNA microarray technology has revolutionized and generated a plethora of data 
related to complex gene expression patterns in cancer. Unfortunately, most of 
this information is not being utilized by researchers due to lack of a consolidated 
platform which integrates all the existing available information. This leads to 
underutilization of the full potential of the data from numerous gene expression 
profiling studies with microarrays. For this reason, Oncomine 
(www.oncomine.org), a cancer microarray data base and web based integrated 
data-mining platform, was designed to provide a unifying bioinformatics resource 
combining information from over 4700 microarray experiments. As a result, 
Oncomine contains 65 gene expression datasets comprising nearly 48 million 
gene expression measurements.  
The list of differential TF candidates was further reduced by mining their 
expression in Oncomine. This is based on the hypothesis that TFs up-regulated 
in senescence should be down-regulated in cancer whereas those down-
regulated upon senescence should be up-regulated in cancer as senescence is 
the flip side of cancer and needs to be bypassed in cancer (Hanahan and 
Weinberg 2011). Oncomine data for each of the differential TFs was obtained 
with the help of Dr. Otavia Caballero who at the time was based at Ludwig 
Institute for Cancer Research, New York, USA and had access to the Oncomine 
data base. On analysing the previously obtained list of differential TFs which 
showed complete reversal, this led to identification of 5 up-regulated and 49 
down-regulated TFs, for which expression correlated inversely with cancer as 
well as showing complete reversal upon senescence bypass (Table 3.3). 
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Table 3.3 List of TFs exhibiting inverse correlation with cancer from Oncomine database that 
showed complete reversal upon senescence bypass previously 
 
 
In addition, on carefully analysing the Oncomine data it was observed that some 
TFs from the previous list of 462 differential TFs that did not show complete 
reversal upon senescence bypass also exhibited inverse correlation with cancer. 
As very strict parameters were initially used for refinement (for example only TFs 
that showed complete reversal for all the multiple different components used for 
senescence bypass were included), the TFs which did not show complete 
reversal but exhibited inverse correlation with cancer were also considered 
relevant to be studied. This led to the identification of 5 other upregulated TFs 
and 25 down-regulated TFs, shown in Table 3.4. 
 
 
 
Fold Change Upregulated Downregulated Number of studies Upregulated Downregulated Number of studies Upregulated Downregulated Number of studies
CD36 1.61 5 21 246 8 55 346 10 76 457
EPAS1 0.93 2 16 242 4 36 334 14 47 445
LARP6 0.87 6 11 203 8 16 280 8 28 391
SLC22A4 0.82 0 18 225 1 23 303 1 23 414
NR1H4 0.69 0 11 246 0 16 324 0 16 436
RBM6 -0.47 3 1 252 4 1 330 7 3 441
MYNN -0.48 2 0 182 4 0 259 4 4 370
EP400 -0.51 3 0 241
NFYC -0.52 4 1 226 4 1 304 4 1 415
MATR3 -0.6 17 1 265 18 1 343 18 2 452
ZNF207 -0.61 7 2 242 10 3 320 13 3 431
PRR3 -0.63 5 3 257 7 3 335
GABPB1 -0.63 6 2 253 6 2 331 7 2 442
TCF3 -0.64 25 4 266 33 4 344 35 7 455
SUZ12 -0.64 4 2 206 8 2 284 8 2 395
ZNF664 -0.65 2 0 124 2 0 183 2 1 284
SMARCE1 -0.67 13 1 225 15 2 303 16 7 414
E2F1 -0.68 7 2 261 15 2 339 18 4 449
PSMD12 -0.69 9 1 258
NOC4L -0.71 5 1 154 5 1 231 5 1 343
MTA1 -0.73 13 1 256 13 1 334 13 1 445
GTF2F1 -0.73 3 1 257 3 1 335 3 3 446
PHB2 -0.77 14 2 268 14 2 346 15 2 457
UBE2K -0.78 10 1 258 11 2 336 13 2 447
SP3 -0.81 8 1 264 9 3 342 11 5 450
RAD51 -0.82 11 3 245 23 3 323 27 4 434
CBFB -0.82 23 0 260 32 1 338 33 3 449
CIZ1 -0.83 5 1 232 8 1 310 8 1 421
POGK -0.84 7 0 155 10 0 232 11 1 343
TTF1 -0.86 7 1 146 7 1 223 7 1 334
PSMD11 -0.91 8 1 254 8 1 330 9 1 441
ZNF511 -0.92 2 0 113 4 0 173 7 0 274
DEK -0.94 15 2 257 17 3 335 19 3 446
NUFIP1 -0.98 8 1 191 13 1 268 13 1 379
HMG2L1 -1 9 1 220 9 1 298 9 1 409
HMGB3 -1.01 26 2 234 36 2 312 49 2 393
TWIST1 -1.03 15 3 222 21 6 300 22 13 411
TCF19 -1.04 5 0 138 7 0 198 8 0 299
TFAM -1.06 10 4 263 10 4 341 11 5 452
TEAD4 -1.06 26 0 246 35 0 324 39 0 435
KNTC1 -1.19 19 3 238 43 4 330 51 4 440
C14orf106 -1.38 4 0 180 9 0 271 10 2 382
YEATS4 -1.39 6 2 192 12 3 283 13 3 394
PRMT3 -1.51 3 0 81 9 0 131 9 0 211
WHSC1 -1.52 16 7 231 26 8 323 32 8 434
HMGB1 -1.54 11 0 246 16 1 336 17 3 443
H1FX -1.64 12 0 220 17 0 312 17 1 423
SSRP1 -1.7 9 1 232 16 1 324 18 1 435
MYBL2 -1.85 20 4 251 45 5 343 51 5 454
EZH2 -1.88 32 4 246 61 6 338 68 6 449
FOXM1 -2.66 37 1 244 61 3 344 75 3 455
HMGB2 -2.84 16 2 206 27 2 298 31 4 409
E2F8 -2.85 11 0 174 21 2 265 27 4 376
DEPDC1B -3.05 10 0 121 26 1 195 31 1 296
Cancer vs. Normal Analysis (March,2011) Cancer vs. Normal Analysis (November,2011) Cancer vs. Normal Analysis (March,2014)
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Table 3.4 List of TFs exhibiting inverse correlation with cancer from Oncomine database that did 
not show complete reversal upon senescence bypass 
 
 
After considering all the above described refining strategies and combining the 
TFs from Table 3.3 and Table 3.4, the following up-regulated and down-regulated 
TFs indicated in Table 3.5 and Table 3.6 were shortlisted and prioritized to be 
included in this study, along with p21WAF1, RELA, RELB and CEBPβ because of 
their previously known role in senescence. 
Table 3.5 List of upregulated TFs shortlisted to investigate their functional role which exhibited 
both reversal upon senesce bypass and inverse correlation with cancer 
 
CD36 NR1H4 
DNAJC21 NR3C2 
EPAS1 RGS7 
LARP6 RORA 
MXD1 SLC22A4 
 
  
Fold Change Upregulated Downregulated Number of studies Upregulated Downregulated Number of studies Upregulated Downregulated Number of studies
NR3C2 1.58 2 21 230 3 48 322 3 57 434
RORA 1.31 2 11 226 5 28 326 3 31 437
RGS7 1.08 1 10 229 2 15 321 2 16 431
DNAJC21 0.81 0 6 139 0 6 199 0 6 300
MXD1 0.65 3 17 268 3 28 346 3 34 458
CUL4A -0.47 8 1 257 9 1 335
TFCP2 -0.49 4 1 256 4 1 334
ZNF280C -0.52 6 0 107 12 0 167 12 0 238
IFI16 -0.52 43 2 266 46 5 344 54 6 455
LARP4 -0.54 7 2 250 12 2 328 18 2 439
RBM22 -0.55 5 2 209 5 2 286 5 2 397
AEBP2 -0.55 7 1 142 7 1 202 8 1 303
LARP1 -0.57 7 2 240 10 2 318 11 2 429
PRRX1 -0.6 18 1 216 20 1 294 31 5 405
GLIS2 -0.6 11 0 136 11 0 196
SMARCA5 -0.63 9 1 236 12 1 314
MET -0.63 34 10 252 47 14 330
ADNP -0.65 15 0 229 20 0 307 20 2 418
ARNTL2 -0.68 19 0 150 26 1 227
GATAD2B -0.69 5 0 144 5 0 204 5 1 305
SMARCC1 -0.71 22 3 250 31 4 328 32 5 439
CEBPG -0.71 12 3 254 14 3 332 15 3 443
ETV4 -0.77 16 2 179 22 2 239 30 2 340
PATZ1 -0.8 12 2 226 14 2 304 15 2 415
DNAJC2 -0.84 8 2 255 10 2 331 10 2 440
ZNF107 -0.9 13 1 186 14 1 263 17 1 374
MYBL1 -0.93 17 5 243 20 5 319 21 10 409
TCF4 -1.05 29 15 265 32 16 343 35 21 454
ETS1 -1.18 5 0 226 8 2 326 9 11 438
ZNF22 -1.34 7 3 250
Cancer vs. Normal Analysis (March,2011) Cancer vs. Normal Analysis (November,2011) Cancer vs. Normal Analysis (March,2014)
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Table 3.6 List of downregulated TFs shortlisted to investigate their functional role which exhibited 
both reversal upon senescence bypass and inverse correlation with cancer 
 
ADNP ETS1 LARP1 PRR3 TEAD4 
AEBP2 ETV4 LARP4 PRRX1 TFAM 
ARNTL2 EZH2 MATR3 PSMD12 TFCP2 
B-MYB FOXM1ΔNΔKEN MET 
RAD51 TTF1 
C14ORF106 GABPB1 MTA1 RBM22 TWIST1 
CBFB GATAD2B MYBL1 RBM6 UBE2K 
CEBPG GLIS2 MYNN SMARCA5 WHSC1 
CIZ1 GTF2F1 NFYC SMARCC1 YEATS4 
CUL4A H1FX NOC4L SMARCE1 ZNF107 
DEK HMG2L1 NUF1P1 SP3 ZNF207 
DEPDC1B HMGB1 PSMD11 SSRP1 ZNF22 
DNAJC2 HMGB2 PATZ1 SUZ12 ZNF280C 
E2F1 HMGB3 PHB2 TCF19 ZNF511 
E2F8 IF16 POGK TCF3 ZNF664 
EP400 KNTC1 PRMT3 TCF4  
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3.2 Preparation of constructs for modulating expression 
3.2.1 Objectives 
To study the functional role of the candidate TFs in our model system, i.e. 
CL3EcoR cells, our aim was to prepare desired lentiviral constructs. For 
downregulated TFs, full length lentiviral constructs were prepared. The two 
commonly used lentiviral vectors in this study for ectopically expressing 
downregulated TFs were pLX301 and pLEX-MCS. For upregulated TFs, the 
pGIPZ lentiviral vector has been used (Figure 2.1). The reason for specifically 
using these vectors is firstly because they use the CMV promoter to drive gene 
expression. Secondly, as CL3EcoR cells are G418, hygromycin and blasticidin 
resistant, these vectors confer puromycin resistance as the mammalian selection 
marker. The objective of this section was to prepare the lentiviral constructs for 
TFs which were studied for their biological role in this study.  
3.2.2 Cloning of expression constructs 
3.2.2.1 Gateway recombination cloning of the expression constructs 
Some of the constructs used in this study were previously cloned by Prof. Parmjit 
Jat. To complete the list, the remaining constructs mentioned in the Table 3.7 
below were ordered as full length Gateway entry vectors from DNASU plasmid 
repository https://dnasu.org/DNASU/ and were cloned into the pLX301 
destination lentiviral vector using the Gateway recombination cloning technology 
described in methods section 2.9.7. Most of the Open Reading Frames (ORFs) 
of clones were ordered from DNASU plasmid repository apart from PSMD11, 
which was a kind gift from Dr. David Vilchez, University of Cologne, Germany 
and C14ORF106, Gateway entry clone that was purchased from the Human 
gene and protein database, Japan http://hgpd.lifesciencedb.jp/cgi/ (Goshima et 
al. 2008). After gateway recombination cloning, each construct was sequence 
verified before studying its bypass potential. 
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Table 3.7 List of TFs cloned by Gateway Recombination Cloning 
 
NUF1P1 E2F8 RBM6 
TCF4 RBM22 MYB 
MTA1 NFYC ZNF626 
GABPB1 ZNF280C LARP4 
PRR3 TFCP2 C14ORF106 
B-MYB DNAJC2 TTF1 
CUL4A YEATS4 PRRX1 
AEBP2 HMGB3 TEAD4 
Full length LIN9 PSMD11  
 
3.2.2.2 Cloning of KNTC1 
Full length ORF gateway entry clone for KNTC1 was not available from any 
repository but a cDNA clone in pBluescript (pBS) was kindly provided by Dr. 
Andrea Musacchio, Max Planck Institute of Molecular Physiology, Germany. The 
objective was to clone the full length ORF for KNTC1 into pLEX-MCS. 
The first step was to confirm the pBS-KNTC1 provided; pBS-KNTC1 was 
transformed, plasmid DNA isolated and the ends of the clone were sequence 
verified using M13 forward and reverse primers detailed in Table 3.8. Upon 
sequencing, it was observed that there was an additional ATG very close to the 
ORF, and extra nucleotides present at the 3’ end. Therefore, the 5’- and the 3’- 
end required trimming. Hence, PCR amplification was performed to amplify the 
KNTC1 ORF. 
Table 3.8 M-13 Primers 
 
Primer Sequence 5’3’ 
M13F GTAAAACGACGGCCAG 
M13R GAAACAGCTATGACCATG 
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Initially, the PCR reaction was set up using primers mentioned in Table 3.9 with 
Vent DNA polymerase enzyme. Spe1 and Not1 site, were used in the forward 
and reverse primers (highlighted in orange) for cloning KNTC1 into pLEX-MCS 
(Figure 3.2) vector as they are single unique cutters and not present within the 
KNTC1 ORF. 
Table 3.9 Primers used to amplify TF KNTC1 
 
Primer Sequence 5’3’ 
KNTC1F CGCGCACTAGTCATGTGGAATGATATTGAGCTGC 
KNTC1R CAGCGGCCGCTTACGATAATCCACTAAGAAACATCTTC 
 
 
Figure 3.2 Polylinker site of pLEX-MCS lentiviral vector 
 
Unfortunately, the PCR amplification did not work. Hence, the PCR amplification 
reaction was optimized using different Mg++ concentrations and using a different 
high-fidelity polymerase called, Phusion DNA polymerase. Phusion DNA 
polymerase was used because it can generate long amplification products with 
very high accuracy and speed which was previously not attainable by a single 
enzyme. Phusion DNA polymerase is 52 times more accurate than Taq DNA 
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polymerase and up to 6 times more accurate than Pfu DNA polymerase. The 
reason for the observed high fidelity and robust amplification by Phusion DNA 
polymerase lies in its unique structure in which a novel Pyrococcus like enzyme 
is fused with a processivity-enhancing domain. This leads to tenfold greater 
processivity than Pfu DNA polymerase and twice that of Taq DNA polymerase. 
Melting temperatures and annealing temperatures for the primers were predicted 
using the Thermoscientific website (www.thermofisher.com/tmcalculator). The 
following PCR amplification reaction described in Table 3.10 was set up using 
the Phusion DNA polymerase with varying Mg++ concentrations. 
Table 3.10 PCR amplification reaction to amplify TF, KNTC1 
 
Component 50 µl Reaction Final Concentration 
Water Add to 50 µl  
5X Phusion HF Buffer 10 µl 1X 
10 mM dNTPs 1 µl 200 µM each 
10 µM Forward primer 2.5 µl 0.5 µM 
10 µM Reverse primer 2.5 µl 0.5 µM 
Template DNA 10 ng <250 ng 
DMSO 1.5 µl 3% 
Phusion DNA 
polymerase 
0.5 µl U/µl 
50 mM MgCl2 0 µl, 1 µl, 2 µl, 5 µl  
 
PCR cycling conditions used for the amplification are described in Table 3.11. 
As the annealing temperature calculated using Thermoscientific website was 
72C, it was decided first to carry out a few cycles (5 cycles), at a slightly lower 
annealing temperature i.e. 65.7C as this was the annealing temperature 
predicted for the primer sequence that is homologous to KNTC1.  
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Table 3.11 PCR cycling conditions used to amplify TF KNTC1 
 
Cycle Step Temperature Time Cycles 
Initial Denaturation 98C 30 seconds 1 
Shorter 
version 
Denaturation 
Annealing 
Extension 
98C 
65.7C 
72C 
10 seconds 
20 seconds 
3 minutes 
5 
5 
5 
Longer 
version 
Denaturation 
Annealing and Extension 
98C 
72C 
10 seconds 
3 minutes 
25 
25 
Final extension 72C 
4C 
5 minutes 
hold 
1 
1 
 
Use of high fidelity Phusion DNA polymerase indeed improved the amplification 
of KNTC1 very efficiently. A correct sized band was obtained as indicated in the 
Figure 3.3 below for all Mg++ concentrations studied, the band obtained at 1 µl 
MgCl2 (Lane 4) looked the best. 
 
Figure 3.3 Amplification of TF KNTC1. 
Amplified PCR product was run on 1.4% agarose gel.   Lane 1: Ladder; Lane 2: No DNA negative 
control; Lane 3: 0 µl MgCl2; Lane 4: 1 µl MgCl2; Lane 5: 2 µl MgCl2; Lane6: 5 µl MgCl2 
1 2 3 4 5 6
6766 bp
 115 
To clone the amplified KNTC1 product into the desired pLEX-MCS lentiviral 
vector, amplified DNA was purified and digested with Spe1 and Not1; pLEX-MCS 
vector was similarly digested. The digested insert and vector were purified and 
ligated overnight at 16C. The ligation reaction was used to transform JS4 
competent cells.  Colonies obtained were picked and used to inoculate LB 
superbroth and plasmid DNA was isolated. To check for the presence of the 
correct KNTC1 insert into the pLEX-MCS vector, isolated plasmids were digested 
with Xho1 and also double digested with BamH1 and Not1 as KNTC1 ORF has 
an internal BamH1 restriction site, to confirm for the presence of correct insert.  
Table 3.12 Primers used to sequence verify the KNTC1 
 
Primer Sequence 5’3’ 
KNTC1SQ1 GTTCCAGCTGATAGACAA 
KNTC1SQ2 GACCAGAAAAATTCAGTG 
KNTC1SQ3 CAACTGGTGAAACAGCAC 
KNTC1SQ4 CTGAATCTTCCTTCCATG 
KNTC1SQ5 CTCAGTACTGATGCCCCAG 
KNTC1SQ6 GTTCCTTCAAGATATCTG 
KNTC1SQ7 CACAGCCACGAGTCCATG 
KNTC1SQ8 GAAGAGACACTGAAGAGC 
KNTC1SQ9 GCAGTCTAGTTTGGGCAG 
KNTC1SQ10 CAGAGTGCTGAAGACAGG 
KNTC1SQ11 CTCCTGTAAGCTAGCAAC 
KNTC1SQ12 GCAACGTGATCAACTCTC 
KNTC1SQ13 GACATCTGAGTACTAACAC 
KNTC1SQ14 GAACCATCCTTCTCAATG 
 
After carefully analysing the bands obtained after further digests most of the 
clones look correct but the best five were chosen for sequence verification. 
Sequencing for all five clones chosen was undertaken using multiple overlapping 
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primers that enabled the sequence to be read forward and backwards (Table 
3.12). After sequence analysis, it was found that clone 1 had the correct 
sequence. 
3.2.3 Lentiviral silencing constructs 
Some shRNA constructs for upregulated TFs were already present in our lab. To 
be able to test each upregulated TF with multiple shRNAs more lentiviral pGIPZ 
shRNAmir constructs corresponding to each up-regulated TF mentioned below 
in Table 3.13 were obtained from UCL RNAi silencing consortium. Each of the 
lentiviral pGIPZ shRNA hairpin-containing bacteria was obtained as a LB agar 
stab culture. Bacteria from the top of the stab culture for each hairpin were 
streaked on a LB agar plate containing zeocin (25 µg/ml) and carbenicillin (100 
µg/ml). Bacteria were allowed to grow overnight at 37C, single colonies were 
picked, and plasmid DNA isolated. To confirm the clones have the correct hairpin 
sequence, the plasmid DNA obtained was sequence verified before packaging 
into lentiviruses.  
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Table 3.13 List of shRNA constructs  
 
Up-regulated TF pGIPZ shRNAmir Construct 
NR1H4 V3LHS_311034 
V2LHS_50021 
LARP6 V3LHS_412840 
V3LHS_412841 
EPAS1 V2LHS_113750 
V3LHS_402392 
V3LHS_318637 
V3LHS_318640 
RGS7 V2LHS_32635 
V3LHS_407580 
CEBPβ V3LHS_371451 
V3LHS_371449 
RELA V3LHS_633760 
V2LHS_98065 
 
3.3 Senescence bypass potential of TFs downregulated during 
senescence, upon ectopic expression 
3.3.1 Objectives 
After successful cloning of TFs in an appropriate lentiviral vector, the next step 
was to study the biological effect of the shortlisted TFs in CL3EcoR cells. Hence, 
the main objective here was to determine if ectopic expression of down-regulated 
TFs individually, can bypass senescence. 
Full length lentiviral expression constructs for each shortlisted down-regulated 
TF prepared either in pLX301 or pLEX-MCS lentiviral vector were used. The 
expression constructs were tested in the senescence bypass assay by 
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packaging as lentiviruses and stably transducing the CL3EcoR cells. This leads to 
stable integration of the ectopically expressed TF into the genome of the host 
cell. 35,000 stably transduced cells were assayed for bypass of senescence by 
determining the number of densely growing colonies of cells at the high non-
permissive temperature after 3 weeks in culture. As negative control, RAD51 and 
empty vector pLX301 were used. RAD51 was used as a negative control 
because previous work by other rotation students showed that it does not bypass 
senescence. 
These studies will enable us to determine if ectopic expression of any of the 
down-regulated TFs, bypasses senescence, if yes, then how efficiently.  
3.3.2 Preliminary experiment to test shortlisted down-regulated TFs 
To identify downregulated TFs that have the potential to bypass senescence 
individually, a bypass assay was performed by ectopically expressing the 
downregulated TFs, mentioned in Table 3.14. 
Table 3.14 Downregulated TFs tested in the preliminary experiment 
 
B-MYB FOXM1ΔNΔKEN* MATR3 RAD51 
E2F1 GTF2F1 MYNN TWIST 
ETV4 HMG2L1 NUF1P1 UBE2K 
EZH2 HMGB2 PATZ1 
 
*FOXM1ΔNΔKEN is a constitutively active version of FOXM1 that was previously shown to be 
capable of bypassing senescence (Rovillain et al. 2011). 
Lentiviruses were prepared by transient transfection of HEK293T cells using the 
three-plasmid transfection procedure. 1.5 µg of DNA was transfected for 
constructs mentioned in Table 3.14 along with 1 µg of packaging vectors, i.e. 
pMDG and p8.91, to make lentiviruses. Infections were done in duplicate for each 
TF, in CL3EcoR cells using the 5 ml of lentiviruses made. To aid infection 
polybrene was used at 8 µg/ml. Successfully transduced cells were selected 
using puromycin at 2 µg/ml as the lentiviral vectors confer puromycin resistance 
as a mammalian selection marker. After allowing minimum of two days for 
successfully infected cells to grow, 35000 cells were counted and plated in 
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duplicate in T-75 flasks. The next day cells were shifted to the non-permissive 
temperature, i.e. 38.5C, to assess the senescence bypass potential of each of 
the TF. After three weeks, flasks were stained with 2% methylene blue to count 
the number of densely growing blue colonies. 
Unfortunately, none of the TFs studied in this preliminary experiment showed a 
significant bypass potential (data not shown). pLX301 and RAD51 were used as 
the negative controls. Ectopic expression should be further confirmed by either 
RT-PCR or western blotting if an antibody is available. This will be particularly 
important if the TF does not exhibit any bypass activity, to ensure that lack of 
activity was not due to lack of expression. 
3.4 Optimization and refinement of different parameters to 
maximize efficiency of the senescence bypass assay. 
As none of the downregulated TF tested in the previous preliminary experiment 
showed any bypass potential, it was decided to optimize and refine the different 
parameters of the senescence bypass assay to maximize its efficiency. Previous 
work in the laboratory had shown that B-MYB bypasses senescence efficiently 
in CL3EcoR, whereas RAD51 was consistently negative. Although B-MYB did not 
show any bypass potential when tested in the previous experiment, for the 
different parameters discussed below, the efficiency of the senescence bypass 
assay was assessed and compared using B-MYB and RAD51. The number of 
blue spots observed on flasks after staining with methylene blue depicts healthy 
growing colonies of cells and therefore is a measure of the bypass potential.  
3.4.1 Temperature 
The model of study used in this thesis i.e. CL3EcoR cell line, is a conditionally 
immortalised stringently temperature sensitive cell line. Temperature therefore, 
is a crucial factor. One possibility owing to why none of TF tested in the previous 
experiment showed significant bypass potential can be the high non- permissive 
temperature. Hence, to determine the optimum temperature for the senescence 
bypass assay, experiments were undertaken at different temperatures.  
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CL3EcoR cells are immortal at 33-34C but undergo growth arrest upon shift to a 
higher temperature where the tsSV40LT antigen (U19tsA58) is inactivated. It has 
been previously shown in the laboratory that irreversibility of the growth arrest is 
dependent upon temperature. If the non-permissive temperature to which the 
cells are shifted is raised quite high, nothing grows. However, if the temperature 
is too low, growth arrest can still occur but there is background due to some cells 
escaping growth arrest. At 37C, the growth arrest is reversible whereas at 
temperature >38C, it is irreversible (Rovillain et al. 2011). 
Hence, in the beginning to ensure the assay would work, the temperature was 
reduced to as low as 37.5C. It was found that 37.5C gave background in the 
negative controls. The background was reduced significantly when the 
temperature was increased to 37.8C as shown in Figure 3.4. This depicts how 
wonderfully the CL3EcoR model system is conditioned with regards to 
temperature. The stringency of the senescence bypass assay can be increased 
by raising the non-permissive temperature by as little as 0.3C. 
 
Figure 3.4 Temperature Optimization 
Representative images of flasks studied to maximize efficiency of senescence bypass assay with 
respect to temperature for the negative control (RAD51). Bypass assay was carried out at 
different non-permissive temperatures i.e. 37.5C and 38.7C, at 5% CO2 and 35,000 cells per 
T-75 flask. Flasks were stained after three weeks with 2% methylene blue. Background was 
observed at 37.5C whereas increasing the temperature by 0.3C led to a significant reduction 
of background. 
RAD51, 37.5ºC RAD51, 37.8ºC
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3.4.2 Sequence verification of expression constructs 
Since some of the expression constructs had been made previously, sequence 
verification was undertaken to ensure that they were all correct before testing 
them for their senescence bypass potential. They were transformed into JS4 
cells and fresh plasmid DNA extracted from two independent colonies, followed 
by setting up the DNA sequencing reaction for all the constructs mentioned in 
Table 3.15 according to the protocol described in 2.9.6.  
Table 3.15 List of TFs tested for sequence verification 
 
ADNP GLIS2 NOC4L TCF19 
ARNTL2 GTF2F1 NUF1P1 TCF3 
B-MYB H1FX PATZ1 TEAD4 
CBFB HMG2L1 PHB2 TFAM 
CEBPG HMGB1 POGK TWIST 
CIZ1 HMGB2 PRMT3 UBE2K 
DEK HMGB3 RAD51 WHSC1 
E2F1 IFI16 SMARCA5 ZNF107 
E2F8 LARP1 SMARCC1 ZNF2017 
EP400 MATR3 SMARCE1 ZNF22 
ETS1 MET SP3 ZNF280C 
ETV4 MYBL1 SSRP1 ZNF511 
EZH2 MYNN SUZ12  
 
Sequences were analysed for each of the two different plasmid DNA isolated for 
each TF. For most of the clones, both the plasmid DNA isolated showed correct 
sequence, for some, one of them showed correct sequence. This enabled the 
preparation of a set of sequence verified expression vectors. Only one of the TFs 
showed incorrect sequence for both plasmid DNA preparations; this was B-MYB. 
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This explained the previous results for senescence bypass assay, where B-MYB 
did not show bypass potential. 
3.4.2.1 Gateway recombination cloning of B-MYB 
As the sequence for TF B-MYB was incorrect, B-MYB was constructed again 
from the original Gateway entry vector by Gateway Recombination Cloning. After 
successful recombination cloning, the sequence was verified again. The 
sequence obtained this time was correct. All future experiments utilised the newly 
cloned and sequence verified B-MYB.  
3.4.3 Clean cell lines 
Our senescence bypass assay utilizes two different cell lines, namely HEK293T 
and CL3EcoR. Both cell lines were checked periodically to ensure that they were 
mycoplasma free. Mycoplasma free clean cultures were expanded and frozen in 
bulk. The cell lines were only used for two rounds of lentiviral production and 
lentiviral infection, before a fresh vial of each cell line was revived.  
3.4.4 Cell number 
Previously in the laboratory (Rovillain et al. 2011), in senescence bypass assays, 
stably transduced cells derived after puromycin selection were reseeded at 
50,000 cells in T-75 flasks and then shifted to a higher non-permissive 
temperature. Subsequently, the cell number was reduced to 35,000 to lower the 
background. 
To determine which of the two cell numbers produce improved results in this 
study, experiments were done using the two different cell numbers i.e. 35,000 
and 50,000 cells per T-75 flask for both B-MYB as positive control and RAD51 
as a negative control.  
The fixed number of cells reseeded is crucial as it maintains constant number of 
cells in a flask for each construct after viral infection which allows accurate and 
precise quantification and hence increases reproducibility. Ensuring constant cell 
numbers is also very important as the viral titres vary between constructs and 
between experiments. This experiment also showed improved and consistent 
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results when the cell counting was done using C-chip haemocytometer as 
opposed to a Beckman Coulter Counter. 
As we increased the cell number to 50,000, a clear improvement was seen in the 
extent of senescence bypass for the positive control B-MYB as shown in Figure 
3.5. B-MYB cultures at 50,000 cells appear to be densely stained compared to 
B-MYB cultures at 35000 cells. Also reseeding 50,000 cells for RAD51 did not 
produce any colonies and no significant background was observed. 
 
Figure 3.5 Cell number optimization 
Representative images of flasks studied to maximize efficiency of senescence bypass assay for 
the positive control (B-MYB) and negative control (RAD51). Assay was performed by seeding 
different cell numbers i.e. 35,000 and 50,000 cells per T-75 flask at 5% CO2 and at 37.8C. Flasks 
were stained after three weeks with 2% methylene blue. Reseeding 50,000 cells produced 
stronger bypass for B-MYB with no background in negative control (RAD51). 
 
Hence, in future experiments, where the bypass assay is required to be 
performed under less stringent conditions, 50,000 cells can be reseeded to study 
the bypass potential of TFs as no background was observed for the negative 
control.  
RAD51, 35000
RAD51, 50000
B-MYB, 35000
B-MYB, 50000
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3.4.5 CO2 level 
CO2, another critical parameter for cell growth in tissue culture, was also 
optimized to maximize bypass efficiency. The DMEM medium used to culture 
cells is suitable for growth between 5-10% CO2. Experiments were therefore 
undertaken at two different percentage of CO2, 5% CO2 and 10% CO2. 
 
Figure 3.6 CO2 percentage optimization 
Representative images of flasks studied to maximize efficiency of senescence bypass assay for 
the positive control (B-MYB) and negative control (RAD51). Bypass assay was done at 5% and 
10% CO2 by reseeding 50,000 cells per T-75 flask at 37.8C. Flasks were stained after three 
weeks with 2% methylene blue. No background was observed for either CO2 percentage for 
RAD51, but a greater number of distinct dark densely stained colonies were observed for 5% 
CO2 as opposed to 10% CO2. 
 
It was observed that under the non-permissive conditions, cells at 10% CO2 for 
B-MYB did not appear to be happy and healthy. The cells also appeared to 
readily detach from the surface of the flask at 10% CO2. Therefore, for all the 
future experiments cells were grown at 5% CO2 as colonies for B-MYB at 10% 
CO2 look lightly stained and were fewer in number compared to 5% CO2 as 
shown in Figure 3.6.  
RAD51, 5% CO
2
RAD51, 10% CO
2
B-MYB, 5% CO
2
B-MYB, 10% CO
2
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3.4.6 Infections 
To increase the bypass efficiency of the assay, it was important that the 
infections were highly efficient, and the virus titres were high as possible. To 
increase the efficiency of infection, the strategy adopted was to perform a double 
infection which involves infecting cells with fresh virus consecutively for 6-8 hours 
for a total of about 24 hours rather than a single overnight infection. It was 
observed that double infections greatly enhanced the efficiency of the 
senescence bypass assay. 
The titre of the virus is very dependent on the HEK293T cells; the healthier 
HEK293T cells are, the higher is the titre of the virus. To produce viruses in 
HEK293T cells, transfections were carried out using Fugene (Promega); 
however, Fugene makes cells clump together. Therefore, an experiment was 
undertaken to determine the optimum time interval for exposing the cells to 
Fugene reagent (i.e. 6 hours, 12 hours or 18 hours) such that the cells would 
clump less. It was found that removal of Fugene 6 hours or 18 hours after addition 
of transfection mix was acceptable. It was also found that if Fugene containing 
medium was removed after 6 hours, then Round 2 (virus harvested between 24 
to 48 hours) virus was as high titre as compared to Round 1(virus harvested at 
24 hours) virus. On the other hand, when Fugene containing medium was 
removed after 18 hours then Round 1 virus was higher titre than Round 2 virus. 
The titre of the virus here was estimated by the number of survivors observed 
after puromycin selection after infecting CL3EcoR cells with these lentiviruses. 
3.4.7 Incubation time at non-permissive temperature 
To reduce the experiment duration, we also compared the senescence bypass 
assay results by staining the flasks with methylene blue at the end of two and 
three weeks. It was observed that two weeks were a little early to visualize large 
distinct darkly stained densely growing colonies as shown in Figure 3.7. Cultures 
were therefore always stained after allowing cells to grow at non-permissive 
temperature for three weeks. 
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Figure 3.7 Incubation time optimization 
Representative images of flasks studied to maximize efficiency of senescence bypass assay for 
the positive control (B-MYB) and negative control (RAD51). Bypass assay was done at 37.8C, 
5% CO2 and 50,000 cells per T-75 flask. Flasks were stained after incubating cells at 37.8C for 
two weeks and three weeks with 2% methylene blue.  Colonies obtained after staining the B-
MYB flasks after two weeks were very lightly stained and small as compared to colonies obtained 
after three weeks which were densely stained, dark and large. 
 
3.5 Assessment of senescence bypass potential after 
standardization of senescence bypass assay 
After optimization and refinement of the various parameters of senescence 
bypass assay, an experiment was designed to study the bypass potential of the 
downregulated TF mentioned in Table 3.16. Lentiviruses were made for each of 
the candidate TF in HEK293T cells and used to stably transduce CL3EcoR cells 
to study the senescence bypass potential following the protocol described in 
section 2.6. The results obtained by staining the flasks with methylene blue after 
three weeks at non-permissive temperature are shown below in Figure 3.8. 
  
RAD51, 2 weeks
RAD51, 3 weeks
B-MYB, 2 weeks
B-MYB, 3 weeks
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Table 3.16 TFs studied after optimization of different parameters of senescence bypass assay 
 
B-MYB FOXM1ΔNΔKEN MYNN WHSC1 
DEK HMG2L1A RAD51 
 
DEPDC1 HMGB2 TWIST1 
 
EZH2 MATR3 UBE2K 
 
 
No background was observed for the negative control i.e. RAD51. The most 
interesting result from this experiment is the strong bypass potential observed 
for B-MYB as significant number of dense dark blue stained colonies were 
observed. This highlighted the importance of the sequence verification which led 
to identification of B-MYB clone being incorrect. Spotting the incorrect clone and 
cloning the correct B-MYB construct, led to the identification of the strong bypass 
potential of B-MYB as depicted clearly in Figure 3.8. For the remaining TFs 
studied in this experiment, no significant number of blue colonies were observed. 
This suggests that these TFs (DEK, DEPDC1, EZH2, FOXM1ΔNΔKEN, 
HMG2L1A, HMGB2, MATR3, MYNN, RAD51, TWIST1, UBE2K and WHSC1) do 
not play a critical role in bypassing senescence when studied individually. Other 
possibility could be that these TFs were not expressed in the cells as biochemical 
analysis has not confirmed their expression.  
 
 128 
 
Figure 3.8 Senescence bypass assay of down-regulated TFs examined individually 
Representative images of flasks of different TFs studied for their senescence bypass potential. 
Bypass assay was done at 37.8C, 5% CO2 and 50,000 cells per T-75 flask. Flasks were stained 
after three weeks with 2% methylene blue. RAD51 was used as a negative control. B-MYB 
displayed the strongest bypass potential among all the TFs studied by producing large, multiple, 
darkly stained colonies. 
 
3.6 Senescence bypass potential of TFs upregulated during 
senescence, upon RNA silencing 
3.6.1 Objective 
The objective of these experiments was to determine if silencing the expression 
of up-regulated TFs had the potential to individually bypass senescence. 
Lentiviral pGIPZ shRNAmir constructs corresponding to each up-regulated TF 
were used to silence expression. To rule out any non-specific bystander effects 
which might arise due to off-target effects from vector based shRNAs, 
senescence bypass was studied using at least two or more different shRNAs 
DEK DEPDC1 EZH2 FOXM1∆N∆KEN HMG2L1
HMGB2 MATR3 B-MYB MYNN
TWIST1
UBE2K
WHSC1 RAD51
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targeting the same upregulated TF (Echeverri et al. 2006; Birmingham et al. 
2006). It is highly unlikely to be an off-target effect if two or more different shRNAs 
targeting the same TF, show strong senescence bypass.  
Senescence bypass assay was performed to assess the bypass potential as 
explained in section 2.6. The senescence bypass assay involves packaging the 
pGIPZ shRNAmir constructs as lentiviruses, followed by infection of CL3EcoR cells 
and selection for the stably transduced cells in puromycin at 6 µg/ml. High 
concentration of puromycin (6 µg/ml) was used for selection to enrich for the cells 
which have the highest expression of the shRNA’s to ensure efficient silencing. 
This had been determined empirically using a p21WAF1 shRNAmiR from the 
pGIPZ shRNAmiR library, by Dr Kat Wanek, a previous PhD student in the 
laboratory (Wanek 2011). As positive control for these experiments, silencing of 
p21WAF1 was used and pRS Lamin A/C was used as a negative control.  
This allowed identification of up-regulated TFs which when silenced, bypass 
senescence. It also aided in studying the efficiency of senescence bypass and 
identification of the most active lentiviral pGIPZ shRNAmiR for each TF.  
3.6.2 Preliminary experiment to test shortlisted up-regulated TFs 
To identify which upregulated TFs have the potential to bypass senescence, 
preliminary senescence bypass assay was performed by silencing each 
shortlisted upregulated TF with at least two different shRNAmiRs. Fourteen 
upregulated TFs were examined once with two different shRNAmiRs, each in 
duplicate. As positive control for these experiments, silencing of p21WAF1 was 
used and as negative control pRS Lamin A/C was used.  
3.6.2.1 Development of an alternative method for analysis of bypass potential 
Until now the colonies obtained after three weeks incubation at non-permissive 
temperature were stained with 2% methylene blue and the dark densely stained 
colonies were counted manually independently twice by placing the flask on a 
light box. To cross check the manual count and validate the results obtained, 
another method was devised to calculate the area of the flask stained in blue. 
Definiens Developer XD software was used to develop an algorithm. The 
algorithm was written to: first, identify the flask, exclude the top of the flask and 
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calculate the surface area of the flask. Additionally, the program could analyse 
scanned flask images to distinguish between the blue stained area of the flask 
and the unstained area of the flask.  Development of this method required 
extensive thresholding to be able to specifically pick up the blue stained colonies. 
The result obtained by the iterative testing of the flasks using the optimised 
method developed, generated the total area of the flask, area stained in blue and 
unstained area. Hence, to assess the extent of bypass, percentage area stained 
in blue was calculated by dividing the area stained in blue to the total area. The 
program was developed by Dr. Matthew Ellis, Image analyst, Division of 
Neuropathology, UCL using Definiens Developer XD software. 
Percentage area stained =  
Area stained in blue (cm2)
Total flask area (cm2)
 ×  100 
Hence, the bypass results obtained for each experiment undertaken in this study 
were analysed by manual counting as well as by computational analysis. For 
each experiment, apart from the representative flask images obtained after 
staining, corresponding flask images are shown for the alternative method used, 
where the blue spots indicate the specific blue area included by the software to 
calculate the area in blue. Therefore, for each experiment, extent of senescence 
bypass is now verified by both manual counting as well as software analysis. 
Figure 3.9 shows multiple optimisation and different thresholding of the program, 
to develop the final version of the analysis method which can specifically pick up 
blue colonies and provide confirmatory evidence for the manual count.  
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Figure 3.9 Optimisation of the software algorithm 
Definiens Developer XD software was used to calculate the area of the flask covered in blue. 
Multiple different versions of the algorithm were developed to set the threshold to specifically pick 
blue colonies and to reduce the background picked up as blue. The first version of the algorithm 
indicated as Version 1 picked up faint shadow of blue present in the original scanned image of 
the flask as blue. This led to computing high area covered in blue than actual area covered in 
blue. Various refinements were undertaken to train the program to specifically pick up blue 
colonies. Area covered in blue calculated by different versions of algorithm is mentioned below 
each flask. 
 
3.6.2.2 Assessment of senescence bypass potential 
For studying the bypass potential of upregulated TFs, silencing of p21WAF1 was 
used as a positive control for these experiments. For ease of representation 
p21WAF1 is discussed here separately as it clearly shows that silencing p21WAF1 
produces a saturated flask covered with blue spots after staining the healthy 
growing colonies obtained after the cultures were allowed to grow for three 
weeks at the non-permissive temperature indicating the strong bypass potential 
observed after silencing p21WAF1 (Figure 3.10). p21WAF1 flask is too confluent to 
be counted manually; therefore, in the experiments discussed below when each 
up-regulated TF is studied individually, p21WAF1 is excluded from analysis. Strong 
bypass potential would be expected upon silencing p21WAF1 because the p53-
p21WAF1 pathway is a key pathway in manifesting senescence, indicating 
appropriate use of CL3EcoR model system for studying senescence bypass. 
Version 1 Version 2 Version 3 Version 4
Version 5 Version 6 Version 7 Version 8
Original Image
Blue area = 32.69 cm2
Blue area = 2.78 cm2Blue area = 2.45 cm2Blue area = 2.11 cm2Blue area = 1.40 cm2
Blue area = 3.74 cm2Blue area = 3.61 cm2Blue area = 2.35 cm2
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Figure 3.10 Senescence bypass assay after silencing of p21WAF1 
p21WAF1 was silenced using shRNAmiR V2LHS_230370. p21WAF1 has been studied multiple times 
in different independent experiments. Bypass assays were performed at 5% CO2, 37.8°C and 
38.9°C reseeding 35,000 cells as well as 50,000 cells per T-75 flask. Flask was stained with 2% 
methylene blue after three weeks. Silencing of p21WAF1 works very efficiently both under stringent 
and non-stringent conditions showing the strongest bypass potential resulting in completely 
saturated flask making it impossible to count individual colonies manually. 
 
RELA is known to have a role in the canonical NF-κB signalling pathway and 
silencing of RELA has been shown to bypass senescence in CL3EcoR previously 
(Rovillain et al. 2011). Silencing RELA showed a weak potential to bypass 
senescence in my experiments as shown in Figure 3.11. Out of the two 
shRNAmiRs studied, one of them (V2LHS_98066) showed stronger bypass 
relative to the other (V2LHS_98068). Interestingly, the preliminary experiment 
identified four other TFs apart from RELA that have for the first-time exhibited 
some senescence bypass potential, where the extent of bypass was greater than 
RELA.  
Silencing EPAS1 (Endothelial PAS Domain Protein1) using two different 
shRNAmiRs generated a greater number of dense dark blue stained colonies 
shown in Figure 3.12. This exhibited the potential of EPAS1 to bypass 
senescence in CL3EcoR cells. RGS7 (Regulator of G-protein Signalling 7) and 
LARP6 (La Ribonucleoprotein Domain Family, Member 6) also exhibited same 
bypass potential which was greater than the negative control. For both RGS7 
and LARP6, silencing by one shRNAmiR i.e. V2LHS_32637 for RGS7 and 
p21
 133 
V3LHS_412842 for LARP6 showed better bypass than silencing with other 
shRNAmiRs (Figure 3.13 and Figure 3.14). NR1H4(Nuclear receptor sub family 
1, Group H, Member 4) showed marginal bypass potential with both different 
shRNAmiRs as shown in Figure 3.15.  
  
 134 
 
  
 
 
V2LHS_98066A V2LHS_98066B
Lamin
V2LHS_98068A V2LHS_98068B
V
2L
H
S
_9
80
66
A
V
2L
H
S_
98
06
6B
V
2L
H
S
_9
80
68
A
V
2L
H
S
_9
80
68
B
La
m
in
0
10
20
30
N
u
m
b
e
r
o
f
g
ro
w
in
g
c
o
lo
n
ie
s
A
V2LHS_98066A V2LHS_98066B
Lamin
V2LHS_98068A V2LHS_98068B
V2
LH
S_
98
06
6A
V2
LH
S_
98
06
6B
V2
LH
S_
98
06
8A
V2
LH
S_
98
06
8B
La
m
in
0.0
0.5
1.0
1.5
2.0
2.5
P
e
rc
e
n
ta
g
e
a
re
a
s
ta
in
e
d
B
Figure 3.11 Senescence bypass assay after silencing of up-regulated TF, RELA.  
RELA was silenced using shRNAmiR V2LHS_98066 and V2LHS_98068 as indicated on top of 
each representative flask. Assay was performed at 5% CO2, 37.8°C and at 35,000 cells per T-
75 flask. Flasks were stained with 2% methylene blue after three weeks.  Silencing of p21WAF1 
was used as a positive control and silencing of Lamin A/C as a negative control. A) Manual 
analysis: Representative flask images obtained after staining and quantitative representation of 
bypass assay depicted graphically by plotting the average number of colonies (+/- SD) obtained 
after independently counting each replicate twice. B) Computational analysis: Corresponding 
flask images shown with blue spots depicting the area of the flask computed as blue areas by 
the computer algorithm and quantitative representation of bypass assay presented graphically 
by plotting the calculated percentage area (+/- SD) covered in blue by Definiens Developer XD 
software for each of the replicates.  
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Figure 3.12 Senescence bypass assay after silencing of up-regulated TF, EPAS1.  
EPAS1 was silenced using shRNAmiR V2HS_113752 and V2HS_22592 as indicated on top of 
each representative flask. Both shRNAs showed senescence bypass. Assay was performed as 
before. A) Manual analysis: Representative flask images obtained after staining and quantitative 
representation of bypass assay depicted graphically by plotting the average number of colonies 
(+/- SD) obtained after independently counting each replicate twice. B) Computational analysis: 
Corresponding flask images shown with blue spots depicting the area of the flask computed as 
blue areas by the computer algorithm and quantitative representation of bypass assay presented 
graphically by plotting the calculated percentage area (+/- SD) covered in blue by Definiens 
Developer XD software for each of the replicates.  
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Figure 3.13 Senescence bypass assay after silencing of up-regulated TF, RGS7.  
RGS7 silenced using shRNAmiR V2LHS_32637 and V3LHS_353896. Silencing of RGS7 using 
shRNAmiR V2LHS_32637 showed stronger bypass than V3LHS_353896. Assay was performed 
as before. A) Manual analysis: Qualitative and quantitative analysis B) Computational analysis: 
Corresponding flask images showing the blue spots which mark the area of the flask computed 
as blue areas by the computer algorithm and quantitative representation of bypass assay 
presented graphically by plotting the calculated percentage area.  
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Figure 3.14 Senescence bypass assay after silencing of up-regulated TF, LARP6.  
LARP6 silenced using shRNAmiR V2LHS_175186 and V3LHS_412842. Silencing of LARP6 
using shRNAmiR V3LHS_412842 exhibited stronger bypass than V2LHS_175186. Bypass 
assay was conducted as before. A) Manual analysis: Qualitative and quantitative analysis B) 
Computational analysis: Corresponding flask images showing the blue spots which mark the 
area of the flask computed as blue areas by the computer algorithm and quantitative 
representation of bypass assay presented graphically by plotting the calculated percentage area.  
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Figure 3.15 Senescence bypass assay after silencing of up-regulated TF, NR1H4.  
NR1H4 silenced using shRNAmiR V3LHS_311033 and V2LHS_50023. Assay was performed 
as before. A) Manual analysis: Qualitative and quantitative analysis B) Computational analysis: 
Corresponding flask images showing the blue spots which mark the area of the flask computed 
as blue areas by the computer algorithm and quantitative representation of bypass assay 
presented graphically by plotting the calculated percentage area.  
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Therefore, of the 14 upregulated TFs tested in this preliminary experiment at 
37.8C, five exhibited some senescence bypass potential whereas, the 
remainder did not show any bypass (CD36, SLC22A4, NR3C2, MXD, RELB, 
CEBPβ, RORA, DNAJC21 and PMS1). Data is shown below for SLC22A4 
(Figure 3.16), CEBPβ (Figure 3.17), RORA (Figure 3.18), and DNAJC21 (Figure 
3.19). It is possible that either these TFs which did not show any bypass do not 
have a critical role in regulating senescence or they were not expressed in our 
model system.  
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Figure 3.16 Senescence bypass assay after silencing of up-regulated TF, SLC22A4.  
SLC22A4 silenced using shRNAmiR V2LHS_153091 and V2LHS_404065. Assay was 
performed at 5% CO2, 37.8°C and at 35,000 cells per T-75 flask. Silencing of p21WAF1 was used 
as a positive control and silencing of Lamin A/C as a negative control. A) Manual analysis: 
Representative flask images obtained after staining and quantitative representation of bypass 
assay depicted graphically by plotting the average number of colonies (+/- SD) obtained after 
independently counting each replicate twice. B) Computational analysis: Corresponding flask 
images shown with blue spots depicting the area of the flask computed as blue areas by the 
computer algorithm and quantitative representation of bypass assay presented graphically by 
plotting the calculated percentage area (+/- SD) covered in blue by Definiens Developer XD 
software for each of the replicates.  
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Figure 3.17 Senescence bypass assay after silencing of up-regulated TF, CEBPβ.  
CEBPβ silenced using shRNAmiR V2LHS_245072 and V2LHS_48323.  
 
 
 142 
  
 
 
V2LHS_32210A V2LHS_32210B
Lamin
V3LHS_376231A V3LHS_376231B
V
2L
H
S
_3
22
10
A
V
2L
H
S
_3
22
10
B
V
3L
H
S
_3
76
23
1A
V
3L
H
S
_3
76
23
1B
La
m
in
0
2
4
6
8
N
u
m
b
e
r
o
f
g
ro
w
in
g
c
o
lo
n
ie
s
A
V2LHS_32210A V2LHS_32210B
Lamin
V3LHS_376231A V3LHS_376231B
V2
LH
S_
32
21
0A
V2
LH
S_
32
21
0B
V3
LH
S_
37
62
31
A
V3
LH
S_
37
62
31
B
La
m
in
0.0
0.2
0.4
0.6
0.8
1.0
P
e
rc
e
n
ta
g
e
a
re
a
s
ta
in
e
d
B
Figure 3.18 Senescence bypass assay after silencing of up-regulated TF, RORA.  
RORA silenced using shRNAmiR V2LHS_32210 and V3LHS_376231.  
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Figure 3.19 Senescence bypass assay after silencing of up-regulated TF, DNAJC21.  
DNAJC21 silenced using shRNAmiR V2LHS_26661 and V2LHS_336001.  
 
 
 144 
3.6.3 Further assessment of senescence bypass potential of upregulated 
TFs identified from the preliminary experiment  
The senescence bypass assay was repeated for the selected TFs which showed 
some bypass potential in the preliminary experiment described above. This time 
the assay was done under stringent temperature conditions i.e. 38.9C and was 
conducted using additional shRNAmiRs for each candidate gene. Senescence 
bypass potential was tested for CEBPβ, EPAS1, LARP6, NR1H4, RELA and 
RGS7. Silencing of p21WAF1 using shRNAmiR V2LHS_230370 was used as a 
positive control and silencing of Lamin A/C was used as a negative control. 
For CEBPβ, the bypass potential was tested using four different shRNAmiRs. 
Very weak bypass potential was obtained under stringent conditions as shown 
in Figure 3.20. Two shRNAmiRs namely, V2LHS_48323 and V3LHS_371449 
showed some bypass potential compared to the negative control. Senescence 
bypass potential of EPAS1 was assesed using five different shRNAmiRs. Some 
marginal bypass potential was observed as shown by presence of few stained 
colonies. However, none of the shRNAmiRs exhibited significantly stronger 
bypass potential than the negative control under the stringent conditions as 
shown in Figure 3.21. For LARP6 and NR1H4, four different shRNAmiRs were 
used to study its bypass potential under stringent conditions. None of the 
shRNAmiR showed a significantly higher bypass potential relative to negative as 
depicted in Figure 3.22 and Figure 3.23 respectively. 
Out of the four different shRNAmiRs used to test the bypass potential of RGS7, 
only one shRNA called V3LHS_407580 showed stronger bypass potential 
compared to negative as shown in Figure 3.24.  For RELA, the bypass potential 
was tested using four different shRNAmiRs. Only one shRNA i.e. V2LHS_98068 
showed significantly higher bypass potential in comparison to the negative 
control as indicated in Figure 3.25. 
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Figure 3.20 Senescence bypass assay after silencing of up-regulated TF, CEBPβ.  
CEBPβ silenced using multiple different shRNAmiRs V2LHS_48323, V2LHS_245072, 
V3LHS_371449 and V3LHS_371451 as indicated on top of each representative flask. This time 
the assay was performed under stringent conditions at 5% CO2, 38.9°C and at 35,000 cells per 
T-75 flask. A) Manual analysis: Representative flask images obtained after staining and 
quantitative representation of bypass assay depicted graphically by plotting the average number 
of colonies (+/- SD) obtained after independently counting each replicate twice. B) 
Computational analysis: Corresponding flask images shown with blue spots depicting the area 
of the flask computed as blue areas by the computer algorithm and quantitative representation 
of bypass assay presented graphically by plotting the calculated percentage area (+/- SD) 
covered in blue by Definiens Developer XD software for each of the replicates. Statistical 
analysis was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, 
**p<0.01, ***p<0.001)  
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Figure 3.21 Senescence bypass assay after silencing of up-regulated TF, EPAS1.  
EPAS1 silenced using multiple different shRNAmiRs V2LHS_113752, V2LHS_225592, 
V3LHS_318637, V3LHS_318640 and V3LHS_402392. The assay was performed under 
stringent conditions at 5% CO2, 38.9°C and at 35,000 cells per T-75 flask. A) Manual analysis: 
Representative flask images obtained after staining and quantitative representation of bypass 
assay depicted graphically by plotting the average number of colonies (+/- SD) obtained after 
independently counting each replicate twice. B) Computational analysis: Corresponding flask 
images shown with blue spots depicting the area of the flask computed as blue areas by the 
computer algorithm and quantitative representation of bypass assay presented graphically by 
plotting the calculated percentage area (+/- SD) covered in blue by Definiens Developer XD 
software for each of the replicates. Statistical analysis was conducted using One-way ANOVA, 
Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001)  
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Figure 3.22 Senescence bypass assay after silencing of up-regulated TF, LARP6.  
LARP6 silenced using multiple different shRNAmiRs V2LHS_175186, V3LHS_412842, 
V3LHS_412840 and V3LHS_412841. Bypass assay was performed under similar stringent 
conditions described above. A) Manual analysis B) Computational analysis Statistical analysis 
was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001)  
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Figure 3.23 Senescence bypass assay after silencing of up-regulated TF, NR1H4.  
NR1H4 silenced using multiple shRNAmiRs V3LHS_311033, V2LHS_50023, V2LHS_50021 
and V3LHS_311034. Bypass assay was performed under the stringent conditions explained 
previously. A) Manual analysis B) Computational analysis Statistical analysis was conducted 
using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001)  
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Figure 3.24 Senescence bypass assay after silencing of up-regulated TF, RGS7.  
RGS7 silenced using multiple different shRNAmiRs V2LHS_32637, V3LHS_353896, 
V2LHS_32635 and V3LHS_407580. Bypass assay was conducted under stringent conditions 
as described before. A) Manual analysis B) Computational analysis Statistical analysis was 
conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001)  
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Figure 3.25 Senescence bypass assay after silencing of up-regulated TF, RELA.  
RELA silenced using multiple different shRNAmiRs V2LHS_98066, V2LHS_98068, 
V2LHS_98065 and V3LHS_633760. Bypass assay was carried out under stringent conditions 
as above. A) Manual analysis B) Computational analysis Statistical analysis was conducted 
using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001)  
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Therefore, the results obtained after studying the shortlisted up-regulated TFs 
identified from preliminary experiments were not very encouraging. It was found 
that under stringent conditions with multiple shRNAmiRs none of the TFs 
reported significantly strong bypass potential with more than two shRNAmiRs. 
Silencing of expression needs to be confirmed by either q-RT PCR or western 
blotting to determine if there is any correlation between the degree of silencing 
and the bypass potential.   
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Chapter 4 Dissecting the role of DREAM complex 
associated components in cellular senescence 
4.1 Reconstituting the active MMB-FOXM1 complex 
4.1.1 Objectives 
Recent studies by DeCaprio and colleagues have shown that in mammalian 
cells, the p107 and p130 RB-like pocket proteins associate with dimerization 
partner (DP), E2F and multi-vulval class B (MuvB) proteins to form the DREAM 
complex which represses most if not all gene expression in quiescence 
(Sadasivam and DeCaprio 2013; Litovchick et al. 2007). The MuvB core complex 
comprises five proteins: LIN9, LIN37, LIN52, LIN54 and RBBP4. DeCaprio and 
colleagues have further shown that in mammalian cells, the MuvB core complex 
dissociates from p130 and sequentially recruits B-MYB, during S phase, and 
FOXM1, in G2 phase, to activate mitotic gene expression as illustrated in Figure 
4.1 (Schmit et al. 2007; Sadasivam et al. 2012).  
 
Figure 4.1 Regulation of cell cycle progression by association of MuvB with B-MYB and FOXM1. 
MuvB core complex comprises five proteins: LIN9, LIN37, LIN52, LIN54 and RBBP4. MuvB 
associates with p107/p130 RB-like pocket proteins, dimerization partner (DP) and E2F to form 
the repressive DREAM complex which is capable of inducing quiescence in G0. Upon 
appropriate signals stimulating cell cycle entry, MuvB core complex dissociates from p130, 
sequentially recruiting B-MYB, during S-phase and FOXM1, during G2/M phase to their 
respective target gene promoters activating mitotic gene expression. Upon signals stimulating 
repression of cell cycle progression, phosphorylation of MuvB is required for re-association of 
MuvB with p107/p130 RB-like pocket proteins, dimerization partner (DP) and E2F leading to re-
assembly of DREAM complex which is capable of repressing cell cycle progression. Adapted 
from (Mowla et al. 2014; Engeland 2017) 
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Previous expression profiling of CL3EcoR cells had shown that B-MYB and 
FOXM1 were highly down-regulated upon senescence growth arrest and this 
was reversed when it was bypassed as shown in Figure 4.2. After studying 
multiple different TFs that are downregulated in senescence for their bypass 
potential, it was found that only B-MYB showed consistently strong bypass 
potential. No other TFs when tested individually in senescence bypass assay 
exhibited significant bypass potential. Along with B-MYB and FOXM1, LIN9 and 
LIN52 were also found to be downregulated during senescence in the expression 
profiling studies done previously in the lab as shown below in Figure 4.2. LIN54 
and RBBP4 were also downregulated upon senescence growth arrest but this 
was not significant (data not shown). In contrast LIN37 was found to be up-
regulated upon senescence arrest as shown below (Figure 4.2). 
 
 
Figure 4.2 Log2 fold changes in expression upon senescence growth arrest (GA) 
Positive numbers for GA indicate up-regulation and are shaded in red, (log2 fold change less 
than 0.5 are shaded in light red). Negative numbers indicating down-regulation are shaded in 
green (log2 fold change less than -0.5 are shaded in light green). Also shown is the effect on 
expression when senescence was bypassed using SV40 LT (wt_LT) antigen, HPV16/18 E7, 
Adenovirus E1A, GSEp53 (dominant negative p53), E2F-DB (dominant negative E2F), 
p53shRNA (pRS_p53) and p21WAF1 shRNA (pRS_p21WAF1).  The changes in expression were 
reversed upon bypass. 
 
The role of DREAM complex in inducing quiescence is well studied. On the other 
hand, the role of DREAM complex in senescence growth arrest has not been 
studied in depth. Therefore, the objective of this section was to study the 
relevance of DREAM complex and associated complexes in regulating 
senescence growth arrest. This was studied by testing if the components of the 
GA wt_LT GSE_p53 E1A E7 E2F-DB pRS_p53 pRS_p21
FOXM1 -2.66 2.57 2.19 2.56 2.07 2.31 2.08 1.89
B-MYB -1.85 1.70 1.15 3.15 1.00 1.09 0.98 0.80
LIN9 -1.58 1.50 1.39 1.80 0.96 1.49 1.33 1.17
LIN9 -0.35 0.33 0.03 0.24 0.18 0.37 0.07 0.11
LIN37 0.54 -0.68 -0.37 -0.79 -0.86 -0.88 -0.66 -0.72
LIN52 -0.67 0.30 0.50 0.53 0.03 0.05 0.13 0.18
RBL1 -1.68 1.12 1.15 1.23 0.90 0.90 0.56 0.77
RBL1 -1.25 0.64 0.49 0.91 0.71 0.55 0.89 1.00
RBL1 -0.86 0.83 0.17 1.09 0.92 0.73 0.58 0.77
DYRK1A -0.77 0.53 0.55 0.54 0.21 0.13 0.40 0.19
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active form of DREAM complex i.e. (MMB-FOXM1) could bypass senescence, 
as they are known to promote cell cycle progression. 
To study this, the approach used was motivated by the strategy used by 
Takahashi and Yamanaka, wherein, they introduced 24 TFs simultaneously, by 
retroviral infection (Takahashi and Yamanaka 2006). As none of the 
downregulated TFs except B-MYB, showed significant bypass potential on its 
own when studied individually, it was decided to mix TFs together and study them 
simultaneously.  
Hence, in this section the functional role of the active form of DREAM complex 
was studied in detail in a series of experiments by reconstituting the components 
of active form of the DREAM complex by mixing the relevant TFs together which 
make up the complex. Also, the key individual components of the active complex 
were characterized in detail where relevant.  
4.1.2 Preliminary reconstitution experiment 
Since B-MYB and FOXM1 have been suggested to play a role in bypassing 
senescence and B-MYB, FOXM1, along with LIN9 and LIN52 are downregulated 
during senescence, it was very interesting to study if the components of the 
active form of DREAM complex (MMB-FOXM1) would have a role in bypassing 
senescence. As in previous experiments only B-MYB could bypass senescence 
in CL3EcoR cells, the aim here was to determine if different components synergise 
when expressed together and if they act in combination with the MuvB proteins. 
Dr. DeCaprio had kindly provided hygromycin resistant expression constructs for 
LIN9, LIN37, LIN52 and LIN54. Since CL3EcoR cells are hygromycin resistant, 
each of the inserts was cloned into the pLEX-MCS puromycin resistant lentiviral 
vector. A preliminary reconstruction experiment was done where B-MYB, 
FOXM1 and MuvB components of the complex were mixed together. 
FOXM1NKEN, a constitutively active form of FOXM1 cloned in pLEX-MCS 
was used in the experiment (Rovillain et al. 2011). Equal amounts of DNA i.e. 
1ug for each TF were mixed first to make a DNA pool as described in Table 4.1. 
From this DNA pool, 1.5ug DNA was then used to prepare lentiviruses in 
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HEK293T cells following the transient packaging protocol described in section 
2.5. 
B-MYB studied individually was used as a positive control for the experiment as 
it had consistently worked previously. For negative control non-infected cells, 
empty vector pLX301 and RAD51 found to be consistently negative were used.  
Table 4.1 DNA pools made to reconstitute active whole complex (MMB-FOXM1) 
 
Reconstituted complex Constituents 
WC1 1 µg each of LIN9, LIN37, LIN52, LIN54, 
FOXM1NKEN13* and B-MYB 
WC2 1 µg each of LIN9, LIN37, LIN52, LIN54, 
FOXM1NKEN17* and B-MYB 
5+1 B-MYB 5 µg of RAD51 (five-sixth) and 1 µg of B-MYB (one 
sixth) 
* 13 and 17 depict two different clones for FOXM1NKEN 
CL3EcoR cells stably transduced after infection with the different lentivirus pools 
and puromycin selection were reseeded at 50,000 cells per T-75 flask and 
studied for bypass potential. The senescence bypass for this reconstruction 
experiment was done under very stringent conditions of temperature as high as 
38.9C. The use of such a high temperature reduced the efficiency of B-MYB, 
minimized the background and allowed us to determine if there was any synergy 
present among the different components.  
The senescence bypass results obtained from this preliminary experiment were 
striking. The results obtained from this preliminary experiment presented in 
Figure 4.3 are revealing in several ways. A large number of densely blue stained 
growing colonies were obtained for the reconstituted MMB-FOXM1 complex. No 
colonies were observed in any of the negative controls whereas B-MYB as 
expected presented lots of blue colonies. Interestingly the cells transduced with 
one sixth B-MYB, which is the amount of B-MYB present in WC1 and WC2, 
produced only very few colonies. However, RAD51 is not an ideal negative 
control for combining with B-MYB as it is possible that RAD51 might oppose the 
effect of B-MYB. 
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The results indicated that reconstitution of the active components of the DREAM 
complex (MMB-FOXM1) bypass senescence very efficiently. It was as efficient 
as when B-MYB was studied alone. Second, the pool of 5+1 B-MYB as shown 
in Figure 4.3, yielded very few densely growing colonies as this flask was infected 
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Figure 4.3 Senescence bypass assay after reconstituting active MMB-FOXM1 
Bypass assay was performed at 5% CO2 and 38.9C with 50,000 cells per T-75 flask. Single 
representative flasks from the internal repeats are shown. B-MYB was used as a positive control 
and cells only, pLX301 empty vector and RAD51 were used as negative controls. A) Manual 
analysis: Representative flask images obtained after staining and quantitative representation of 
bypass assay depicted graphically by plotting the average number of colonies (+/- SD) obtained 
after independently counting each replicate twice. B) Computational analysis: Corresponding 
flask images shown with blue spots depicting the area of the flask computed as blue areas by 
the computer algorithm and quantitative representation of bypass assay presented graphically 
by plotting the calculated percentage area (+/- SD) covered in blue by Definiens Developer XD 
software for each of the replicates.  
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with only one sixth the quantity of B-MYB which is equivalent to the amount of B-
MYB present in WC1 and WC2, where the whole active complex (MMB-FOXM1) 
is reconstituted. This suggested that B-MYB alone when present in the same 
ratio as in whole complex lacking other components, did not exhibit a similar level 
of strong bypass potential as observed with the reconstituted active MMB-
FOXM1 complex. This suggests that B-MYB can be synergized by the presence 
of other components of MuvB and FOXM1 of the MMB-FOXM1 complex as B-
MYB works better in presence of these other genes. The results obtained have 
been verified both by the manual analysis as well as the computational analysis. 
Hence, this experiment for the first time in this study showed that mixing different 
TFs together to reconstitute the active DREAM complex works very efficiently. 
The results obtained from this experiment also suggested the presence of a 
synergistic effect with respect to one of the components of the active complex 
(MMB-FOXM1) i.e. B-MYB. However, potentially alternative explanation of the 
variation in senescence rescue obtained could be due to differences in relative 
titre of active viruses in the different packaging reactions. 
4.2 Identification of the critical components of the active MMB-
FOXM1 complex that are crucial for bypassing cellular 
senescence 
4.2.1 Objective 
Previous experiment demonstrated that the active (MMB-FOXM1) complex can 
bypass senescence strongly and consistently; the next obvious question was to 
determine the key components of the complex which are crucial for the strong 
bypass observed. Therefore, in this section the contribution of each individual 
component of the complex towards the strong bypass observed, was analysed.  
The rationale behind performing this experiment is, if a critical component that 
has a role to play in synergizing the assay is omitted, its absence will reduce the 
bypass potential which can be analysed both qualitatively and quantitatively. 
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4.2.2 Bypass potential of the reconstituted complex lacking one 
component 
A reconstruction experiment was designed in which different lentiviruses were 
produced from DNA pools where one component of the complex was omitted in 
each reconstitution as shown in Table 4.2. 1.5 µg of DNA from each of the DNA 
pools was packaged as lentiviruses in HEK293T cells and subsequently used to 
stably transduce CL3EcoR cells.  
Table 4.2 List of DNA pools for the reconstruction experiment of the MMB-FOXM1 complex 
lacking one component 
 
 RAD51 LIN9 LIN37 LIN52 LIN54 FOXM1 B-MYB 
5+1 B-MYB 5 µg X X X X X 1 µg 
WC X 1 µg 1 µg 1 µg 1 µg 1 µg 1 µg 
X LIN9 1 µg X 1 µg 1 µg 1 µg 1 µg 1 µg 
X LIN37 1 µg 1 µg X 1 µg 1 µg 1 µg 1 µg 
X LIN52 1 µg 1 µg 1 µg X 1 µg 1 µg 1 µg 
X LIN54 1 µg 1 µg 1 µg 1 µg X 1 µg 1 µg 
X 
FOXM1NKEN 
1 µg 1 µg 1 µg 1 µg 1 µg X 1 µg 
X B-MYB 1 µg 1 µg 1 µg 1 µg 1 µg 1 µg X 
RAD51 6 µg X X X X X X 
RAD51 was used as the negative control. The cross indicates the absence of that particular 
component. RAD51 was used to replace the missing component. 
Results obtained from the experiment are shown in Figure 4.4. The highest 
numbers of densely growing colonies were observed with the whole complex 
“WC” and “X LIN54” in which LIN54 had been omitted. “X LIN9” and “X LIN37” 
produced the next highest whereas “X LIN52”, “X FOXM1NKEN” and “X B-
MYB” produced the least of which “X LIN52” lacking LIN52 was the lowest. This 
was very interesting as it suggested that LIN52 was more, or as important as 
FOXM1 and B-MYB. LIN52 was not found to be highly differentially 
downregulated in the microarray data as opposed to LIN9 which was highly 
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downregulated as shown in Figure 4.2. This demonstrated the importance of 
undertaking functional assays to determine role of each TF rather than relying 
on expression profiling as protein levels might be affected or modification such 
as phosphorylation can alter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The key finding from this experiment after carefully analysing the results obtained 
both qualitatively and quantitatively was that it demonstrated that three 
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Figure 4.4 Senescence bypass assay for the reconstituted active form of DREAM complex 
lacking one component.  
Bypass assay was performed three times independently at 5% CO2 and 38.9C with 50,000 cells 
per T-75 flask. For qualitative analysis single representative flasks from internal repeats are 
shown with the component absent from the reconstituted complex indicated. “X” indicated in 
front of a component depicts its absence in the reconstituted complex. For quantitative analysis 
the bar charts depict an overall average (+/- SD) of all three-independent repeat experiments. 
RAD51 was used as the negative control. A) Manual analysis B) Computational analysis. 
Statistical analysis was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test 
(*p<0.05, **p<0.01, ***p<0.001) 
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components out of the six components which form the MMB-FOXM1 complex 
were critical for the strong bypass potential. They were: LIN52, FOXM1NKEN 
and B-MYB. Absence of LIN52 showed the strongest reduction followed by 
FOXM1NKEN and B-MYB. 
4.3 Senescence bypass potential of each of the components of 
the MMB-FOXM1 complex 
4.3.1 Objective 
Until now I have studied the bypass potential of the MMB-FOXM1 complex and 
have indirectly identified the crucial components to be: LIN52, FOXM1 and B-
MYB. It was therefore important to study the senescence bypass potential of 
each of the six components on their own. Hence, in this section the bypass 
potential of each of the components of MMB-FOXM1 complex was examined 
individually. 
4.3.2 Senescence bypass assay of the individual components of the active 
MMB-FOXM1 complex 
Experiment was designed where lentiviruses were prepared for each of the 
individual components of the complex i.e. LIN9, LIN37, LIN52, LIN54, 
FOXM1NKEN and B-MYB in HEK293T cells. They were then used to infect 
CL3EcoR cells and the bypass potential analysed after three-week incubation at 
the non-permissive temperature.  
Senescence bypass potential observed for each of the component is shown in 
Figure 4.5. The most striking result was that LIN52 on its own for the first time 
was clearly able to bypass senescence. Until now in this study no other 
downregulated TF when ectopically expressed individually had shown any 
bypass potential apart from B-MYB. This was very encouraging as it validates 
the finding from the previous experiment where absence of LIN52 showed a 
strong reduction in bypass potential, highlighting its importance. Apart from 
LIN52, B-MYB as observed previously showed a strong bypass potential.  
The third important component identified in the previous experiment was 
FOXM1NKEN, which showed a marginal bypass potential that was similar to 
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that observed after ectopically expressing LIN9. The remaining components 
LIN37 and LIN54 did not show any bypass potential when studied individually. 
The reconstituted MMB-FOXM1 complex was also studied simultaneously and 
again showed a strong and efficient bypass as demonstrated by the 
representative flask (WC) in Figure 4.5. 
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Figure 4.5 Senescence bypass assay of the individual components of the MMB-FOXM1 complex 
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. Single representative flasks from internal repeats are shown with the ectopically 
expressed component name indicated. For quantitative analysis the bar charts depict an overall 
average (+/- SD) of the independent repeat experiments. Empty vector pLEX-MCS was used as 
negative control. Constitutively active form of LIN52 and FOXM1 were used. A) Manual analysis 
B) Computational analysis.  
 
 
 162 
4.4 Further Characterization of the individual components of 
the active MMB-FOXM1 complex 
4.4.1 LIN9 
4.4.1.1 Objective 
The original LIN9 clone was kindly given to us by Prof. James A. DeCaprio, 
Dana-Farber Cancer Institute, Boston, U.S.A. Before studying every TF 
functionally for its bypass potential in this thesis, they were sequence verified. 
After analysing the sequence of LIN9, it was observed that the LIN9 clone was 
in frame but lacked sixteen amino acids at its 5’ end. Therefore, to rule out the 
possibility that the lack of observed bypass was due to the lack of the sixteen 
amino acids, the aim was to compare and study both the truncated and the full 
length LIN9 for their bypass potential. Both forms of LIN9 were studied by 
ectopically expressing them individually as well as part of the MMB-FOXM1 
complex. This allowed us to determine any difference in bypass potential of LIN9 
that might arise due to the missing amino acids, when expressed individually or 
as part of the reconstituted complex. 
4.4.1.2 Gateway recombination cloning of Full length LIN9 
A full length LIN9 clone (HsCD00515936) was obtained as a stab from the 
DNASU plasmid repository (https://dnasu.org/DNASU/), plated on an 
appropriate antibiotic plate, colonies picked, plasmid isolated and the sequence 
checked before cloning, to verify the sequence. Comparison of the protein coding 
sequence of full length and the truncated LIN9 is shown in Figure 4.6. 
Gateway recombination cloning was used to clone the full length LIN9 into the 
puromycin resistant pLX301 destination vector. Plasmid DNA isolated from two 
colonies picked after successful cloning and transformation was sequenced 
verified for presence of full length LIN9 in pLX301 lentiviral vector.  
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4.4.1.3 Comparison of bypass potential of full length and truncated LIN9 
To compare the bypass potential of both full length and truncated LIN9, 
lentiviruses were prepared for both forms of LIN9 in HEK293T cells. Also, to 
study the effect of both the forms of LIN9 in the whole complex, two DNA pools 
were made to reconstitute the whole complex with full length and truncated LIN9 
(Table 4.3). The lentiviruses were used to stably transduce CL3EcoR cells and 
assess the bypass potential.  
  
A.  
MHRGGQPLKKRRGSFKMAELDQLPDESSSAKALVSLKEGSLSNTWNEKYSSLQKTPVWKGRNTSSAVEMPFRNSKRSRL
FSDEDDRQINTRSPKRNQRVAMVPQKFTATMSTPDKKASQKIGFRLRNLLKLPKAHKWCIYEWFYSNIDKPLFEGDNDF
CVCLKESFPNLKTRKLTRVEWGKIRRLMGKPRRCSSAFFEEERSALKQKRQK 
IRLLQQRKVADVSQFKDLPDENSFASGYXNESYSTITWCS  
 
B. 
Query  17   MAELDQLPDESSSAKALVSLKEGSLSNTWNEKYSSLQKTPVWKGRNTSSAVEMPFRNSKR  76 
             
Sbjct  1    MAELDQLPDESSSAKALVSLKEGSLSNTWNEKYSSLQKTPVWKGRNTSSAVEMPFRNSKR  60 
 
Query  77   SRLFSDEDDRQINTRSPKRNQRVAMVPQKFTATMSTPDKKASQKIGFRLRNLLKLPKAHK  136 
             
Sbjct  61   SRLFSDEDDRQINTRSPKRNQRVAMVPQKFTATMSTPDKKASQKIGFRLRNLLKLPKAHK  120 
 
Query  137  WCIYEWFYSNIDKPLFEGDNDFCVCLKESFPNLKTRKLTRVEWGKIRRLMGKPRRCSSAF  196 
            WCIYEWFYSNIDKPLFEGDNDFCVCL ESFPNLKTRKLTRVEWGKIRRLMGKPRRCSSAF 
Sbjct  121  WCIYEWFYSNIDKPLFEGDNDFCVCLXESFPNLKTRKLTRVEWGKIRRLMGKPRRCSSAF  180 
 
Query  197  FEEERSALKQKRQKIRLLQQRKVADVSQFKDLPDE  231 
            FEEERSALKQKRQK +LLQQRKVADVSQFKDLPDE 
Sbjct  181  FEEERSALKQKRQKNKLLQQRKVADVSQFKDLPDE  215 
 
Figure 4.6 Comparison of LIN9 sequences 
A. Protein sequence of LI 9 depicting the missing 16 amino-acids indicated in red box. B. After 
sequence verification it was found that LIN9 clone lacked sixteen amino acids at its N-terminus. 
On aligning the sequences of full length (Query) and truncated (Sbjct) LIN9 clone, the homology 
started from the seventeenth amino acid residue confirming the absence of sixteen amino acids 
at the N-terminus. 
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Table 4.3 DNA pools made to reconstitute the MMB-FOXM1 complex with full length and 
truncated LIN9  
 
Reconstituted complex Constituents 
WC-LIN9 LIN9, LIN37, LIN52, LIN54, FOXM1NKEN and B-
MYB 
WC-FL*-LIN9 FL-LIN9, LIN37, LIN52, LIN54, FOXM1NKEN and B-
MYB 
*Full length 
Three weeks later after staining with methylene blue, it was observed that both 
the full length LIN9 and truncated LIN9 produced few colonies. On the other 
hand, the reconstituted MMB-FOXM1 complex generated significantly higher 
numbers of colonies. Moreover, the number of colonies obtained for full length 
and truncated LIN9 were not significantly different both when studied individually 
or as part of the whole complex as shown in Figure 4.7.  This indicated that 
presence of sixteen amino acids in LIN9 did not change the bypass potential 
significantly compared to the truncated LIN9. Therefore, in subsequent 
experiments, truncated LIN9 was used when required as truncated LIN9 was in 
pLEX-MCS. This means that wherever possible all MMB-FOXM1 components 
were in same vector. 
This experiment together with previous experiments suggests that although LIN9 
has been known to be a key component of the MuvB complex (Schmit et al. 
2007), in our model system, it was not found to be a component which was 
required for the observed senescence bypass. 
  
 165 
 
 
 
 
  
 
 
LIN9 FL-LIN9
pLEXMCS
WC-LIN9 WC-FL-LIN9
LI
N
9
FL
-L
IN
9
W
C
-L
IN
9
W
C
-F
L-
LI
N
9
pL
E
X
M
C
S
0
50
100
150
200
ns
ns FL-LIN9: Full length LIN9
WC-LIN9: LIN9,
LIN37,LIN52,LIN54,
FOXM1∆N∆KEN and
B-MYB
WC-FL-LIN9: Full length
LIN9, LIN37, LIN52,
LIN54, FOXM1∆N∆KEN
and B-MYB
N
u
m
b
e
r
o
f
g
ro
w
in
g
c
o
lo
n
ie
s
A
LIN9 FL-LIN9
pLEXMCS
WC-LIN9 WC-FL-LIN9
LI
N
9
FL
-L
IN
9
W
C
-L
IN
9
W
C
-F
L-
LI
N
9
pL
E
XM
C
S
0
5
10
15
20
ns
ns
FL-LIN9: Full length LIN9
WC-LIN9: LIN9,
LIN37,LIN52,LIN54,
FOXM1∆N∆KEN and
B-MYB
WC-FL-LIN9: Full length
LIN9, LIN37, LIN52,
LIN54, FOXM1∆N∆KEN
and B-MYBP
e
rc
e
n
ta
g
e
a
re
a
s
ta
in
e
d
B
Figure 4.7 Comparison of senescence bypass assay of full length and truncated LIN9  
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of the 
independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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4.4.2 FOXM1 
4.4.2.1 Objective 
In this study FOXM1 did not show a strong bypass potential when studied 
individually, suggesting that it might not be sufficient on its own in regulating 
senescence even though Rovillain et al., 2011, had previously observed some 
bypass activity (Rovillain et al. 2011). Moreover, this does not rule out the 
possibility that there may be some synergism between FOXM1 and other MMB 
complex associated components. Interestingly, while studying bypass after 
removing each component from the reconstituted complex, FOXM1 was found 
to be crucial as its absence led to a significant reduction in the bypass potential 
of the whole complex, indicating indirectly that it is a key component. 
Activity of FOXM1 is kept low in the G1/S phase of cell cycle by the presence of 
an auto-inhibitory domain at its N-terminus. The N-terminus also contains KEN 
box sequences which are required for the proteolytic targeting and degradation 
of the FOXM1 via binding of the APC/CCdh1 adaptor protein. There exists a 
mutant of FOXM1 where the N-terminus and KEN have been deleted called 
FOXM1NKEN which is constitutively active, non-degradable and does not 
require cyclin-CDK activity for its activation. Park et al., 2008, presented a 
comprehensive study comparing wild type FOXM1 and N-terminus deleted 
FOXM1 (Park et al. 2008). The findings from their study showed that deletion of 
N-terminal 232 residues led to more than 20-fold increase in the transcriptional 
activity of FOXM1 compared to wild type FOXM1. N-terminal deleted mutant also 
showed a significant increase in transforming ability of FOXM1. This study also 
reported that N-terminal deleted FOXM1 mutant is maintained at constitutively at 
high levels throughout the cell cycle as opposed to the wild type FOXM1, which 
is regulated by growth factors (Park et al. 2008). Therefore, for our experiments 
we have utilised the constitutively active FOXM1NKEN. 
It will of course be interesting to compare the bypass potential of wild type 
FOXM1 and the constitutively active FOXM1ΔNΔKEN, both individually and as 
part of the reconstituted complex in our model system. Both the constitutively 
active and the wild type form of FOXM1 were provided by Prof. Rene Medema, 
Netherlands Cancer Institute, Amsterdam, Netherlands and recloned into pLEX-
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MCS lentiviral vector for uniformity. Previously Rovillain et al., 2011, showed that 
FOXM1NKEN did exhibit some bypass potential when expressed from the 
pLNCX2 retroviral vector (Rovillain et al. 2011). 
4.4.2.2 Comparison of the bypass potential of wild type and constitutively active 
FOXM1 
Apart from ectopically expressing wild type and the constitutively active form of 
FOXM1 individually, two different DNA pools were made to reconstitute the 
whole complex, one with WT-FOXM1 and the other with the constitutively active 
non-degradable FOXM1ΔNΔKEN (Table 4.4). Respective lentiviruses were 
made in HEK293T cells, followed by stable transduction of CL3EcoR cells. 
Table 4.4 DNA pools made to reconstitute whole MMB-FOXM1 complex with WT and 
constitutively active FOXM1 
 
Reconstituted complex Constituents 
WC-FOXM1-WT* LIN9, LIN37, LIN52, LIN54, Wild type FOXM1 and B-
MYB 
WC-FOXM1NKEN LIN9, LIN37, LIN52, LIN54, FOXM1NKEN and B-
MYB 
*Wild type 
Similar to the previous observations, both wild type and constitutively active 
FOXM1 yielded only few darkly stained growing colonies as shown in Figure 4.8. 
This indicated a weak senescence bypass potential of FOXM1 when analysed 
individually. In contrast, the cells stably transduced with components of MMB-
FOXM1 complex exhibited strong bypass potential as significantly higher number 
of blue darkly stained colonies were obtained, as shown in Figure 4.8. However, 
on comparing the bypass potential of the two different MMB-FOXM1 complexes, 
a small but significant difference was observed between the active complex 
reconstituted with the constitutively active form and the wild type FOXM1. The 
complex reconstituted with constitutively active form of FOXM1 presented a 
greater number of colonies than the complex reconstituted with WT FOXM1, 
thereby indicating that the bypass observed with the active complex reconstituted 
with constitutively active FOXM1 was higher than the complex containing wild 
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type FOXM1. Therefore, for all the experiments conducted in this study, the 
constitutively active form of FOXM1 i.e. FOXM1NKEN has been used.  
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Figure 4.8 Comparison of senescence bypass assay of wild type and constitutively active form 
of FOXM1.  
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of the 
independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
 
 
 169 
4.5 LIN52 
4.5.1 Objective 
It has recently been found that LIN52 is a key MuvB component which is essential 
for the switch between the repressive DREAM complex which promotes 
quiescence and the active MMB-FOXM1 complex which initiates cell cycle 
progression. Litovchick et al., 2011, have described the critical role of 
phosphorylation of LIN52 at serine 28 in promoting the binding of MuvB core to 
p130/E2F4 in quiescence  (Litovchick et al. 2011). This binding leads to the 
assembly of the repressive DREAM complex that inhibits the progression of cell 
cycle and leads to quiescence. This phosphorylation is promoted by DYRK1A 
(dual-specific tyrosine-(Y)-phosphorylation regulated kinase 1A), that promotes 
entry into quiescence by promoting assembly of the DREAM complex (Litovchick 
et al. 2011). Rather surprisingly, DYRK1A, was found to be significantly down-
regulated upon senescence growth arrest which was reversed upon senescence 
bypass, shown in Figure 4.2. Litovchick et al., 2011, also highlighted the 
importance of phosphorylation of Serine-28 by showing that inhibition of Ser-28 
phosphorylation by DYRK1A results in the failure of cells to undergo growth 
arrest (Litovchick et al. 2011).  
As phosphorylation of the LIN52 at Ser-28 is crucial, it was very important to 
examine the effect of phosphorylation of Ser-28 of LIN52 on senescence bypass 
in our model system. The rationale is that the non-phosphorylated form of LIN52 
will inhibit assembly of repressive DREAM complex thereby promoting the 
formation of the active MMB-FOXM1 complex which promotes cell proliferation. 
Non-phosphorylated form can be mimicked by point substitution of Ser-28 to Ala-
28. Therefore, non-phosphorylated LIN52 should show a strong bypass 
potential, whereas, phosphorylated LIN52, which can be mimicked by 
substitution of Ser-28 to Glu-28, should result in binding of p130, aiding the 
assembly of the repressive DREAM complex and hence should lead to a 
reduction in the senescence bypass potential. 
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4.5.2 LIN52 Alanine and Glutamic acid mutants 
4.5.2.1 Cloning of LIN52 mutant forms 
The 28th amino acid residue of LIN52 was mutated to alanine to mimic the non-
phosphorylated form of LIN52, as alanine cannot be phosphorylated. Glutamic 
acid has been used in many cancer studies to mimic phosphorylated serine. 
Another mutant of LIN52 was designed where the 28th amino acid residue was 
mutated to glutamic acid to mimic phosphorylated LIN52. ORFs for both mutant 
forms of LIN52 were designed and ordered from GeneArt Gene Synthesis and 
Services [ThermoFisher Scienctific (https://www.thermofisher.com/)] (Figure 
4.9). Mutant ORFs obtained were cloned into pLEX-MCS vector.  
Multiple colonies were picked, plasmid DNA isolated and outsourced to 
SourceBioScience (https://www.sourcebioscience.com/) for sequence 
verification. For both mutants, LIN52 clones for which complete ORF sequence 
was checked for the presence of the mutation at the correct position, were 
chosen to study their effect on their ability to bypass senescence. 
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A. >LIN52-Ser  
GGATCCACTAGTGACATGGGTTGGAAGATGGCGTCTCCCACAGACGGGACAGATCT
GGAAGCATCTTTGCTAAGTTTTGAAAAACTTGACCGTGCCTCACCAGATCTTTGGC
CAGAACAATTACCAGGTGTTGCTGAATTTGCAGCTTCCTTCAAAAGTCCTATTACT
AGTTCTCCACCCAAATGGATGGCTGAGATAGAACGTGATGACATCGACATGTTGAA
AGAACTGGGGAGTCTCACCACGGCTAATTTGATGGAGAAGGTTCGAGGCCTACAGA
ACCTAGCCTATCAGCTGGGGCTGGATGAGTCCAGAGAGATGACACGGGGGAAATTC
CTCAATATTCTAGAGAAGCCCAAGAAGTAGGCGGCCGC 
 
B. >LIN52-Ala aligned to LIN52-Ser  
 
C. >LIN52-Glu aligned to LIN52-Ser 
 
Figure 4.9 LIN52 mutants. 
 A) WT LIN52-Ser sequence depicting the key 28th Serine marked in red. B) LIN52-Ser aligned 
to LIN52-Ala where 28th residue is mutated to Alanine, indicated by red oval. C) LIN52-Ser 
aligned to LIN52-Glu where 28th residue is mutated to Glutamic acid, indicated by red oval. 
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4.5.2.2 Comparison of the bypass potential of LIN52 mutants 
The bypass potential of both LIN52 mutants was studied individually as well as 
part of the reconstituted MMB-FOXM1 complex. Lentiviruses were prepared for 
both LIN52 mutants i.e. LIN52-Ala and LIN52-Glu individually in HEK293T cells. 
DNA pools described in Table 4.5 were prepared to reconstitute the active whole 
complex with LIN52 mutant forms as well as one without LIN52. Respective 
lentiviruses made were used to stably transduce CL3EcoR cells and assess the 
senescence bypass potential. 
Table 4.5 DNA pools made to reconstitute whole complex (MMB-FOXM1) to study the effect of 
different LIN52 mutants  
 
Reconstituted complex Constituents 
WC-Ala 1 µg LIN9, 1 µg LIN37, 1 µg LIN52-Ala, 1 µg LIN54, 1 
µg FOXM1NKEN and 1 µg B-MYB 
WC-Glu 1 µg LIN9, 1 µg LIN37, 1 µg LIN52-Glu, 1 µg LIN54, 1 
µg FOXM1NKEN and 1 µg B-MYB 
WC w/o LIN52 1 µg LIN9, 1 µg LIN37, 1 µg LIN54, 1 µg 
FOXM1NKEN, 1 µg B-MYB and 1 µg pLEX-MCS 
 
The results of the senescence bypass assay are shown in Figure 4.10. They 
were somewhat counterintuitive. LIN52-Ala on its own exhibited a high number 
of densely stained dark blue colonies. Similarly, MMB-FOXM1 complex with 
LIN52-Ala also generated significant number of stained colonies. This indicates 
that LIN52-Ala mutant which mimics the non-phosphorylated form showed a 
strong bypass potential as expected, both when expressed individually as well 
as part of the whole complex. Variant LIN52 is expected to dominantly disrupt 
formation of the DREAM complex and hence leading to bypass of senescence. 
Therefore, the strong bypass observed by LIN52-Ala is due to loss/interference 
with normal LIN52-Ser function. 
On the other hand, the bypass observed for LIN52-Glu mutant which was 
supposed to mimic the phosphorylated form, did not show the expected reduction 
in the bypass potential as a similar number of densely blue stained colonies were 
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obtained for LIN52-Glu as were observed for LIN52-Ala shown in Figure 4.10. 
Similarly, the MMB-FOXM1 complex reconstituted with LIN52-Glu presented the 
unexpected high number of colonies which were comparable to the number of 
colonies generated by the complex consisting LIN52-Ala. Therefore, no 
significant reduction in the bypass potential of LIN52-Glu mutant was observed 
neither individually nor as a part of the complex, compared to LIN52-Ala mutant, 
shown graphically in Figure 4.10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, the results presented in Figure 4.10 show a marked reduction in the 
bypass potential of the MMB-FOXM1 complex reconstituted without LIN52. This 
highlights the huge importance of the role played by loss of LIN52 towards the 
strong senescence bypass potential observed.  
Figure 4.10 Comparison of senescence bypass assay for LIN52-Ala and LIN52-Glu mutants. 
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of the 
independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis. Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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4.5.3 WT LIN52-Ser 28 
4.5.3.1 Cloning 
Previous experiment had set out to distinguish between the bypass potential of 
phosphorylated and non-phosphorylated forms of LIN52 but unfortunately it 
failed. It has been seen in many studies that glutamic acid does not perfectly 
mimic the phosphorylation of serine (Chen and Cole 2015). The other possibility 
for not being able to detect a reduction in bypass potential could be because the 
phosphomimic glutamate residue binds weakly with p130, thereby enabling cell 
cycle progression. 
As initially only the ends of the sequences were verified, during the course of 
previous experiment the whole sequence for all LIN52 forms was also 
determined. Surprisingly the whole sequence revealed that the original LIN52 
clone that we had received from Prof. DeCaprio actually had alanine at the 28th 
amino acid residue. Hence, as the WT LIN52-Ser form had never been tested in 
this study, another LIN52 ORF where 28th amino acid residue was serine was 
designed and ordered from GeneArt Gene Synthesis and Services 
[ThermoFisher Scienctific ( https://www.thermofisher.com/)]. WT LIN52-Ser was 
successfully cloned into pLEX-MCS.  After successful cloning into pLEX-MCS, 
multiple colonies were picked to isolate plasmid DNA and outsourced for 
sequence verification to identify a correct clone before studying its bypass 
potential.  
4.5.3.2 Senescence bypass potential of WT LIN52-Ser  
Lentiviruses were prepared for WT LIN52-Ser individually along with the LIN52-
Ala and LIN52-Glu and were used to stably transduce CL3EcoR to compare the 
bypass potential.  
The results were striking. Similar to the results obtained from the previous 
experiment both LIN52-Ala and LIN52-Glu showed a high number of densely 
stained blue colonies indicating strong bypass potential. To our surprise, CL3EcoR 
cells transduced with WT-LIN52-Ser were unable to bypass senescence. No 
healthy growing colonies were obtained for WT-LIN52-Ser after staining with 
methylene blue after the culture was allowed to grow for three weeks. The 
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bypass potential of the WT LIN52-Ser was drastically reduced, shown 
qualitatively and quantitatively in Figure 4.11. There was a highly significant 
reduction in the bypass potential of WT LIN52-Ser compared to LIN52-Ala and 
LIN52-Glu as no colonies were obtained for WT LIN52-Ser. To draw definite 
conclusions from the results of this experiment, biochemical confirmatory 
experiment ensuring the expression of WT-LIN52-Ser is must. 
The results suggest that in our model system non-phosphorylated forms of LIN52 
exhibit a consistent, strong and efficient bypass potential highlighting the 
importance of the non-phosphorylated form of LIN52 in bypassing senescence 
by blocking DREAM complex assembly. Another suggestion from this 
experiment was the critical role played by phosphorylation of LIN52 as WT 
LIN52-Ser showed a strong reduction in the bypass potential. It was no higher 
than the empty vector control. These results suggest that phosphorylation of 
Serine residue of LIN52 was inhibitory towards bypassing the senescence in 
CL3EcoR cells indirectly suggesting a role for the repressive DREAM complex in 
regulating senescence as the phosphorylated form of LIN52 can lead to the 
assembly of the repressive DREAM complex, thereby preventing cell cycle 
progression and a reduction in the bypass of senescence.  
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Figure 4.11 Comparison of senescence bypass assay for different LIN52 mutants. 
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. Both LIN52 mutants showed strong senescence bypass whereas WT-LIN52-Ser did 
not show any pass. For quantitative analysis the bar charts depict an overall average (+/- SD) of 
the independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis. Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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4.5.4 Comparison of bypass potential of LIN52 mutants after dilution 
4.5.4.1 Objective 
As both LIN52-Ala and LIN52-Glu showed very strong bypass potential as 
depicted in Figure 4.11, to rule out the possibility that a difference in bypass 
potential was not observed due to saturation, an independent preliminary 
experiment was designed. The three LIN52 mutants were diluted ten times with 
empty vector i.e. pLEX-MCS at the lentivirus production stage. The rationale 
behind doing this was to reduce the total number of colonies to be able to observe 
any small differences.  
4.5.4.2 Comparison of the bypass potential 
Lentiviruses made from each of the LIN52 mutants individually as well as after 
diluting them ten times, shown in Table 4.6 were used to stably transduce 
CL3EcoR cells. 
Table 4.6 LIN52 mutants diluted tenfold. 
 
Reconstituted 
complex 
Constituents 
9+1 LIN52-Ala 1 µg LIN52-Ala + 9 µg pLEX-MCS 
9+1 LIN52-Glu 1 µg LIN52-Glu + 9 µg pLEX-MCS 
9+1 LIN52-Ser 1 µg LIN52-Ser + 9 µg pLEX-MCS 
 
The results of this preliminary experiment are shown in Figure 4.12. For both 
LIN52-Ala and LIN52-Glu a high number of densely stained colonies were 
obtained. LIN52-Ser, similar to the results obtained previously, hardly exhibited 
any blue healthy growing colonies. This again confirmed the severe reduction in 
bypass potential with WT-LIN52-Ser, highlighting the crucial role of LIN52 
phosphorylation in senescence in our model system. As expected after dilution, 
a clear reduction was observed in the total number of colonies obtained after 
diluting the DNAs. Interestingly, upon analysis of the results obtained from this 
preliminary dilution experiment, it was observed that the number of colonies 
obtained for LIN52-Glu were slightly less than LIN52-Ala. This indicated a small 
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reduction in the bypass potential for LIN52-Glu when compared to LIN52-Ala, 
which contrasted with the bypass observed for undiluted LIN52, where no 
significant reduction was observed here as well as previously. This dilution 
experiment was conducted only once and therefore needs to be repeated to 
clarify and establish any significant difference between the bypass potential of 
LIN52-Ala and LIN52-Glu. 
Nevertheless, diluting the LIN52 mutants ten times did lower the total number of 
colonies obtained and suggested the possibility of a difference between the 
bypass potential of LIN52-Ala and LIN52-Glu mutants, but this needs to be 
further validated by carrying out more repeats. 
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Figure 4.12 Comparison of bypass potential of different LIN52 mutants after dilution  
Bypass assay was performed at 5% CO2 and 38.9C with 35,000 cells per T-75 flask. Empty 
vector pLEX-MCS was used as negative control. A) Manual analysis B) Computational analysis.  
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4.5.5 Comparison of the bypass potential of active whole complex 
reconstituted with different LIN52 mutants 
4.5.5.1 Objective 
As WT LIN52-Ser showed clear reduction in senescence bypass potential when 
assayed on its own, the next obvious question was: would WT LIN52-Ser as part 
of the MMB-FOXM1 complex influence the strong bypass potential observed by 
the complex.  
4.5.5.2 Comparison of senescence bypass 
To compare the bypass potential of the whole complex containing different LIN52 
mutants, an experiment was designed with two different DNA pools to 
reconstitute the whole complex, Table 4.7. One DNA pool contained the 
constitutively active form of LIN52 i.e. LIN52-Ala and the other DNA pool included 
WT LIN52-Ser which is capable of being phosphorylated thereby potentially 
leading to the formation of the inhibitory DREAM complex. Lentiviruses from both 
these DNA pools were packaged in HEK 293T cells and used to stably transduce 
CL3EcoR cells. 
Table 4.7 DNA pools made to study the effect of WT LIN52-Ser in reconstituted MMB-FOXM1 
complex 
 
Reconstituted 
complex 
Constituents 
WC 1 µg LIN9, 1 µg LIN37, 1 µg LIN52-Ala, 1 µg LIN54, 1 µg 
FOXM1NKEN and 1 µg B-MYB 
WC-Ser 1 µg LIN9, 1 µg LIN37, 1 µg LIN52-Ser, 1 µg LIN54, 1 µg 
FOXM1NKEN and 1 µg B-MYB 
 
Figure 4.13 shows the results obtained after staining the flasks after three weeks. 
Sufficient number of stained growing colonies were obtained for the cells 
transduced with DNA pool consisting of MMB-FOXM1 complex containing the 
LIN52-Ala. Fewer stained colonies were obtained upon stable transduction with 
DNA pool of MMB-FOXM1 complex consisting of WT-LIN52-Ser. Upon analysis 
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Figure 4.13 Comparison of the bypass potential of active whole complex reconstituted with 
different LIN52 mutant forms.  
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of the 
independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis. Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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the data indicated a reduction in the bypass potential when WT LIN52-Ser was 
present in the MMB-FOXM1complex compared to when LIN52-Ala was present 
as part of the MMB-FOXM1 complex. This highlighted the importance of the non-
phosphorylated form of LIN52 for the strong bypass observed by MMB-FOXM1 
complex in CL3EcoR cells.  It also demonstrated the ability of the WT LIN52-Ser 
to significantly reduce the bypass potential not only when expressed individually 
but also as part of the MMB-FOXM1 complex. 
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4.6 Examination of synergy between the three identified critical 
components of the active MMB-FOXM1 complex  
4.6.1 Objective 
The previous series of experiments conducted in this study showed that three 
most important components for the bypass potential observed by active whole 
complex were: LIN52, FOXM1 and B-MYB.  When studied individually both 
LIN52 and B-MYB have shown a strong bypass potential whereas FOXM1 
exhibited marginal bypass. Interestingly in the previous experiments’ synergy 
was established with respect to B-MYB as described in section 4.1.2. Therefore, 
it was important to study if there was any synergy present with respect to the 
remaining two key components, LIN52 and FOXM1.  
The rationale of this experiment was to rule out the possibility that the strong 
bypass potential observed for the whole complex was solely due to the presence 
of any one of the critical components. This would also help to establish if there 
was any synergy between the components of the active complex i.e. is the 
bypass observed simply a sum of the activity of the three critical components or 
is the effect greater? 
4.6.2 Study of bypass potential to check for synergy 
To establish any synergy present with respect to the three key components, 
experiment was designed where the extent of bypass of each of the relevant 
component was assessed with the same amount of DNA as was present in the 
reconstituted MMB-FOXM1 complex. This was then compared to the bypass of 
the whole MMB-FOXM1 complex to identify synergy. Lentiviruses for the DNA 
pools in Table 4.8 were made in HEK293T cells followed by stable transduction 
of CL3EcoR cells.  
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Table 4.8 DNA pools prepared to check for synergy 
 
Reconstituted 
complex 
Constituents 
WC 1 µg LIN9, 1 µg LIN37, 1 µg LIN52, 1 µg LIN54, 1 µg 
FOXM1NKEN and 1 µg B-MYB 
5+1 LIN52 1 µg LIN52+ 5 µg pLEX-MCS 
5+1 FOXM1NKEN 1 µg FOXM1NKEN+ 5 µg pLEX-MCS 
5+1 B-MYB 1 µg B-MYB+ 5 µg pLEX-MCS 
 
Qualitative and quantitative results obtained after staining the flasks from this 
experiment are presented in Figure 4.14. The highest number of densely stained 
colonies were observed with the reconstituted MMB-FOXM1 complex. 
Comparatively a smaller number of stained colonies were obtained for cells 
transduced with one-sixth of each of LIN52, FOXM1 and B-MYB component of 
the complex. Quantitative analysis revealed that the number of colonies obtained 
with one sixth LIN52 were significantly lower than the number of colonies 
obtained with whole complex. This indicated that even though LIN52 is capable 
of strongly bypassing senescence on its own, bypass on its own was less 
efficient than when all the components of the complex were present together. 
The number of colonies obtained when one sixth of B-MYB and FOXM1 were 
present were even lower and comparable to the negative control indicating 
presence of clear synergy among the different components of MMB-FOXM1 
complex.  
There was a clear reduction in the bypass potential observed for LIN52, FOXM1 
and B-MYB when they were present in the same amount as in the complex i.e. 
one sixth. Taken together, these results suggest that none of the three critical 
components show similar extent of bypass when studied individually in the same 
ratio, as shown when all the components of the complex were present together. 
Therefore, these experiments clearly indicate synergy between the components 
of the whole complex. 
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Figure 4.14 Study of bypass for presence of synergy with respect to the three identified critical 
components of the MMB-FOXM1 complex.  
Bypass assay was performed thrice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of all three-
independent repeat experiments. Empty vector pLEX-MCS was used as a negative control. A) 
Manual analysis B) Computational analysis. Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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4.7 Comparison of the bypass potential of the active whole 
complex (MMB-FOXM1) to the combination of the three 
critical components 
4.7.1 Objective 
This experiment was motivated by the finding that there was synergy when three 
critical components were present as part of the whole complex. Therefore, it was 
interesting to study the bypass potential of the three critical components when 
present together and compare it to the bypass potential of the whole complex 
containing all six components. This will also allow us to determine if a 
combination of the three key components identified in this study would work as 
well as the whole MMB-FOXM1 complex in the senescence bypass assay. 
4.7.2 Comparison of bypass potential 
Following DNA pools were made to compare the bypass potential of 
reconstituted MMB-FOXM1 whole complex to a combination of the three critical 
components, described in Table 4.9. Lentiviruses for the DNA pools were 
prepared in HEK293T cells along with the negative vector control (pLEX-MCS). 
The lentiviruses were used to stably transduce CL3EcoR cells and assayed for 
senescence bypass. 
Table 4.9 DNA pools made to compare bypass of whole complex (MMB-FOXM1) to three critical 
components 
 
Reconstituted complex Constituents 
WC 1 µg LIN9, 1 µg LIN37, 1 µg LIN52, 1 µg LIN54, 1 µg 
FOXM1NKEN and 1 µg B-MYB 
3+3 3 µg pLEX-MCS, 1 µg LIN52, 1 µg FOXM1NKEN and 1 
µg B-MYB 
 
Results obtained are displayed in Figure 4.15. Staining with methylene blue after 
three weeks resulted in growing blue colonies for both the whole MMB-FOXM1 
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complex as well as for three components (LIN52, FOXM1NKEN and B-MYB) 
present together.  
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Figure 4.15 Comparison of the bypass potential of the whole MMB-FOXM1 complex to three 
components together  
Bypass assay was performed twice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. For quantitative analysis the bar charts depict an overall average (+/- SD) of the 
independent repeat experiments. Empty vector pLEX-MCS was used as negative control. A) 
Manual analysis B) Computational analysis. Statistical analysis was conducted using One-way 
ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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Quantitative analysis of the results showed that a combination of the three 
components demonstrated weaker bypass potential when compared to the 
bypass of the whole MMB-FOXM1 complex, but the reduction was not significant 
as shown in Figure 4.15.  
This was a very important finding that demonstrated for the first time the bypass 
potential of the combination of LIN52, FOXM1 and B-MYB. They further 
demonstrated that the strong bypass potential observed by the whole complex 
observed in our model system is mainly because of the combined synergistic 
actions of the three key components namely: LIN52, FOXM1 and B-MYB. 
4.8 Construction of multi-cistronic vectors expressing LIN52, 
FOXM1 and B-MYB using 2A-self cleaving peptides 
4.8.1 Objective 
Previous experiments clearly established that LIN52, FOXM1 and B-MYB were 
the key components for the bypass observed by the MMB-FOXM1 complex in 
CL3EcoR cells.  Moreover, the bypass observed for three components together 
was comparable to the whole MMB-FOXM1 complex.  
Until now all the experiments were undertaken by preparing pools of different 
constructs and packaging them in lentiviruses and using these pools to infect 
cells. Even more importantly they relied on cells being infected by multiple 
viruses. We therefore decided it would be very informative to prepare multi-
cistronic constructs to directly compare the bypass potential of these critical 
components. Multi-cistronic vectors constructed using 2A- self cleaving peptides 
can express multiple proteins from the same mRNA as opposed to traditional 
approach of using different vectors or cistrons to co-express multiple genes. 
The rationale behind designing multi-cistronic constructs is to ensure that all 
genes are transduced and expressed simultaneously in each cell after successful 
infection. In contrast, when the infections are done with lentiviruses made from 
mixed pool of TFs, there is a possibility that an infected cell could be infected by 
any one, two or multiple lentiviruses. Hence, to rule out this possibility and to 
investigate the functional role of the key identified components in detail, varying 
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combinations of multi-cistronic viral vectors were designed and successfully 
constructed using the 2A ‘self-cleaving’ peptide  strategy (Szymczak et al. 2004). 
Cloning experiments were performed with the help of Ms. Marta Benedekova, a 
UCL MSci rotation student. 
Self-cleaving 2A peptides offer many advantages over other strategies for co-
expressing genes. Firstly, 2A peptides are short peptides about 20 amino acids 
long as opposed to IRES elements which are quite big; the short size of 2A 
peptides therefore allows room to clone larger gene sequence as there is a 
restriction on the size of insert that can be packaged. This is relevant in this study 
as we were interested in cloning large fragments like B-MYB which is 4284 bp 
long. Secondly, no external factors are required to initiate the cleavage of 
polyproteins due to their self-cleaving because of ribosome skipping. Thirdly, as 
opposed to IRES elements where the second gene is expressed at a lower level 
compared to the first one, 2A peptides produce equimolar amounts of protein 
from the multiple genes from the same mRNA, irrespective of being present 
upstream or downstream of 2A peptide. 
Kim et.al., 2011, studied the cleavage efficiency of four different 2A peptides 
derived from foot-and-mouth disease virus (F2A), Thosea asigna virus (T2A), 
porcine teschovirus-1 (P2A) and equine rhinitis virus (E2A) in widely used human 
cell lines, adult mice and zebra fish embryos (Kim et al. 2011a). Detailed 
experimental investigations from this study reported that P2A peptide has the 
highest cleavage efficiency among the four 2A peptides followed by T2A, E2A 
and F2A (Kim et al. 2011a). Based on these results, in this study P2A and T2A 
peptides were used to generate different combinations of multi-cistronic vectors 
shown in Figure 4.16A. It has been suggested that addition of Gly-Ser-Gly 
nucleotide sequence at the N-terminus of 2A peptides leads to a further increase 
in cleavage efficiency. The cleavage occurs between the glycine and proline 
residue as indicated in Figure 4.16B (Ryan et al. 1991). 
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4.8.2 Design and construction of multi-cistronic vectors using 2A ‘self-
cleaving’ peptides 
To construct the bi-cistronic and multi-cistronic cassettes, P2A and T2A peptides 
were used. It was ensured that all the internal gene constructs in the multi-
cistronic vector did not have a terminator codon as the cleavage of 2A peptides 
occurs post translationally. A detailed schematic illustration of the cloning 
approach used is presented in Figure 4.17. It describes the position and direction 
of corresponding primers and specifies their sequences.  
  
 
P2A T2A
P2A
P2A
T2A
P2A GGA AGC GGA GCTACT AACTTCAGCCTG CTG AAG CAGGCT GGAGAC GTGGAG GAGAACCCT GGA CCT
G S G A T N F S L L K Q A G D V E E N P G P
T2A GGA AGCGGAGAGGGCAGAGGA AGT CTG CTA ACATGC GAG AATCCTGGA CCT
G S G E G R G S L L G D V E E N P G P
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T     C
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B
Figure 4.16 2A ‘self-cleaving’ peptides used to generate different multi cistronic constructs  
A. Diagrammatic representation of different multi-cistronic constructs designed in this study and 
2A peptides used to connect the genes in each construct. B. P2A: Porcine teschovirus-1 (66 bp) 
and T2A: Thosea asigna virus (63 bp), sequences of the two peptides. Boxed areas indicate 
conserved residues. Green underlined GSG sequence, depict residues added to improve the 
cleavage efficiency. Red arrow shows the cleavage point of 2A peptides between Glycine and 
Proline residue. Constitutively active forms for both LIN52 and FOXM1 i.e. LIN52-Ala and FOXM1
ΔNΔKEN respectively were used.  
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A. 
 
B. 
Primer 
Code 
Sequence (5’3’) 
F1: ((LIN52)) CCATAGAAGACACCGACTCTACTAGAGGATCCACTAGTGGAC((ATGGGTTGGAAGATGGCG)) 
F2:P2A((FO
XM1)) 
CTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT((ATGGATTAC
AAGGATGACGAC)) 
F3: T2A((B-
MYB)) 
CGGAGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACTCGAGGAGAATCCTGGACCT((ATGTCTCG
GCGGACGCGCTGC)) 
F4: 
((FOXM1)) 
CCATAGAAGACACCGACTCTACTAGAGGATCCACTAGTGAC((ATGGATTACAAGGATGACGACGATAA
G)) 
F5: P2A((B-
MYB)) 
CTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT((ATGTCTCGG
CGGACGCGCTGC))  
R1: 
P2A((LIN52)
) 
CTCCACGTCTCCAGCCTGCTTCAGCAGGCTGAAGTTAGTAGCTCCGCTTCC((CTTCTTGGGCTTCTCT
AGAATATTGAGG)) 
R2:T2A((FO
XM1)) 
CAGGATTCTCCTCGACGTCACCGCATGTTAGCAGACTTCCTCTGCCCTCTCCGCTTCC((CTGTAGCTC
AGGAATAAACTGGGACCAGTTGATGTTG)) 
R3: ((B-
MYB)) 
GACGCGTCGGGCCCTCTAGACTCGAGCGGCCGCTCACTATACTGTAGC((TCAGGACAAGATGAGGGT
C)) 
R4: 
((FOXM1)) 
CGCGTCGGGCCCTCTAGACTCGAGCGGCCGC((TCACTACTGTAGCTCAGGAATAAACTGGGACCAGT
TGATGTTG)) 
 
Figure 4.17 Cloning strategy used to create 2A peptide linked multi-cistronic constructs.  
To construct the desired multi-cistronic constructs recombinant PCR was used. A. Diagrammatic 
representation of the different primers used to set up relevant PCR reactions F: Forward primer; 
R: Reverse primer) B. The oligonucleotide sequences of the different primers used in 5’3’ 
direction. Different regions of the sequence are colour coded. To clone multi-cistronic constructs 
created into the desired pLEX-MCS lentiviral vector, BamHI (red coloured sequences) and NotI 
(blue coloured sequences) restriction sites were used. The regions within brackets correspond 
to the sequence of either LIN52, FOXM1NKEN or B-MYB genes as indicated in the Primer 
Code and the bold regions depict the relevant 2A peptide used to link different genes as indicated 
in the Primer Code. 
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Additionally, Figure 4.18 demonstrates the step-wise construction of different 
multi-cistronic vectors generated. Primary PCR reactions were setup to amplify 
the single construct with desired overhangs. Secondary PCRs were conducted 
to combine and amplify respective bi-cistronic constructs. The tertiary PCR 
reaction finally combined B-MYB amplified in the primary PCR with LIN52 and 
FOXM1 from the secondary reaction. The amplification products were inserted 
into pLEX-MCS after digestion with BamHI and NotI, shown in Figure 4.19. 
Sequencing was carried out after cloning the amplified fragments into pLEX-MCS 
before studying its biological activity.  
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Figure 4.18 Schematic flow diagram depicting sequential generation of PCR products  
First gel picture shows the amplification of single constructs using primers with overhangs. 
Second gel picture shows the construction of bi-cistrionic cassettes made by PCR annealing 
different combination of previously amplified single constructs. The final gel picture presents the 
construction of LFM by annealing B-MYB from the first amplification together with the LF from 
the second amplification. 
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4.9 Bypass potential of the multi-cistronic constructs 
4.9.1 Objective 
To allow a deeper insight into the functional activity of multi-cistronic constructs, 
bypass potential of the varying combinations of the multi-cistronic constructs was 
compared in CL3EcoR cells. The rationale was first to determine if the multi-
cistronic constructs would bypass senescence in CL3EcoR cells and second, to 
determine if any synergy was present amongst the three key identified 
components i.e. LIN52, FOXM1NKEN and B-MYB.  
4.9.2 Comparison of senescence bypass activity 
Lentiviruses were prepared by transient transfection of HEK293T cells for the 
multi-cistronic constructs and used to stably transduce CL3EcoR cells (Table 
4.10). 
 
 
 
 
Figure 4.19 Sequences of the bi-cistronic and multi-cistronic expression cassette.  
Start and terminator codons are depicted in orange. Only the final cistron in each multi-cistronic 
construct has a terminator codon. P2A peptide is shown in red and T2A in blue. BamHI and NotI 
restriction sites used to clone in pLEX-MCS vector are shown in green. A-C. DNA sequences of 
bi-cistronic constructs namely: A. LIN52-FOXM1NKEN (total size=2109 bp) B. LIN52-B-MYB 
(total size=2532 bp) C. FOXM1NKEN-B-MYB (total size=3870 bp) D.DNA sequence of multi-
cistronic LIN52-FOXM1NKEN-B-MYB construct (total size=4284 bp). 
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Table 4.10 List of Multi-cistronic constructs studied for bypass potential 
 
Multi-cistronic 
constructs 
Constituents 
LFM LIN52, FOXM1NKEN and B-MYB in a single construct 
LF LIN52 and FOXM1NKEN in a single construct 
LM LIN52 and B-MYB in a single construct 
FM FOXM1NKEN and B-MYB in a single construct 
LFMS LIN52, FOXM1NKEN and B-MYB in separate 
constructs 
 
Senescence bypass assay for this experiment was performed under very 
stringent conditions to be able to see any differences in bypass potential and 
spot any synergy that might exist. The non-permissive temperature used was as 
high as 39.5C. 35,000 cells were reseeded after successful infection to lower 
the background and keep flasks less saturated. After three weeks, flasks were 
stained with methylene blue and the densely growing blue colonies were counted 
and the bypass potential analysed. pLEX-MCS empty vector was used as a 
negative control to determine the background level of bypass. 
Senescence bypass potential of the multi-cistronic LFM construct was compared 
to the bypass of varying combinations of bi-cistronic constructs (LF, LM and FM), 
individual components alone and to the separately reconstituted mix of three 
components as shown in Figure 4.20. 
From the results obtained shown in Figure 4.20, it was apparent that the multi-
cistronic constructs functioned very well in CL3EcoR cells as large number of blue 
dense healthy growing colonies were visible after staining the flasks after three 
weeks. It was observed that all the multi-cistronic constructs, reconstituted mix 
of three components and the individual components except FOXM1 showed a 
strong senescence bypass activity. This experiment for the first time showed the 
functional ability of multi-cistronic constructs to bypass senescence in CL3EcoR 
cells. For the purpose of clear understanding of the different comparisons done 
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in this experiment the data have been extracted from the same experiment 
(Figure 4.20) and compared separately in Figure 4.21. 
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Figure 4.20 Study of senescence bypass potential of different multi-cistronic constructs.  
Bypass assay was performed thrice independently at 5% CO2 and 39.5C with 35,000 cells per 
T-75 flask. Flasks were stained with 2% methylene blue after three weeks. Single representative 
flasks from internal repeats are shown. For quantitative analysis the bar charts depict an overall 
average (+/- SD) of all three-independent repeat experiments. Empty vector pLEX-MCS was 
used as a negative control. A) Manual analysis B) Computational analysis. Statistical analysis 
was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001) 
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The first comparison undertaken was to study if it is more efficient to express 
different TFs from one construct rather than mixing them separately. On 
analysing the results obtained it was found that there was no numerical 
difference between the extent of bypass observed when the three constructs 
were expressed either from the same vector as in multi-cistronic construct or 
reconstituted separately. In both cases a similar strong bypass potential was 
observed as shown in Figure 4.21A. Results from this experiment further showed 
how well mixing of different TFs works, as the bypass obtained by multi-cistronic 
single LFM construct was comparable to the bypass observed by LFMS, where 
the constructs were mixed separately. 
Next, to study if the three components together were better at bypassing 
senescence than the individual components alone, bypass potential of single 
multi-cistronic LFM construct was compared to LIN52, FOXM1NKEN and B-
MYB when expressed individually. Similar to the results obtained in previous 
experiments, both LIN52 and B-MYB exhibited strong bypass whereas FOXM1 
showed marginal bypass when assayed individually as observed by the 
presence of large number of stained colonies. Comparing the bypass observed 
with the multicistronic construct consisting of all three components to the bypass 
of individual components, no numerical difference was observed with regards to 
LIN52 and B-MYB alone. However, a highly significant difference was seen with 
FOXM1NKEN as shown quantitatively in Figure 4.21B. 
Finally, comparing the bypass potential of multi-cistronic construct to the bypass 
of varying combinations of bi-cistronic constructs, it was found that there was no 
numerical difference between the bypass potential of any of the bi-cistronic 
constructs and the multi-cistronic LFM construct as shown in Figure 4.21C. This 
indicated that presence of any two components out of the three showed similar 
levels of bypass as when three components were present together confirming 
that there is no synergy between three components. 
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4.10  Bypass potential of multi-cistronic constructs after dilution 
4.10.1 Objective 
After analysing the results from the previous experiment, one possibility why no 
difference was observed between different constructs studied could be due to 
saturation as most of them worked efficiently to bypass senescence in our model 
system. It suggests that the higher densities somehow reduce the detection of 
rescued cells through cell overcrowding. Therefore, to identify any differences in 
the bypass potential that might exist between the different constructs, an 
independent experiment was performed, where the experiment was repeated 
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Figure 4.21 Different comparisons of multicistronic constructs.  
A) LFM vs LFMS B) LFM vs Individual components C) LFM vs Bicistronic constructs. For each 
comparison both manual and computational analysis are shown. Statistical analysis was 
conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001) 
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under stringent conditions as before and was also performed after diluting. The 
rationale behind diluting was to lower the total number of colonies obtained 
proportionately for every construct to be able to spot any small differences that 
might be present among the different constructs.  
There are two potential ways of diluting to reduce the efficiency of the bypass. 
First by diluting DNA at the transfection stage and the other is the classical 
approach of mixing the stably transduced cells with non-transduced cells. Here, 
the classical approach was taken. Dilutions were therefore done by mixing the 
successfully infected CL3EcoR cells selected after puromycin selection with non-
infected CL3EcoR cells as we also wanted to maintain a uniform cell density. This 
will reduce the large number of growing colonies observed as non-infected cells 
will not be able to grow at the non-permissive temperature. To optimize the 
dilution experiment, two different dilutions were used i.e. fivefold dilution and 
tenfold dilution. For fivefold dilution, to reseed a total of 35000 cells, 7000 
successfully infected cells were mixed with 28,000 non-infected CL3EcoR before 
reseeding in T-75 flasks. Similarly, for tenfold dilution, 3500 infected cells were 
mixed with 31,500 non-infected CL3EcoR cells. The assay was performed under 
the same stringent high temperature conditions to minimize the background. 
4.10.2 Comparison of the bypass potential of each construct upon dilution 
Here, the bypass potential of each of the construct used in this study is compared 
individually, when its undiluted and diluted. There was a clear trend of gradual 
proportionate reduction in the total number of colonies obtained for each of the 
construct as the fold dilution increased, apart from FOXM1NKEN and pLEX-
MCS empty vector as shown in Figure 4.22, neither of which bypass senescence. 
This showed that the dilution approach used to reduce the total number of 
colonies worked successfully.  
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Figure 4.22 Study of bypass potential of each construct compared upon dilution  
Bypass assay was performed thrice independently at 5% CO2 and 39.5C with 35,000 cells per 
T-75 flask. Bar charts depict an overall average (+/- SD) of all three-independent repeat 
experiments for each dilution. Empty vector pLEX-MCS was used as negative control. A) Manual 
analysis B) Computational analysis.  
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4.10.3 Fivefold dilution 
After five-fold dilution, all the multi-cistronic constructs, reconstituted mix of three 
components and all individual components except FOXM1 were able to bypass 
senescence as shown in the Figure 4.23. Similar comparisons were done here 
as previously for the undiluted constructs. The combined results for bypass 
potential after fivefold dilution are shown in Figure 4.23.  Separate comparisons 
are discussed separately for easier understanding after extracting the data from 
the same experiment. 
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Figure 4.23 Study of the bypass potential of different multi-cistronic (LFM) constructs after 
fivefold dilution  
Bypass assay was performed thrice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. Empty vector pLEX-MCS was used as a negative control. For quantitative analysis 
the bar charts depict an overall average (+/- SD) of all three-independent repeat experiments.  
A) Manual analysis B) Computational analysis. Statistical analysis was conducted using One-
way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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No numerical difference was observed between the multi-cistronic single LFM 
construct and the separately reconstituted LFMS mix as depicted in Figure 
4.24A. This reconfirmed that reconstitution works very well in our model system. 
Although no numerical difference was observed, closer inspection of the colonies 
obtained after staining suggests that having all three constructs from one vector 
tends to work better than mixing them separately. 
Multi-cistronic LFM construct and the single LIN52 and B-MYB constructs 
showed higher bypass potential than the negative control pLEX-MCS and 
FOXM1, after five-fold dilution. On comparing the bypass potential of LFM with 
the individual constructs, no numerical difference was observed between LFM 
and LIN52 or LFM and B-MYB whereas with respect to FOXM1 there was a 
highly significant difference Figure 4.24B. 
After five-fold dilution, similar to undiluted, multi-cistronic construct LFM and the 
three different bi-cistronic constructs (LF, LM and FM) showed bypass potential 
higher than the negative control, pLEX-MCS. When compared all of them worked 
equally well and showed similar level of bypass potential. Hence, no numerical 
difference was observed in the bypass potential of LFM and any of the bi-
cistronic construct as shown in Figure 4.24C. This indicates that presence of any 
two out of three identified critical components works as efficiently as all three 
components present together. Even after diluting five times, no numerical 
differences were detected between the multi-cistronic construct and different bi-
cistronic constructs. 
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Figure 4.24 Different comparisons of multi-cistronic constructs after five-fold dilution.  
A) LFM vs LFMS B) LFM vs Individual components C) LFM vs Bicistronic constructs. For each 
comparison both manual and computational analysis are shown. Statistical analysis was 
conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001) 
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4.10.4 Tenfold dilution 
Next, comparisons were done after tenfold dilutions to identify any difference in 
bypass that might exist. The combined results for bypass potential obtained after 
diluting ten times are shown in Figure 4.25.  Strong reduction in the total number 
of colonies obtained was observed for all the constructs after dilution. Separate 
comparisons for a clearer understanding are discussed below after extracting the 
data. 
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Figure 4.25 Comparison of the bypass potential of different multi-cistronic constructs designed 
after tenfold dilution  
Bypass assay was performed thrice independently at 5% CO2 and 39.5C with 35,000 cells per 
T-75 flask. Empty vector pLEX-MCS was used as a negative control. For quantitative analysis 
the bar charts depict an overall average (+/- SD) of all three-independent repeat experiments.  
A) Manual analysis B) Computational analysis. Statistical analysis was conducted using One-
way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, ***p<0.001) 
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This comparison between multi-cistronic (LFM) construct and the reconstituted 
mix (LFMS) after tenfold dilution is interesting, as this time a statistically 
significant difference was observed, as shown in Figure 4.26A. This indicates 
that although reconstitution does work very well, using a single multi-cistronic 
construct was far more efficient. The greater reduction observed upon tenfold 
dilution enabled us to identify the significant difference. 
As observed previously the multi-cistronic LFM construct, individual constructs 
LIN52 and B-MYB showed higher bypass potential than the negative control 
pLEX-MCS and FOXM1 as shown in Figure 4.26B.  The most interesting aspect 
of the results obtained from this experiment was that when the bypass potential 
of the multi-cistronic LFM construct was compared to bypass of individual 
constructs, a significant difference was observed not only with respect to FOXM1 
but also with LIN52 for the first time. This indicated the presence of potential 
synergy with respect to FOXM1 and LIN52. No numerical difference was 
detected with regards to B-MYB, as B-MYB works extremely well and showed a 
very strong bypass potential on its own. B-MYB was affected the least after 
dilution. 
Interesting results were obtained while comparing the multi-cistronic LFM 
construct to the different combination of bi-cistronic constructs after tenfold 
dilution. For the first time, we noticed a significant difference between the bypass 
of multi-cistronic LFM construct and bi-cistronic LF construct as shown in Figure 
4.26C. No numerical difference was observed when other two bi-cistronic i.e. LM 
and FM were compared as depicted, even though LM presented bypass similar 
to LF. These results obtained after tenfold dilution indicate towards the presence 
of potential synergy between two and three components when present together. 
Another key aspect of the results obtained from this experiment was that it helps 
to establish the importance of the dilution approach used, in detecting small 
differences in efficiencies among the different key TFs. 
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Figure 4.26 Different comparisons of multicistronic constructs after ten-fold dilution.  
A) LFM vs LFMS B) LFM vs Individual components C) LFM vs Bicistronic constructs. For each 
comparison both manual and computational analysis are shown. Statistical analysis was 
conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001) 
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4.11 Protein analysis 
4.11.1 Objective 
Western blot analysis was undertaken to validate the results obtained from the 
senescence bypass assays. It is important to verify the protein expression to 
ensure that the senescence bypass potential observed is due to overexpression 
or downregulation of a protein. 
4.11.2 Western blot analysis 
Due to time constraints and lack of specific antibodies, every TF tested in this 
study to assess its functional role in senescence could not be verified by protein 
analysis. As LIN52, FOXM1 and B-MYB turned out to be key TFs which have 
shown to play crucial role in senescence bypass, it was decided to test the 
expression of these proteins first. Cell lysates were prepared from stably 
transduced CL3EcoR cells with the desired constructs and grown for at least seven 
days at the non-permissive temperature i.e. 38.9C. To compare protein 
expression of desired proteins in non-infected senescent cells and proliferating 
cells, cell lysates were made from non-infected CL3EcoR cells grown for at least 
five days at 38.9C and 33C respectively. In this study silencing p21WAF1 has 
consistently worked very efficiently resulting in saturated flask as shown in Figure 
3.9. Hence, cell lysates were also prepared from CL3EcoR cells stably transduced 
with p21WAF1 shRNA after allowing them to grow for seven days at the non-
permissive temperature. To study basal level of proteins, control cell lysates were 
prepared from healthy growing HEK293T cells at 37C. 
Western blots were performed to investigate protein expression for LIN52, 
FOXM1 and B-MYB. The details of the antibodies used are provided in section 
2.10.5. The results obtained from western blots were rather disappointing as 
western blots for all three proteins after developing resulted in appearance of 
multiple non-specific bands as shown in Figure 4.27. This could be due to poor 
antibody specificity. Due to multiple non-specific bands, the results obtained for 
protein analysis are therefore uninterpretable.  
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Hence, western blot analysis needs to be optimized with different antibodies with 
further standardization of experimental conditions as well as antibody 
calibrations. 
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Figure 4.27 Western blot analysis to test expression of A) LIN52, B) FOXM1NKEN and C) B-
MYB.  
Cell lysates were prepared from CL3EcoR cells transduced with desired respective constructs 
after growing them at 38.9C for at least seven days. As control to study basal level of expression 
lysates were prepared from HEK293T cells after 5 days at 37C (HEK293T cells). To study how 
protein levels, change after silencing, p21WAF1 lysates were prepared from CL3EcoR cells where 
p21WAF1 is silenced (p21WAF1). Additionally, to study the contrast between growing cells and 
senescent cells lysates were prepared from non-infected CL3EcoR cells after growing them for 
five days at 33C and 38.9C respectively (33C and 38.9C). No specific bands corresponding 
to the desired proteins were observed. All three western blots showed number of non-specific 
bands indicating that antibody used was not very specific and as a result could not detect the 
specific protein.  
A) L1: LF, L2: LM, L3: LIN52, L4: LFMS, L5: p21WAF1, L6: WC, L7: 33C, L8: 38.9C and L9: 
HEK293T cells 
B) F1: LFM, F2: LF, F3: FM, F4: LFMS, F5: p21WAF1, F6: WC, F7: 33C, F8: 38.9C and F9: 
HEK293T cells 
C) B1: LM, B2: B-MYB, B3: LFMS, B4: p21WAF1, B5: WC, B6: 33C, B7: 39C and B8: 
HEK293Tcells  
*LFM: LIN52, FOXM1NKEN and B-MYB, LF: LIN52, FOXM1NKEN, LM: LIN52 and B-
MYB, FM: FOXM1NKEN and B-MYB and LFMS: LIN52, FOXM1NKEN and B-MYB 
reconstituted separately. 
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Chapter 5 Assaying the bypass potential of different 
identified TFs after simultaneous modulation of 
expression  
5.1 Comparison of bypass potential of p21WAF1 with the 
reconstituted active whole complex 
5.1.1 Objective 
In this study so far, the strongest bypass potential was observed by silencing 
p21WAF1. One of the most striking findings from this study was that it has shown 
how efficiently reconstituting the active whole complex i.e. (MMB-FOXM1) works 
in bypassing senescence in CL3EcoR cells. It was therefore interesting to compare 
the bypass induced by p21WAF1 silencing to that with the reconstituted MMB-
FOXM1 complex. 
5.1.2 Comparison of bypass 
Densely dark blue stained colonies were obtained after silencing p21WAF1 as well 
as expressing the components of the MMB-FOXM1 complex. On comparing the 
bypass potential of CL3EcoR where p21WAF1 had been silenced to CL3EcoR cells 
which had been transduced with reconstituted whole MMB-FOXM1 complex, it 
was observed that even though reconstituting the whole complex bypasses 
senescence strongly it is less efficient in comparison to the extent of bypass 
observed by silencing p21WAF1. This is shown both qualitatively and quantitatively 
in Figure 5.1. This comparison was only possible by using the software analysis 
algorithm as it was not possible to count the colonies obtained manually after 
silencing p21WAF1 due to a completely saturated flask. The result in Figure 5.1, 
show that silencing of p21WAF1 reported a significantly high bypass potential than 
that observed by reconstituting the whole active complex (MMB-FOXM1). 
Although computational analysis suggests that about 24% of the area of the flask 
was stained blue indicating presence of healthy growing colonies, I believe this 
is an underestimation as on close examination it appears that at least 60-70% of 
the flask was stained blue. This is possible as the computer algorithm was not 
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developed for completely saturated flasks, it was developed to identify blue spots 
against transparent background. 
This comparison suggested the possible involvement of other factors and/or 
signalling pathways apart from DREAM in regulating senescence. If the DREAM 
complex is all there is downstream of p21WAF1, then the efficiency of bypass 
should be the same, but it is not. This suggests that p21WAF1 causes senescence 
by acting on a multitude of effectors, one of which could be the DREAM complex. 
 
 
Figure 5.1 Comparison of bypass potential of silencing p21WAF1 to MMB-FOXM1 complex 
Bypass assays were performed at 5% CO2 and 38.9C with 35,000 cells per T-75 flask. Flasks 
were stained with 2% methylene blue after three weeks. Single representative flasks when 
p21WAF1 was silenced and when the MMB-FOXM1 complex was reconstituted and ectopically 
expressed are shown. Due to completely saturated flask obtained after silencing p21WAF1 only 
the software analysis was feasible. Hence, flask images shown with blue spots depict the area 
of the flask computed as blue areas by the computer algorithm. Quantitative representation of 
bypass potential is also presented graphically by plotting the calculated percentage area (+/- SD) 
covered in blue by Definiens Developer XD software for each of the replicates. Statistical analysis 
was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (***p<0.001) 
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5.2 Identifying additional downstream mediators involved in 
bypassing senescence 
5.2.1 Objective 
An initial objective of this thesis was to identify, if there is a cocktail of TFs that 
can bypass senescence as efficiently as silencing of p21WAF1 in CL3EcoR cells. In 
the previous section it is described how efficiently silencing of p21WAF1 bypasses 
senescence. The bypass obtained after reconstituting the MMB-FOXM1 complex 
is approximately five-fold reduced in comparison to the bypass obtained after 
p21WAF1 silencing. This significant difference raised the question as to what 
silencing of p21WAF1 is doing? Hence, our objective was to try and identify other 
mediators that might be involved in addition to the components of MMB-FOXM1 
complex which synergize when present together. We were particularly 
encouraged by the remarkable strategy used by Takahashi and Yamanaka who 
initially selected 24 TFs as candidates for reprogramming adult fibroblasts into 
iPS cells based on them playing pivotal roles in the maintenance of ES cell 
identity. They introduced all 24 TFs simultaneously, by retroviral infection, into 
adult fibroblasts and selected for cells which had been reprogrammed into iPS 
cells. They then left out one TF in turn until they were able to identify a cocktail 
of four TFs that can reprogram adult fibroblasts into iPS cells (Takahashi et al. 
2007; Takahashi and Yamanaka 2006). This procedure relied on multiple viruses 
infecting the same cell and a very stringent assay which could detect a very small 
number of iPS cells in a background of non-programmed cells.  
The experimental approach in this section is based on a similar strategy wherein, 
we have used a combination of high titre lentiviruses transducing all candidate 
TFs shortlisted in this study, as our starting point. Our aim was to identify a 
combination of TFs, which enhance the efficiency of bypassing senescence 
under very stringent conditions and if possible, improve it to the levels obtained 
after silencing p21WAF1. This will allow us to determine if there is any potential 
synergism between the TFs that individually were not capable of bypassing 
senescence. 
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Hence, in this section silencing of the shortlisted up-regulated TFs was tested in 
conjunction with ectopic expression of the shortlisted down-regulated TFs to 
identify a cocktail that bypasses senescence efficiently. 
5.2.2 Studying the bypass potential after mixing 73 TFs together 
Firstly, a candidate list of TFs was assembled based on the initial list of up- and 
down-regulated TFs depending on availability of constructs.  To this list some 
additional TFs were also added such as LIN52 which exhibited strong bypass 
potential in this study as discussed in the previous chapter. Also RELA, RELB 
and CEBPβ were included to the Pool (73) as they had shown some bypass 
activity upon silencing in previous studies conducted in the lab (Rovillain et al. 
2011). Table 5.1 presents the list of 13 upregulated and 60 downregulated TFs. 
Some of these TFs were studied individually for their bypass potential as 
described in Chapter 3; due to time constraints all of them were not studied 
individually. In the previous experiments, mixing of six TFs to reconstitute the 
MMB-FOXM1 complex worked efficiently and produced strong bypass. 
Takahashi and Yamanaka’s remarkable experiment where they studied 24 
factors together, provided the motivation to try something far-fetched wherein, I 
tested the bypass potential after mixing 73 TFs together listed in Table 5.1 
(Takahashi and Yamanaka 2006).   
After assembling a candidate list, a DNA pool containing the most effective 
lentivirus shRNAmiRs for silencing up-regulated TFs were mixed together with 
lentiviral expression constructs for the down-regulated TFs (Table 5.2). As by 
now in this study we had established that LIN52, FOXM1NKEN and B-MYB 
show a very strong bypass potential when present together therefore, another 
DNA pool called ‘Pool Control’ was made containing only LIN52, 
FOXM1NKEN and B-MYB. This was undertaken to estimate the basal level of 
bypass observed because these three components that were present in the Pool 
in addition to 70 other TFs.  
The aim of this experiment was to assess the efficiency of bypass of the other 
TFs, when present together and identify if there was any synergy. It was 
hypothesised that if we detected a stronger bypass activity in Pool (73) as 
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compared to Pool Control, this will suggest that there are TFs apart from LIN52, 
FOXM1NKEN and B-MYB which might have an additional role to play in 
regulating senescence. 
Table 5.1 List of 73 TFs which make up the pool of 73 TFs 
 
ADNP GABPB1 MYNN SSRP1 CD36 
ARNTL2 GLIS2 NOC4L SUZ12 CEBPβ 
B-MYB H1FX NUF1P1 TCF19 DNAJC21 
C14ORF106 HMG2L1 PATZ1 TCF3 EPAS1 
CBFB HMGB1 PHB2 TCF4 LARP6 
CEBPG HMGB2 POGK TEAD4 MXD1 
CIZ1 HMGB3 PRMT3 TFAM NR1H4 
DEK IF16 PRRX1 TWIST1 NR3C2 
DEPDC1 LARP1 PSMD11 UBE2K RELA 
E2F1 LARP4 RAD51 WHSC1 RELB 
E2F8 LIN52 ROD YEATS4 RGS7 
EP400 MATR3 SMARCA5 ZNF107 RORA 
ETV4 MET SMARCC1 ZNF207 SLC22A4 
EZH2 MTA1 SMARCE1 ZNF280C  
FOXM1NKEN MYBL1 SP3 ZNF511  
*Genes listed in green were ectopically expressed whereas genes listed in red were silenced. 
Lentiviruses were prepared for both Pool (73) and Pool Control to infect CL3EcoR 
cells. Freshly collected viruses were used to maximize viral titre and double 
infections were conducted to allow multiple infections of the same cell and stably 
transduced cells were assayed for bypass of senescence. pLEX-MCS was used 
as a negative control. The flasks were stained with methylene blue after three 
weeks to assess and compare the bypass potential. 
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Table 5.2 DNA pools made to study 73 TFs together 
 
Reconstituted complex Constituents 
Pool (73) 1 µg of each of 73 TFs  
Pool Control 70 µg pLEX-MCS+1 µg LIN52+1 µg FOXM1NKEN 
and 1 µg B-MYB 
 
Striking results were obtained. Dark blue stained colonies were obtained for both 
Pool (73) as well as the Pool Control. However, a greater number of densely 
stained colonies were obtained for Pool (73) compared to Pool Control. Pool 
Control had fewer faintly stained colonies. Quantitative analysis revealed a highly 
significant increase in the bypass potential when all 73 TFs were present 
together compared to Pool Control as shown in Figure 5.2. These results were 
independently verified in three different biological experiments. This indicated 
that there were other TFs present apart from LIN52, FOXM1NKEN and B-
MYB which may have a role in regulating senescence or can synergize with other 
TFs when expressed together. 
  
 215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pool (73) Pool Control pLEXMCS
P
oo
l (
73
)
P
oo
l C
on
tr
ol
pL
E
X
M
C
S
0
20
40
60
80
Pool (73): Mix of 73 TFs
Pool Control:
70µg pLEXMCS+
1μg LIN52+1μg
FOXM1∆N∆KEN+1μg
B-MYB
***
N
u
m
b
e
r
o
f
g
ro
w
in
g
c
o
lo
n
ie
s
A
Pool (73) Pool Control pLEXMCS
Po
ol
(7
3)
Po
ol
C
on
tr
ol
pL
E
XM
C
S
0
5
10
15
*** Pool (73): Mix of 73 TFs
Pool Control:
70μg pLEX MCS+
1μg LIN52+1 μg
FOXM1∆N∆KEN+1μg
B-MYBP
e
rc
e
n
ta
g
e
a
re
a
s
ta
in
e
d
B
Figure 5.2 Study of bypass potential of 73 TFs when present together  
Bypass assay was performed thrice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. Single representative flasks from internal repeats are shown. Bypass potential of 73 
TFs was tested against Pool Control containing LIN52, FOXM1NKEN and B-MYB. Empty 
vector pLEX-MCS was used as negative control. A) Manual analysis B) Computational analysis. 
Statistical analysis was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test 
(*p<0.05, **p<0.01, ***p<0.001) 
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5.3 Identification of TFs that were enriched in senescence 
bypassed cells stably transduced with Pool of 73 TFs 
5.3.1 Objective 
The results obtained from previous experiments were very encouraging as it 
showed that bypass potential of 73 shortlisted TFs was greater than bypass 
observed with Pool Control. It was possible therefore that other TFs are present 
within 73 TFs which have the potential to synergize or play a role in regulating 
senescence growth arrest.  
To narrow down the candidate TFs to find out the minimum number of key TFs 
that have a role in senescence two approaches could be used. First approach 
can be similar to the one used by Takahashi and Yamanaka (Takahashi and 
Yamanaka 2006). This would involve repeating the bypass assays and leaving 
out one TF per assay. The hypothesis for this approach is that if the TF that is 
removed is critical, a reduction in bypass potential will be observed. A second 
approach that can be used is to identify the TFs which have been enriched in 
CL3EcoR cells in which senescence has been bypassed by Deep sequencing.  
The first approach would require setting up 73 senescence bypass assays 
removing one TF per assay. As we do long term senescence bypass growth 
assays this approach would require a lot of time. Therefore, due to time 
constraints the second approach was taken in this study. This should allow us to 
narrow down the TFs that may be enabling senescence to be bypassed.  
5.3.2 Deep sequencing 
Three independent experiments were performed to test the bypass potential of 
Pool (73) over Pool Control. The results obtained from these experiments 
established that Pool (73) works better than Pool Control. The next aim was to 
identify from the pool of 73 exogenously introduced TFs which have been 
enriched in the bypassed cells. It was hypothesized that if a TF is important, it 
should be enriched within the cells in which senescence has been bypassed and 
contribute towards the observed bypass.  
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Deep sequencing was undertaken on genomic DNA extracted from CL3EcoR cells 
which had bypassed senescence after being stably transduced with DNA Pool 
(73) from three independent biological experiments. Isolated genomic DNA was 
amplified using P7-tagged primers specific for the three different types of vectors 
present in the pool: pLX301, pLEX-MCS and pGIPZ shRNAmiR. Amplified DNA 
was outsourced to UCL Genomics Services based at Institute of Child Health for 
MiSeq Micro 300 Cycle Sequencing. The results after deep sequencing were 
obtained as a count table that indicated how many times each sequence was 
uniquely identified by a sequencing read. In addition to the isolated genomic DNA 
from CL3EcoR cells, the starting mixture of DNA Pool (73) was similarly amplified 
followed by deep sequencing. This was done to determine the baseline count for 
sequencing reads when all TFs are added in similar amount in Pool (73) as the 
efficiency of amplification may vary between different constructs; it is possible 
that some TFs may amplify better than others. Hence, for every TF if the 
sequencing reads obtained in experimental samples of genomic DNA was 
significantly higher than the reads obtained for DNA pool, that TF was considered 
to be enriched. Analysed results are presented in Figure 5.3 for all the 73 TFs, 
which are an average of all the six samples. This led to identification of 18 down-
regulated TFs and 5 up-regulated TFs which were found to be enriched. 
The findings reported here suggest that overall 23 TFs were enriched in CL3EcoR 
cells in which senescence had been bypassed after being stably transduced with 
the Pool of 73 TFs. 
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A. 
 
B. 
 
 
 
 
 
 
Down-regulated TFs Length of sequence (bp)
Percentage of DNA amplified
 from DNA Pool (73)  
Average percentage enrichment in 
bypassed CL3
EcoR 
cells
Ratio
ADNP 3426 0.68 0.04 0.06
ARNTL2 1849 1.76 0.96 0.54
B-MYB 2154 1.63 3.84 2.36
C14ORF106 3461 0.52 0.04 0.08
CBFB 609 3.18 9.06 2.85
CEBPG 505 3.07 6.08 1.98
CIZ1 2446 0.03 0.01 0.34
DEK 1174 0.39 1.24 3.21
DEPDC1 1722 0.58 0.26 0.45
E2F1 1477 0.00 0.00 0.00
E2F8 2651 0.48 0.08 0.17
EP400* 3002 0.00 0.00 0.00
ETV4 1504 0.06 0.01 0.10
EZH2 2302 1.32 0.46 0.35
FOXM1ΔNΔKEN 475 0.36 0.11 0.29
GABPB1 1128 19.63 4.20 0.21
GLIS2 1639 0.09 0.00 0.03
H1FX 1665 3.61 4.86 1.35
HMG2L1 1855 1.70 1.46 0.86
HMGB1 694 3.38 5.81 1.72
HMGB2 679 2.04 3.95 1.93
HMGB3 646 1.80 0.64 0.36
IFI16* 2222 0.00 0.00 0.00
KNTC1 6766 0.03 0.00 0.00
LARP1 3104 0.30 0.00 0.00
LARP4 1169 2.59 1.26 0.49
LIN52 668 1.62 2.02 1.24
MATR3 2586 0.60 0.13 0.22
MET 4276 0.39 0.00 0.01
MTA1 812 0.21 0.07 0.35
MYBL1 2125 1.53 0.29 0.19
MYNN 1885 2.15 0.44 0.21
NOC4L 1600 1.67 1.05 0.63
NUF1P1 896 2.59 5.45 2.10
PATZ1 1661 0.16 0.01 0.03
pLEXMCS 334 5.19 3.87 0.75
POGK 1877 0.11 0.00 0.00
PRMT3 1648 2.10 3.16 1.51
PRRX1 787 0.61 1.48 2.40
PSMD11 1379 0.01 0.41 68.29
RAD51 1069 6.53 4.76 0.73
SMARCA5 3203 0.48 0.10 0.22
SMARCC1 3370 0.32 0.01 0.03
SMARCE1 1285 1.67 2.08 1.25
SP3 2393 0.54 0.06 0.10
SSRP1 2178 1.64 0.82 0.50
SUZ12* 2264 0.00 0.00 0.00
TCF19 1090 1.38 1.46 1.06
TCF3 805 2.14 1.39 0.65
TCF4 2104 1.43 0.59 0.41
TEAD4 1336 1.33 3.07 2.31
TFAM 787 3.34 7.30 2.19
TWIST1* 654 0.00 0.01 0.00
UBE2K 652 3.73 5.92 1.59
WHSC1 4162 0.28 0.00 0.01
YEATS4 749 2.36 5.28 2.24
ZNF107 2897 0.22 0.00 0.01
ZNF207 1231 0.63 0.09 0.14
ZNF280C 2222 1.51 0.70 0.47
ZNF511 803 2.31 3.60 1.55
Up-regulated TFs Length of sequence (bp)
Percentage of DNA amplified
 from DNA Pool (73)  
Average percentage enrichment in 
bypassed CL3
EcoR 
cells
Ratio
CD36 520 6.28 6.95 1.11
CEBP 520 7.44 15.16 2.04
DNAJC21 520 13.38 10.88 0.81
EPAS1 520 9.70 4.02 0.41
LARP6 520 3.22 5.55 1.72
MXD 520 11.74 9.39 0.80
NR1H4 520 11.98 9.94 0.83
NR3C2 520 10.16 11.97 1.18
RELA 520 2.50 4.48 1.80
RELB 520 5.58 7.15 1.28
RGS7 520 6.25 5.43 0.87
RORA 520 11.78 9.07 0.77
SLC22A4 520 0.00 0.00 0.00
Figure 5.3 Identification of enriched TFs from 73 TFs.  
A) Down-regulated TFs B) Up-regulated TFs. Ratio was calculated after dividing the average 
percentage enrichment obtained from the genomic DNA samples of three independent biological 
experiments to the Percentage of reads obtained for TFs amplified from Pool DNA. TFs for which 
the ratio was greater than 1 (highlighted in yellow) were considered to be enriched and 
shortlisted for further study. ‘*’ marked are the ones which did not amplify from DNA Pool (73). 
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5.3.3 Studying the bypass potential after mixing together the identified 23 
TFs 
Deep sequencing identified 23 TFs which were found be enriched in CL3EcoR 
cells transduced with 73 TFs over other TFs. The next step was to analyse the 
bypass potential of the 23 TFs when studied together. Surprisingly 
FOXM1NKEN was not found to be highly enriched in CL3EcoR cells transduced 
with pool of 73 TFs. Therefore, FOXM1NKEN was excluded from the Pool of 
23 TFs and the pool control designed for this experiment did not contain 
FOXM1NKEN as shown in Table 5.3. 
To compare the bypass of Pool (23) to Pool Control, respective lentiviruses were 
made, and infections performed in CL3EcoR cells. After three weeks bypass 
potential was analysed by staining the flasks with 2% methylene blue. 
Table 5.3 DNA pools made to study 23 TFs that were found to be enriched together 
 
Reconstituted complex Constituents 
Pool (23) 1 µg of each of 23 TFs  
Pool Control 21 µg pLEX-MCS+1 µg LIN52 and 1 µg B-MYB 
 
Interestingly, the Pool (23) exhibited large number of stained growing colonies. 
Pool control also presented some growing colonies, but they were much less 
than the number of colonies obtained for Pool (23). Quantitative analysis showed 
that the bypass potential obtained for Pool (23) was significantly higher than Pool 
Control as illustrated in Figure 5.4. This is very interesting as it suggests the 
presence of other key TFs within the identified 23 TFs which might have a role 
in regulating senescence growth arrest. 
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Figure 5.4 Study of bypass potential of 23 TFs when present together  
Bypass assay was performed thrice independently at 5% CO2 and 38.9C with 35,000 cells per 
T-75 flask. Single representative flasks from internal repeats are shown. Bypass potential of 23 
TFs was tested against Pool Control containing LIN52 and B-MYB. Empty vector pLEX-MCS 
was used as negative control. A) Manual analysis B) Computational analysis. Statistical analysis 
was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test (*p<0.05, **p<0.01, 
***p<0.001) 
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5.4 Comparison of bypass potential of 73 TFs to 23 TFs 
Previously, we have tested the bypass potential of 73 TFs as well as 23 TFs. 
However, it was important to compare and analyse the bypass potential for both 
pools together. Our aim was to test the hypothesis that the bypass potential for 
Pool (23) should be more than Pool (73) as Pool (23) only contains the TFs which 
were enriched and should therefore present a stronger bypass. 
Lentiviruses were successfully made for both the pools (Table 5.4) and assayed 
for their ability to bypass senescence in CL3EcoR cells. 
Table 5.4 DNA pools made to compare bypass potential of 73 TFs to 23 TFs 
 
Reconstituted complex Constituents 
Pool (73) 1 µg of each of 73 TFs  
Pool (23) 1 µg of each of 23 TFs 
 
Unfortunately, the results obtained were not as expected. Staining with 
methylene blue after the stably transduced cultures of CL3EcoR cells were allowed 
to grow for three weeks generated healthy growing colonies for both Pool (23) 
as well as Pool (73). The bypass potential observed by both DNA pools of 23 
and 73 TFs together were similar as shown by the representative flask images 
for each pool in Figure 5.5.  
Also, an anomaly was present between the quantitative analysis of the results 
obtained when analysed by the two different methods. Quantitative analysis done 
by manual method showed that there was no numerical difference between the 
bypass potential of Pool (23) and Pool (73). On the other hand, analysis using 
software revealed a small significant difference between the bypass. 
Computational analysis showed that the extent of bypass obtained by Pool (73) 
was slightly higher than the bypass of Pool (23). To be able to understand this 
result thoroughly, further experimental investigations are required. 
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Figure 5.5 Comparison of the bypass potential of pool of 73 TFs to pool of 23 TFs.  
Bypass assay was performed thrice independently under the similar stringent conditions 
described above. Single representative flasks from internal repeats are shown. Empty vector 
pLEX-MCS was used as negative control. A) Manual analysis B) Computational analysis. 
Statistical analysis was conducted using One-way ANOVA, Tukey’s Multiple Comparison Test 
(*p<0.05, **p<0.01, ***p<0.001)  
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Chapter 6 Discussion 
Cellular senescence is a stable growth arrest that normal cells undergo after a 
finite number of divisions, the Hayflick limit (Hayflick and Moorhead 1961).   
Senescence is triggered in response to a variety of intrinsic and extrinsic stimuli, 
for example, progressive telomere shortening; changes in telomeric structure, or 
other forms of genotoxic stress resulting in a DNA damage response; and growth 
arrest mainly via activation of p53 (Adams 2009).  Other forms of stress lead to 
senescence via activation of the pRB pathway (Adams 2009).  
Senescence can compromise tissue repair and regeneration and contribute to 
tissue and organismal ageing due to accumulation of senescent cells, depletion 
of stem/progenitor cell compartments and secretion of SASP proteins. Removal 
of senescent cells can prevent or delay age-related tissue dysfunction and 
extend healthspan (Baker et al. 2011, 2016). Senescence can also lead to the 
removal of defective and potentially cancerous cells from the proliferating pool, 
thereby limiting tumour development and acting as a potent tumour suppressor 
mechanism (Campisi 2005). A greater understanding of the molecular events 
that lead to cellular senescence is therefore essential if we are to prevent tissue 
dysfunction without increasing the risk of cancer.  
To facilitate the study of senescence, the Jat laboratory has used a thermolabile 
mutant of SV40 LT antigen, in conjunction with hTERT, to develop unique 
conditionally immortalised human mammary CL3EcoR fibroblasts that are 
stringently temperature sensitive (O’Hare et al. 2001). These cells are immortal 
if grown at 34C, but upon inactivation of thermolabile LT antigen at 38C, 
resulting in activation of p53 and pRB, they undergo a stable growth arrest within 
7 days, induce senescence-associated (SA)--galactosidase and have 
morphological features and express genes in common with senescent cells 
(Rovillain et al. 2011). 
Many studies in addition to those undertaken by Rovillain et al., 2011, have 
shown that mechanisms underlying senescence growth arrest primarily involve 
p53/p21WAF1 and p16INK4A/pRB tumour suppressor pathways (Rovillain et al. 
2011; Adams 2009; Campisi and D’Adda Di Fagagna 2007; Ben-Porath and 
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Weinberg 2005). But it is not known what makes the growth arrest stable; what 
the critical targets are; and what downstream TFs are involved, as they are likely 
to be the key for the establishment and maintenance of senescent state.  Hence, 
the aim of this thesis was to identify transcription factors that act downstream of 
the p53/p21WAF1 and p16INK4A/pRB pathways and assess their functional role in 
regulating senescence growth arrest. 
Genome-wide expression profiling, coupled with inactivation of p16INK4A/pRB and 
p53/p21WAF1 pathways in human mammary fibroblasts cells (CL3EcoR), previously 
conducted in the laboratory had derived a comprehensive catalogue of genes 
whose levels are altered upon senescence but then reversed when senescence 
was bypassed (Rovillain et al. 2011).   
As TFs regulate gene expression at different stages of embryonic development 
and are key to the establishment and maintenance of specific cell fates 
(Vaquerizas et al. 2009), in this thesis I undertook an overlay of the differential 
gene set with 1391 manually curated sequence-specific DNA binding factors.  
This gene list was then further refined using Oncomine, a cancer microarray 
database, hypothesising that gene expression in senescence and cancer should 
be opposite i.e. genes ‘turned on’ in cancer should be ‘turned off’ in senescence 
and vice versa. Once the list of differential TFs was assembled, the next step 
was functional validation to determine if the candidate TFs had a role in 
senescence by stably silencing expression of genes that were ‘turned on' and 
ectopically expressing genes that were ‘turned off'.  Although other investigators 
have successfully utilised short-term senescence bypass assays, we have 
chosen to undertake a long-term senescence bypass assay as described by 
Rovillain and colleagues (Rovillain et al. 2011). 
Long term senescence bypass assay involves stably transducing cells at 34ºC 
and then plating a fixed number of cells (35,000 or 50,000) per T-75 flask and 
shifting the cells to the non-permissive temperature and cultivating them for three 
weeks.  Plating a fixed number of cells ensures that the cell density is same 
across the experiment. Moreover, culturing the cells for 3 weeks ensures that the 
cells that are growing are those in which senescence has been stably bypassed 
especially since in cultured cells onset of stable senescence growth arrest 
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requires a prolonged period (>4 days) to become fully arrested (Chen et al. 2002; 
Dai and Enders 2000; He and Sharpless 2017).  The CL3EcoR cells only become 
fully growth arrested after 5 to 7 days.  Therefore, this protocol measures a much 
more stringent bypass than the short-term transient expression and silencing 
assays. 
To determine, if the up-regulated TFs can bypass senescence individually, 
senescence bypass assays were conducted by silencing the upregulated TFs 
using different pGIPZ shRNAmiRs. To determine if ectopic expression of 
downregulated TFs can individually bypass senescence, senescence bypass 
assays were performed by ectopically expressing full-length ORFs.  To study 
synergistic effects, reconstruction experiments were undertaken, where 
lentiviruses were prepared from pools of DNAs consisting of different TFs to be 
tested simultaneously.  
6.1 Summary and Discussion of Results 
6.1.1 Assessment of the functional role of differentially regulated TFs in 
senescence.   
Use of the refining approaches which included the overlapping with DNA binding 
factors and Oncomine database, discussed in Chapter 3, led to the identification 
of 10 upregulated TFs and 74 downregulated TFs.  Interestingly six differential 
candidate TF genes identified in this study i.e. ARID2, PATZ1, PDS5B, PLXNA3, 
ZBTB7A and ZC3H4 were amongst the senescence transcriptome signature 
genes identified in a recent study by Hernandez-Segura et al., 2017, 
(Hernandez-Segura et al. 2017). They incorporated datasets from whole-
transcriptome profiles from six different strains of fibroblasts (BJ, HCA-2, HFF, 
IMR90, MRC5, WI-38) that were subjected to three different senescence 
inducing stimuli, replicative senescence, oncogene-induced senescence and 
ionizing radiation-induced senescence (Hernandez-Segura et al. 2017).   
ARID2 is a transcriptional regulator which is a subunit of SWI/SNF multi-protein 
chromatin remodelling complex. Inactivating mutations in AT-rich Interaction 
domain 2 (ARID2) has been shown to be involved in non-small cell lung 
carcinoma, liver cancer related to Hepatitis C virus (HCV) infection and in 
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melanoma (Manceau et al. 2013; Li et al. 2011b). These findings predict the 
tumour suppressive role of ARID2.  
POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) acts as a 
transcriptional repressor and plays an important role in chromatin remodelling 
and transcription regulation (Cho et al. 2012).  Study by Cho et al., 2012, has 
reported PATZ1 to be downregulated in endothelial cell senescence (Cho et al. 
2012). This study demonstrated that knockdown of PATZ1 in young human 
umbilical vascular endothelial cells accelerated premature endothelial cell 
senescence whereas overexpression of PATZ1 led to the reversal of a senescent 
phenotype.  Additionally, results from this study suggested that PATZ1-induced 
senescence is mediated by a ROS-mediated p53-dependent DDR pathway (Cho 
et al. 2012).  However, the role of PATZ1 as an oncogene or tumour suppressor 
gene is still debatable.  
For PDS5 Cohesin Associated Factor B (PDS5B) and Plexin A3 (PLXNA3), no 
direct known links to senescence are known.  However, PLXNA3 has been 
suggested to be involved in tumour progression (Hernandez-Segura et al. 2017).  
Zinc Finger and BTB Domain containing 7A (ZBTB7A) is a member of POK 
(POZ/BTB and Kruppel) TF family.  It has been identified as a potential proto-
oncogene by multiple different studies to be involved in different types of cancer 
such as ovarian cancer, breast cancer, non-small cell lung carcinoma and 
chondrosarcoma (Jiang et al. 2010; Aggarwal et al. 2010; Qu et al. 2010; 
Vredeveld et al. 2010; Zhao et al. 2008; Maeda et al. 2005; Kumari et al. 2012).  
Study by Kumari et al., 2012, has demonstrated the use of ZBTB7A in 
chondrosarcomas, both as a therapeutic target as well as a diagnostic marker 
(Kumari et al. 2012). ZBTB7A has recently been identified as a context-
dependent cancer gene which in addition to acting as a key proto-oncogene in 
multiple tissues, can also act as a tumour suppressor (Wang et al. 2013).  It was 
demonstrated that inactivation of ZBTB7A greatly enhanced the progression of 
Pten-loss driven prostate cancer by overcoming Pten loss induced cellular 
senescence. Furthermore, a concomitant loss of ZBTB7A expression at both 
mRNA and protein level is reported in a subset of advanced human prostate 
cancers (Wang et al. 2013).  
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ZC3H4 (Zinc Finger CCCH-Type Containing 4) was recently reported to be 
among the top candidate genes that were downregulated upon silencing of 
Endogenous bornavirus-like nucleoprotein 1 (EBLN1) expression in infected 
oligodendroglial cells.  Silencing of EBLN1 induces G2/M phase growth arrest, 
promotes apoptosis and inhibits cell proliferation (He et al. 2016). 
The ability of the prioritized TFs to directly bypass senescence was examined in 
the conditionally immortalized fibroblasts by lentivirus-mediated RNA silencing 
or ectopic expression.  Testing of all the 10 shortlisted up-regulated TFs along 
with other key up-regulated TFs that are known to play a crucial role in 
senescence i.e. p21WAF1, RELA, RELB and CEBPβ for their bypass potential led 
to identification of four TFs (EPAS1, RGS7, LARP6 and NR1H4) in addition to 
RELA (Rovillain et al. 2011) that were able to bypass senescence to certain 
extent.  The remainder were inactive.  The strongest bypass was observed after 
silencing p21WAF1, which generated a completely saturated flask of healthy 
growing colonies.  To further confirm these findings, the bypass assay was 
repeated with multiple pGIPZ shRNAmiRs for each candidate TF and the assay 
was conducted under more stringent conditions. Unfortunately, this time none of 
the TFs reported significant bypass potential.  Close examination of the results 
indicated that the only TF which showed any bypass activity under the very 
stringent conditions was RELA. This is in accordance with multiple previous 
studies indicating a role for RELA activation in senescence (Rovillain et al. 2011; 
Korc 2016; Lesina et al. 2016; Wang et al. 2009b; Adler et al. 2007; Penzo et al. 
2009; Osorio et al. 2016; Salminen et al. 2012, 2008; Kriete and Mayo 2009).  
Recently ROS-activated NF-κB signalling has been reported to be involved in 
senescence bystander effect seen in human fibroblasts (Nelson et al. 2018). 
Functional validation of the down-regulated TFs in the senescence bypass assay 
by their ectopic expression found that none of the TFs examined, exhibited any 
bypass potential.  This was very surprising since previous work in the laboratory 
had shown that B-MYB, EZH2 and DEK, for example, were able to bypass 
senescence.  Therefore, conditions and different parameters for the assay were 
optimized.  In addition, all lentiviral expression clones were sequence verified.  
While sequence verifying TFs, it was found that some of the clones were 
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rearranged and none of the B-MYB clones were correct.  We have found lentiviral 
vectors transformed into super competent DH5α cells were highly prone to 
recombination often leading to rearrangements and deletions.  In contrast, it was 
found that all lentiviral constructs transformed into JS4 cells, a recA derivative of 
MC1061 (Sedivy et al. 1987), were highly stable and did not exhibit 
rearrangements.   
After optimization, ectopic expression of full-length verified B-MYB was found to 
bypass senescence very efficiently in the CL3EcoR cells (Figure 3.8).  However, 
rather surprisingly no bypass was observed upon ectopic expression of 
constitutively active FOXM1 that lacks the amino-terminal and the KEN box i.e. 
FOXM1(ΔNΔKEN) as observed previously (Rovillain et al. 2011).  One possibility 
for this difference could be due to the lentiviral pLEX-MCS vector in this study 
whereas previously a retroviral pLNCX2 was used even though the CMV 
promoter was used to drive FOXM1 expression in both vectors.  Apart from B-
MYB, no other downregulated TF when studied individually exhibited strong 
bypass activity.  This could be due to many reasons.  First, the TF does not have 
a direct causal role in senescence.  Second, ectopic expression of the TF is not 
able to bypass senescence due to inappropriate cellular localization or acts in 
conjunction with other components.  Third, the construct used for expressing the 
TF did not express or did not express at sufficiently high levels in CL3EcoR cells 
under the experimental conditions. 
For most of the experiments it was observed that on plating 35,000 cells, around 
20-100 colonies were obtained after successful senescence bypass apart from 
with p21WAF1. One plausible explanation for this could be that even though 35000 
cells are infected, it is impossible to say that every infected cell is expressing the 
gene at the correct level for bypassing senescence. We do not know what that 
correct level is, so we can only score the positive and compare it to our best 
possible controls. Also, every insertion site does not give the same level of 
expression. Therefore, it is all a question of how well the test gene works relative 
to the positive control. 
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6.1.2 Role of DREAM complex associated components in cellular 
senescence 
Microarray analysis of the conditionally immortal CL3EcoR fibroblasts (Rovillain et 
al. 2011) indicated that B-MYB, FOXM1, LIN9 and LIN52 were all significantly 
down-regulated upon senescence and the down-regulation was reversed when 
senescence was bypassed upon inactivation of the p16INK4A/pRB and 
p53/p21WAF1 pathways, shown in Figure 4.2.  LIN54 and RBBP4 were also down-
regulated upon senescence arrest but this was not significant (data not shown).  
In contrast, LIN37 was significantly up-regulated upon senescence arrest, shown 
in Figure 4.2. All the above-mentioned components are the members of the 
MMB-FOXM1 complex (Sadasivam and DeCaprio 2013).   
As most of the components of the MMB-FOXM1 complex were downregulated 
in the microarray analysis (Rovillain et al. 2011), a reconstruction experiment 
was undertaken by preparing a DNA pool comprising B-MYB, FOXM1, LIN9, 
LIN37, LIN52, LIN54, to determine if these components would act in conjunction 
to bypass senescence under stringent conditions.  This led to one of the most 
striking observations in this thesis; the components of the MMB-FOXM1 complex 
together bypassed senescence efficiently in the CL3EcoR cells.   
To identify the critical components within the MMB-FOXM1 complex, further 
reconstruction experiments were undertaken similar to Yamanaka approach 
where the complex was reconstituted but lacked one component.  This revealed 
that LIN52, FOXM1 and B-MYB were the crucial components for the strong 
bypass observed by the whole MMB-FOXM1 complex; their omission resulted in 
a strong reduction in the bypass activity.  Rather surprisingly the strongest effect 
was observed when LIN52 was omitted. Moreover, the results from this 
experiment clearly demonstrated a role for FOXM1 in bypassing senescence.  
This suggested a key role of these three components in regulating senescence 
growth arrest.  
Next, the extent of bypass of the three critical components identified was 
compared individually to the bypass potential of the whole complex containing 
six components.  It was found that none of the three components exhibited very 
strong bypass when present on their own in the same amount as in the whole 
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complex thus demonstrating a clear synergy and showed that for the strong 
bypass observed for the complex, these three components must be present 
together. The results obtained from this experiment also validated the results 
from the indirect approach taken in the previous experiment where the complex 
was reconstituted but lacking one component at a time.  
An alternative experiment design where the mixing of individually packaged and 
titered viruses is used to assess component synergy within the MMB-FOXM1 
complex, as opposed to co-packaging viral backbones. This alternative strategy 
should mitigate the risk that differences in rescue reflect differences in packaging 
preference of specific backbones in different contexts. 
Furthermore, when the bypass potential of each of the components of the MMB-
FOXM1 complex was tested individually, surprising results were obtained.  
LIN52, a 116 aa protein, found to be the critical component of the MMB-FOXM1 
complex, exhibited a strong bypass potential. This was the first time in this study, 
that any TF apart from B-MYB, exhibited strong bypass when expressed 
individually.  Like previous experiments B-MYB showed a strong bypass potential 
whereas FOXM1 exhibited marginal bypass potential along with the other 
components of the complex i.e. LIN9, LIN37 and LIN54.  This clearly 
demonstrated a role for mutant LIN52 in bypassing senescence.  This is in 
accordance with the study by Litovchick et al., 2011, where they showed that 
point mutations in LIN52 disrupt the DREAM assembly and significantly reduced 
the ability of human fibroblasts to undergo oncogenic RAS-induced senescence 
(Litovchick et al. 2011).   
FOXM1 and B-MYB were highly down-regulated upon senescence arrest; they 
were the 5th and 7th most highly down-regulated transcription factors. FOXM1 is 
also down-regulated upon replicative senescence in primary human fibroblasts 
(Hardy et al. 2005) and markedly reduced in cells from elderly patients and 
patients with progeria (Ly et al. 2000). It regulates the G2-specific gene 
expression signature genes which were all down-regulated upon senescence 
arrest in our CL3EcoR fibroblasts (Rovillain et al. 2011).   
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FOXM1 is widely known to promote cell proliferation and hence contribute to 
tumour progression.  FOXM1 is one of the genes in the subset of 69 genes 
identified by Rhodes et al., 2004, which comprises the meta-signatures of genes 
commonly overexpressed in various types of undifferentiated cancer (Rhodes et 
al. 2004).  FOXM1 has also been linked to melanoma, the most lethal form of 
skin cancer.  It is reported to be elevated and activated in metastatic melanoma 
(Kruiswijk et al. 2016; Ito et al. 2016; Miyashita et al. 2015).  
Recently, many studies have suggested the therapeutic use of targeting FOXM1 
to treat advanced melanoma. Recent encouraging results have shown that 
inhibition of FOXM1 expression using siRNA or inhibitors such as thiostrepton 
and siomycinA, significantly suppressed the proliferation of the melanoma cells 
(Miyashita et al. 2015; Ito et al. 2016).  Another study by Kruiswijk et al., 2016 
has suggested the therapeutic use of Pin1-FOXM1 inhibitors in metastatic 
melanoma treatment (Kruiswijk et al. 2016).  Pin1 is an enzyme that has shown 
to be a key regulator of FOXM1 activity mediated by MEK-dependent regulation 
during the cell cycle (Kruiswijk et al. 2016).  
B-MYB is a member of the Myb family of genes that is ubiquitously expressed in 
proliferating somatic cells and represses transcription of p16INK4A (Huang et al. 
2011).  Silencing of B-MYB expression in primary human foreskin fibroblasts 
induces senescence (Johung et al. 2007), whereas ectopic expression rescues 
Ras-induced premature senescence in primary rodent cells (Masselink et al. 
2001).  B-MYB is known to be a key physiological regulator of cell survival, cell 
cycle progression and cell differentiation in tumorigenesis (Musa et al. 2017).  
Initially, it was believed that B-MYB promotes expression of cell cycle genes by 
binding to Myb sites in the promoters of target genes (Zhu et al. 2004; Knight et 
al. 2009).  However, recent studies have now demonstrated that B-MYB, after 
interacting with MuvB, binds to CHR elements present in the promoter region of 
G2/M cell cycle genes (Müller et al. 2012, 2016, 2014). Furthermore, these 
studies have shown that Myb sites were not enriched in the promoters of G2/M 
genes (Müller et al. 2014). 
Evidence in the literature suggests that there may be a potential link between B-
MYB and FOXM1. They have common downstream targets such as CCNB1, 
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PLK1 and AURK1, which are required for progression into mitosis. Their levels 
are also repressed during G0 and their activities are regulated by cell cycle-
dependent phosphorylation.  They also undergo cell cycle-dependent ubiquitin-
mediated proteasome degradation as shown in Figure 1.5.  
It has been shown that LIN52 plays a crucial role in DREAM complex assembly 
(Litovchick et al. 2011).  Phosphorylation of LIN52 at serine 28 by DYRK1A (dual-
specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is central/crucial to 
regulating the switch in the binding of MuvB complex from B-MYB to DREAM 
(Litovchick et al. 2011).  Rather surprisingly, Rovillain et al., 2011, found that 
DYRK1A which promotes entry into quiescence by promoting assembly of the 
DREAM complex was also significantly down-regulated upon senescence arrest 
and this was reversed upon senescence bypass (Rovillain et al. 2011) (Figure 
4.2).   
The other major finding was that LIN52 was found to be the most critical 
component out of LIN52, FOXM1 and B-MYB as the removal of LIN52 led to the 
highest reduction in bypass potential. Results obtained from experiments 
conducted with different LIN52 isoforms i.e. LIN52 with Ala, Glu or Ser at the 28th 
amino acid residue, showed that LIN52-Ala that cannot be phosphorylated 
exhibited a strong bypass potential whereas LIN52-Ser was unable to bypass 
senescence.  LIN52-Ser showed bypass activity similar to the negative control 
as shown in Figure 4.11 indicating that under physiological conditions Ser-28 
was most likely to be constitutively phosphorylated thereby promoting assembly 
of the inhibitory DREAM complex.  A similar reduction in bypass was obtained 
when the MMB-FOXM1 complex was reconstituted with WT-LIN52-Ser.  Rather 
surprisingly LIN52-Glu which was expected to mimic constitutively 
phosphorylated LIN52, showed a similar bypass potential to LIN52-Ala.  The 
LIN52-Ala results show that non-phosphorylated LIN52 was required for the 
strong bypass potential exhibited by LIN52 when studied individually or as part 
of the reconstituted MMB-FOXM1 complex, indicating a role for phosphorylated 
LIN52 and the DREAM complex in inducing senescence.   
As the subunit composition of DREAM complex is different from repressive RB-
E2F complex, it is likely that the DREAM complex containing MuvB represses 
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genes required for cell cycle progression by mechanisms that are partially 
different from the repressive RB-E2F complexes.  A recent study has suggested 
that the DREAM complex downregulates expression of cell cycle genes by 
nucleosome positioning (Marceau et al. 2016). 
Recently, studies have examined the structural basis for DREAM assembly to 
understand the biochemical mechanisms behind DREAM function.  Guiley et al., 
2015, highlighted the importance of phosphorylation of Ser-28 by DYRK1A as 
they identified the LxSxExL sequence in LIN52 which binds directly with LxCxE 
in the pocket domain of p107 and p130 thereby promoting the assembly of the 
DREAM complex (Guiley et al. 2015). This highlighted the critical role of 
phosphorylation of nearby Ser-28 residue which provided specific binding of 
MuvB to only p107/p130 and not to RB protein as the binding pocket of RB is not 
able to bind to phosphorylated LIN52. They also studied DREAM complex 
assembly upon cell cycle entry as MuvB complex is capable of binding to both 
p107/p130 pocket proteins to facilitate DREAM assembly whereas it can also 
bind to B-MYB to promote cell cycle progression.  It was found that upon cell 
cycle entry, phosphorylation of p130 by CDKs weakens its association with 
MuvB. Therefore, phosphorylation of LIN52 Ser-28 by DYRK1A promotes 
DREAM assembly whereas phosphorylation of sites in p107/p130 by CDKs 
facilitates DREAM disassembly to promote cell cycle progression (Guiley et al. 
2015).  LIN52 therefore plays dual role in recruiting components for assembly of 
repressive DREAM complex as well as assembling the activating MMB-FOXM1 
complex, since it is essential for binding of B-MYB with MuvB which is then 
required for the recruitment of FOXM1(Fischer and Müller 2017; Guiley et al. 
2015). 
The microarray expression profiling study conducted in the laboratory found 
miRNA146a was the most highly up-regulated miRNA with a log2 fold change of 
4.33 upon senescence (Rovillain 2011). Promoter analysis studies by Taganov 
et al., 2006, showed that miR-146a was an NF-κB dependent gene (Taganov et 
al. 2006). According to biological prediction, miR146a regulates the expression 
of LIN52 by binding to 3’ UTR of LIN52. A recent study (Luo et al. 2017) has 
interestingly evaluated the negative correlation between the expression of 
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miR146a and LIN52 in different clinicopathological parameters of gastric cancer, 
a malignancy which affects the gastrointestinal system. Therefore, miR146a 
mediated LIN52 inhibition is associated with improved treatment efficiency and 
high chemotherapeutic sensitivity in patients with gastric cancer (Luo et al. 2017). 
Also, it was observed that in comparison to normal non-cancerous tissue, LIN52 
was distributed predominantly in the cytoplasm of advanced gastric cancer 
tissues (Luo et al. 2017). Inhibition of LIN52 expression in Gastrointestinal 
stromal tumours (GIST) has been demonstrated to be involved in tumour 
suppression due to imatinib-induced apoptosis (Boichuk et al. 2013).   
Poor efficiency is observed for several chemotherapeutic drugs against tumour 
cells which are in G0 phase of cell cycle suggesting this may be one of the major 
reasons for resistance to chemotherapeutic drugs (Shah and Schwartz 2001). 
This explains the possible mechanism behind the improved chemotherapeutic 
sensitivity observed in advanced gastric cancer patients where high levels of 
miR146a driven LIN52 inhibition decreases the number of cells in G0 phase as 
low levels of LIN52 prevent DREAM assembly thereby reducing the number of 
cells in G0 resting phase (Luo et al. 2017). 
None of the MuvB components apart from LIN52 exhibited strong senescence 
bypass activity upon ectopic expression nor did they affect the activity of the 
MMB-FOXM1 reconstituted complex when they were absent when assayed in 
CL3EcoR cells.  LIN37 was the only MuvB component found to be upregulated 
(Figure 4.2) in senescent cells suggesting a role in cell cycle growth arrest.  This 
is in accordance with a recent study (Mages et al. 2017) where knockout of LIN37 
led to complete loss of DREAM repressor function whereas activation of cell 
cycle gene expression was not affected, as mouse myoblasts or fibroblasts 
continued to proliferate normally. Thus, demonstrating a role for LIN37 as an 
essential factor for DREAM repressor functions but dispensable for the activating 
MuvB related activator functions (Fischer and Müller 2017; Mages et al. 2017).  
Unlike LIN9, LIN52 and LIN54 which play a crucial role in both repressor and 
activator functions of the MuvB complex, LIN37 is important only for the 
repressor functions. 
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To enable simultaneous expression of the three key TFs, LIN52, B-MYB, and 
FOXM1, different multi-cistronic constructs were prepared using 2A-peptides 
that allow expression of multiple genes from same mRNA (Szymczak et al. 2004; 
Kim et al. 2011a). The results obtained were very encouraging as all the bi-
cistronic and the multi-cistronic constructs worked very efficiently in our system 
of CL3EcoR cells and exhibited a very strong bypass potential. These multi-
cistronic constructs will be highly relevant for studying the role of these TFs in 
primary human cells which are not as highly infectable as the immortalized 
CL3EcoR cells.  
As the multi-cistronic constructs worked very efficiently, to detect any differences 
that might exist between LIN52, B-MYB and FOXM1, the bypass assay was 
conducted under very stringent conditions in addition to lowering the bypass 
potential by two following approaches. In the first approach, the amount of 
expression construct was reduced prior to lentiviral packaging whereas, in the 
second approach, stably transduced cells obtained after puromycin selection 
were mixed with non-transduced cells.  On comparing the results obtained from 
both the approaches, it was found that the second classical approach produced 
a consistent gradual decrease in bypass potential as opposed to the dilution at 
DNA level which produced inconsistent results.  This might be due to the different 
size of the constructs being tested.  Constructs with large inserts tend to generate 
lower viral titres in comparison to those with smaller inserts.  
Comparison of the extent of senescence bypass observed after silencing 
p21WAF1 and RELA and ectopic expression of the reconstituted MMB-FOXM1 
complex, shown in Figure 6.1, indicated that silencing of p21WAF1 was the most 
efficient.  It would have been interesting to check the percent rescue obtained by 
p21WAF1 for which cells would have needed to be plated more sparsely to obtain 
countable colonies. The rescue obtained by p21WAF1 is a lot higher than B-MYB 
which is rescuing of the order of 1/1000. It is important to understand what 
happens with the remaining 999/1000. One possibility might be the small fraction 
of rescued cells already possess some further required genetic change before 
the addition of B-MYB. Furthermore, reconstitution of the MMB-FOXM1 complex 
was more active at bypassing senescence than silencing RELA and therefore 
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inactivation of the canonical NF-κB signalling pathway. It suggested that 
silencing p21WAF1 must be affecting other pathways in addition to RELA mediated 
NFκB signalling and MMB-FOXM1 related DREAM pathway. 
Also, examination of the results obtained from experiments indicated that there 
was a lot of experimental variation.  This variability is mainly due to the variation 
from individual experiment to experiment arising from different batches of cells, 
virus titre and fluctuations in the incubator temperature.  This was also the cause 
of the high error bars for the quantitative analysis because there was variation 
between independent experiments rather than within an experiment.  Results 
within experiments were reproducible.  
 
 
 
 
 
 
 
 
 
6.1.3 Analysis of the bypass potential of different TFs after simultaneous 
modulation of expression 
It was found that many TFs from the identified list did not show bypass potential 
when studied on their own.  FOXM1, for example, did not show strong bypass 
when studied alone whereas it was a very important component of the MMB-
FOXM1 complex.  Reconstructing MMB-FOXM1 exhibited strong bypass 
potential and showed that a complex can work better than single factors.  
Therefore, it was decided to undertake an experiment wherein multiple different 
                p21WAF1                           MMB-FOXM1                            RELA 
   
Figure 6.1 Comparison of bypass potential after silencing p21WAF1 and RELA and ectopically 
expressing MMB-FOXM1 complex 
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TFs were pooled together as TFs may not work or work poorly when alone but 
may work in combination.  
The question was: Is it feasible to pool a large number of factors together?  
Previously this was considered impossible. Takahashi and Yamanaka set the 
precedent by demonstrating that this can be done.  They showed that it was 
possible to pool 24 factors together to convert somatic cells to induced 
pluripotent stem cells. Then they were able to leave one factor out at a time until 
they identified a combination of four factors which can reprogram somatic cells 
into induced pluripotent stem cells, one of the biggest advances in the field. Their 
study suggested using constitutively active factors wherever possible and also 
high titre viruses as high efficiency is required to ensure multiple hits which 
cannot be easily achieved by transfection (Takahashi and Yamanaka 2006). 
Their strategy relied on the requirement for multiple simultaneous infection 
events which can be readily achieved by using lentiviruses.   
Hence, the aim was to pool together the 73 transcription factors comprising 
ectopic expression constructs for the downregulated TFs, shRNAmiRs for the 
upregulated TFs and shRNAmiRs for RELA, RELB and CEBPβ.  There was a 
clear requirement for high stringency for this experiment to minimise the 
background as it was not possible to know how efficiently the pool (73) would 
work.  It may work poorly and therefore the use of correct controls was absolutely 
critical to be able to discern a positive result above background even if the 
efficiency was low.   
As many of the factors were constructs prepared in pLX301 by gateway 
recombination cloning, the control we used initially was a pool comprising 70 µg 
pLX301 with 1 µg each of LIN52, FOXM1 and B-MYB, as these factors were 
present within the pool of 73 factors.  Since we know that both LIN52 and B-MYB 
exhibit senescence bypass on their own and combine with FOXM1 to 
reconstitute the MMB-FOXM1 complex, it was important that our pool of 73 
factors should bypass more efficiently than the ‘Pool Control’.  Moreover, as we 
thought that this was likely to be very inefficient, ten independent biological 
replicates for the pool (73) were prepared.  The results obtained are shown in 
Figure 6.2.  We were very surprised to find that all five replicates of the 
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experiment worked very efficiently; a lot of growing colonies of cells were 
obtained.  In contrast, the pLX301 vector alone yielded no colonies, so none of 
the growing colonies were due to the background.  However, the ‘Pool control' 
containing the 1 µg of LIN52, B-MYB and FOXM1 also produced lots of growing 
colonies which were only slightly reduced in number compared to the Pool (73). 
This was very discouraging and suggested that perhaps most of the bypass 
observed in the experimental pool was due to the presence of LIN52, B-MYB 
and FOXM1.   
However, while undertaking further bypass experiments with the multi-cistronic 
constructs prepared in the pLEX-MCS lentiviral vector and undertaking controls 
the pLX301 and pLEX-MCS vectors side by side, it was observed that puromycin 
resistant cells obtained after transduction with pLX301 grew very slowly in 
comparison to those with pLEX-MCS.  The pLEX-MCS cultures were ready to be 
reseeded within 4-5 days maximum whereas the pLX301 cultures required at 
least ten days.   
Since LIN52 and FOXM1 had been cloned into pLEX-MCS, we hypothesised that 
in the pool of these factors with pLX301, it was likely that cells that had been 
transduced with LIN52, FOXM1 and B-MYB were likely to be overrepresented in 
comparison to cells that only contained pLX301 as cells derived with pLEX-MCS 
vector grow more rapidly.  This could easily explain the high number of growing 
colonies obtained with the ‘Pool Control’ in Figure 6.2.   
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Figure 6.2 Comparison of bypass activity of Pool (73) to the bypass of Pool control reconstituted 
with the pLX301 vector. 
The bypass assay was performed under stringent conditions at a large scale with ten technical 
replicates for each infection. The pool control was reconstituted with the pLX301 vector. Empty 
pLX301 vector was used as a negative control. 
 
Therefore, we compared the ‘Pool Control’ prepared using pLX301 and pLEX-
MCS and found that there was a significant difference in the number of growing 
colonies obtained.  The bypass potential of Pool Control reconstituted with 
pLX301 was significantly higher than pLEX-MCS Pool Control, as shown in 
Figure 6.3.  The empty vector did not exhibit any strong bypass potential when 
studied on its own (Figure 6.3).  This highlighted the utmost importance of using 
the correct controls in an experiment.  
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Figure 6.3 Comparison of the bypass activity of Pool Control reconstituted with pLX301 and 
pLEX-MCS. 
Bypass assay was conducted under stringent conditions. Bypass activity of both the empty vector 
i.e. pLX301 and pLEX-MCS is shown. 
 
When the 73 TF pool experiment was repeated using the pLEX-MCS vector pool 
control, the results obtained were very encouraging.  It showed that the pool of 
73 TFs exhibited a significantly higher bypass potential than the ‘Pool Control’ 
shown in Figure 5.2 both qualitatively and quantitatively.  Although Yamanaka 
and colleagues identified the critical factors for generating iPS cells by simply 
leaving out one factor at a time, we hypothesised that if a factor was important 
for senescence bypass, it should be enriched in cells in which senescence has 
been bypassed.  Therefore, deep sequencing was undertaken in genomic DNA 
extracted from multiple independent pools of cells derived from three bypass 
experiments, looking for factors that were enriched.  This identified 23 factors 
that showed some enrichment after senescence bypass in cells infected with 
pool of 73 TFs.   
Due to time limitations, a pool of these 23 factors was prepared and shown to be 
able to bypass senescence.  Although we had hypothesised that this pool should 
be more efficient at bypassing senescence than the pool of 73 TFs, this was not 
found to be the case.  Unfortunately, due to the lack of time, it was not possible 
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are crucial for the senescence bypass. It is, of course, possible that factors may 
work by a hit and run mechanism and may not be enriched.  Therefore, it may 
be necessary to go back to 73 factors and leave out the 50 factors that were not 
enriched one at a time to identify if there is a factor which acts in this way.   
Experiments involving Pool 73 and Pool 23 TFs but lacking B-MYB and LIN52 
should also be looked at.  Alternative experiments should also be designed and 
conducted where lentiviruses for these known active components are mixed in 
as opposed to co-packaged, again to mitigate the risk that these active 
components are present at differential titres in control and test infections. 
6.2 Future directions 
Based on the exciting results obtained from the reconstruction experiments 
conducted to study the effect of MMB-FOXM1 complex or upon combining all the 
prioritized TFs, this study has thrown up many questions in need of further 
investigation.  
As shown in Figure 6.1, silencing p21WAF1 bypasses senescence very efficiently 
whereas none of the TFs tested so far individually, as part of the MMB–FOXM1 
complex or as multi-cistronic constructs have shown equivalent bypass potential. 
Even though reconstituting the MMB-FOXM1 complex exhibited strong bypass 
potential, the extent of the bypass was still not comparable to the level of bypass 
obtained after silencing p21WAF1.  This suggests that p21WAF1 silencing involves 
other pathways in addition to the DREAM and NF-κB signalling pathways.  Since 
the TF list was put together using expression profiling data from cells in which 
senescence had been bypassed by p21WAF1 silencing, there is the possibility that 
the additional pathways may involve TFs that are components of our list of 73 
critical TFs.  Experiments should be conducted to study if the bypass potential of 
Pool (73) is affected after removing B-MYB, FOXM1ΔNΔKEN, and LIN52. 
Similarly, bypass of Pool (23) should be assessed after removal of B-MYB and 
LIN52. Future experiments should be conducted to refine the 23 TFs to develop 
a cocktail of TFs that can bypass senescence efficiently and study if it is as 
effective as silencing p21WAF1.  If not, investigate what is missing?  To undertake 
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this, it may be necessary to go back to the list of TFs to identify any that act by a 
‘hit and run mechanism’.  
Another important experiment which needs to be done is to measure the 
proliferative potential and the growth characteristics of cells which have 
bypassed senescence as we have not examined the biology and/or the 
biochemistry of these rescued cells. As the main focus in this study relied upon 
looking at the functional aspects of the role played by different TFs in the 
senescence bypass assay, it is highly relevant to confirm the findings at multiple 
levels such as an in-depth biochemical analysis. It will be important to 
demonstrate at the RNA and/or protein level that the bypass of senescence is 
associated with silencing or ectopic expression of up-regulated and down-
regulated TFs respectively. Since expression at the level of RNA does not always 
correlate with protein levels, expression at the protein level can be determined 
by western blotting, if suitable antibodies are available commercially or from 
another source. 
Very importantly, it is essential to establish and reproduce the findings from the 
current model system of conditionally immortal CL3EcoR cells that was developed 
to facilitate studies on senescence in a range of other cellular senescence 
systems including primary human fibroblasts such as BJ, WI-38, IMR90 cells or 
adult mammary fibroblasts. We will also aim to determine if the key TFs play a 
similar role in replicative senescence in primary human fibroblasts. These studies 
will enable us to refine our list of candidate TFs to those that are differentially 
expressed both, upon the cell, and replicative senescence. The stably 
transduced human fibroblasts will be serially cultivated to determine if they are 
immortal.  Since this will involve serial passaging for many generations taking 
many months, the cells can also be challenged with activated Ras since 
expression of an activated oncogene results in premature senescence due to a 
DNA damage response if the cells are not immortal. Cells derived with hTERT 
alone undergo premature senescence upon challenge with an activated Ras 
oncogene.  This will enable a better understanding of the genes and their function 
in different physiological contexts.   
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It will be important to assay the cocktail of TFs directly in primary human cells to 
determine if they are able to immortalise them. Also, check if our factors work in 
other human cells such as epithelial cells or neural cells or are they fibroblast 
specific. Also, important to assay MMB-FOXM1 complex in these other primary 
cells to see if they can immortalise and if they bypass other forms of senescence.   
CL3EcoR cells are highly infectable which enabled the reconstruction experiments 
to work very efficiently.  Primary cells, on the other hand, will not exhibit a similar 
level of infectivity and hence expressing different ORFs from a single vector will 
prove highly beneficial to enable polycistronic expression driven from a single 
promoter.  Hence, the multi-cistronic constructs designed in this study will be 
highly useful in studying the role MMB-FOXM1 complex and other TFs in primary 
cells.  It may be necessary to prepare multi-cistronic constructs for the TF 
cocktail.   
Expression profiling of RNA extracted from independent cultures of CL3EcoR cells, 
in which senescence has been bypassed by ectopic expression of constitutively 
active LIN52, FOXM1 and B-MYB, should be undertaken.  As the MMB-FOXM1 
complex bypasses senescence very efficiently, cultures of these cells should be 
established, and RNA should be extracted for expression profiling.  The 
expression data should be analysed to identify genes that are differentially 
expressed upon senescence arrest but whose expression is reversed upon 
senescence bypass.  If the ectopic expression of constitutively active LIN52, 
FOXM1 or B-MYB bypasses senescence in IMR90 (with silencing of p53) or BJ 
fibroblasts, they should also be profiled.  The expression profiling data sets 
should be overlapped to identify common downstream targets of B-MYB, MuvB 
and FOXM1 in CL3EcoR, IMR90 and BJ fibroblasts. 
To identify direct downstream targets of these genes, chromatin 
immunoprecipitation (ChIP) can be performed, in proliferating CL3EcoR fibroblasts 
as well as primary human IMR90 and BJ fibroblasts.  The ChIP-Seq data can be 
overlapped with the expression profiling data to identify downstream targets of 
B-MYB, MuvB and FOXM1.  These targets should be validated by carrying out 
ChIP on CL3EcoR cells in which senescence has been bypassed by B-MYB, MuvB 
or FOXM1 and analysing the immunoprecipitated DNA by q-PCR.   
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Overlap of the ChIP-Seq data, with the expression profiling data, from both 
CL3EcoR and human IMR90/BJ fibroblasts, as well as cells in which senescence 
has been bypassed, followed by ontological analysis, should identify direct 
targets of B-MYB-MuvB-FOXM1 for further analysis as mediators of senescence 
bypass by ectopic expression or shRNA silencing.  Identification of critical 
downstream targets of the transcription factor complexes in primary proliferating 
cells and whether they are the same in cells where senescence has been 
bypassed should also be looked at.  After confirming that changes in expression 
in CL3EcoR cells are also observed in primary fibroblasts, reciprocal co-
immunoprecipitation experiments could be undertaken.  These experiments will 
enable us to determine if B-MYB and FOXM1 are in a complex with MuvB 
proteins in growing versus senescent cells.  More importantly, they will enable 
us to determine if B-MYB and FOXM1 are present in the same MuvB complex, 
or in different complexes; and what happens to these complexes upon 
senescence arrest, both in CL3EcoR and primary (IMR90 and BJ) fibroblasts.  It 
will also be relevant to test if the same complexes are present in cells in which 
senescence has been bypassed. They will also enable us to determine if DREAM 
complexes are present and if they change upon senescence arrest.  Also, bypass 
of senescence in IMR90 cells will require silencing of p53 in addition.  We can 
also determine if they can immortalise primary human fibroblasts in conjunction 
with reconstitution of telomerase activity.  
Mostly all the in vitro studies of cellular senescence are performed using a single 
senescence inducing stimulus such as oncogenes or high dose of radiations 
whereas within an organism individual cells experience various cellular stresses 
like mitotic, genotoxic and proteotoxic stresses at the same time. Therefore, our 
long-term focus should be to examine how combinations of different senescence-
inducing stimulus affect the downstream effector pathways and resulting 
senescent phenotypes. This will enable a better understanding of the 
multifunctional nature of cellular senescence and provide a clear picture of 
whether fundamentally different senescence mechanisms underlie the diverse 
biological roles performed by senescence which are being discovered recently.  
 245 
6.3 Concluding Remarks 
Together this study enabled us to identify 10 upregulated and 74 downregulated 
TFs that are differentially expressed upon entry into cellular senescence in 
CL3EcoR cells and has highlighted the causal role played by DREAM complex and 
associated (MMB-FOXM1) complex in senescence.  One of the most significant 
findings to emerge from this study is that it very clearly illustrated the role of 
components of the DREAM complex and associated components in bypassing 
senescence.  Reconstitution of MMB-FOXM1 complex demonstrated that it can 
bypass senescence under very stringent conditions and that LIN52, FOXM1 and 
B-MYB were the crucial components. Furthermore, this required non-
phosphorylated LIN52, suggesting a role for phosphorylated LIN52 and the 
DREAM complex in inducing senescence. This study has gone some way 
towards enhancing our understanding of the role of DREAM complex and 
associated components in senescence as very little is known about the role of 
DREAM complex in senescence. Much is known about the importance of 
DREAM complex in quiescence and its role in repressing cell cycle-dependent 
gene expression. Additional reconstitution experiments wherein all the prioritized 
TFs were combined, revealed the presence of synergy amongst the TFs implying 
the presence of other potential pathways for regulating senescence; these 
remain to be identified and studied further.   
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